

Usage Of Medicines In Secondary Care

Reference Number: F4867
Date of Response: 13/10/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

SACT Cancer report

Please select data records from the chemotherapy ePMA system between *Oct 2021 and Mar 2022*, for all solid tumour or haematological malignancies (ICD-10 primary diagnosis codes = C* or D*).

Field number	Data Field from NHS Data Model and Dictionary for SACT
10	ORGANISATION IDENTIFIER (CODE OF PROVIDER)
11	PRIMARY DIAGNOSIS (tumour type)
12	PRIMARY DIAGNOSIS CODE (SNOMED CT OR ICD-10 3 or 4 digit)
13	ADJUNCTIVE THERAPY TYPE
	TNM STAGE
14	SACT TREATMENT INTENT
15	SACT DRUG REGIMEN ACRONYM
	DRUG REGIMEN DESCRIPTION
	NUMBER OF PLANNED CYCLES
22	CLINICAL TRIAL INDICATOR
27	SACT DRUG NAME
28	SACT DRUG SNOMED CT DM+D
29	SACT ACTUAL DOSE
30	SACT UNIT OF MEASUREMENT
35	SACT THERAPY ADMINISTRATION DATE
	ADMINISTRATION MONTH
	ADMINISTRATION YEAR
	LINE OF THERAPY
36	ORGANISATION IDENTIFIER (OF SACT THERAPY ADMINISTRATION)
	NUMBER OF PATIENT RECORDS

Please find attached Trust response to your request in the form of an Excel sheet. Please note, patient numbers can be found in column 0 (Record count). However, please also note we have used Section 40 ≤5.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles

ICD10 Description	Primary Diagnosis	Adjunctive Therapy	TNM	Intent Of Treatment	Regimen	Clinical Trial	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM+D)	Admin Month	Admin Year	Line	Organisation Identifier Of SACT Administration	Record Count
Malignant neoplasm: Breast, unspecified	C509	3		3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	3	2022		RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3		3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	12	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	BLINAT MRD>45kg+	2	DEXAMETHASONE	20	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	Methotrexate intrathecal	2	METHOTREXATE	12	258684004	1	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	Methotrexate intrathecal	2	METHOTREXATE	12	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL 14 MAINT +	1	METHOTREXATE	42.5	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	20	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	20	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	30	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	40	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	40	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	METHOTREXATE	30	258684004	1	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	VINCRISTINE SULFATE	2	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	METHOTREXATE	37.5	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		98	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	1	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		98	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		98	UKALL60 C CONSOL	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		98	UKALL60 C CONSOL	2	VINCRISTINE SULFATE	1.3	258684004	11	2021		RH8	<5
Acute myeloblastic leukaemia [AML]	C920	2		98	GILTERITINIB>	2	GILTERITINIB	200	258684004	3	2022		RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3		3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	BLIN MRD >45kg	2	BLINATUMOMAB	133.75	258685003	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	BLIN MRD >45kg	2	DEXAMETHASONE	20	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	Methotrexate intrathecal	2	METHOTREXATE	12	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL 14 PH1 -	1	DAUNORUBICIN	42.5	258684004	12	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL 14 PH1 -	1	DEXAMETHASONE	14.5	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL 14 PH2 -	1	MERCAPTOPYRINE	90	258684004	12	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	DEXAMETHASONE	5	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	20	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	20	258684004	12	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	MERCAPTOPYRINE	120	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	METHOTREXATE	15	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	MERCAPTOPYRINE	140	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	MERCAPTOPYRINE	140	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	MERCAPTOPYRINE	140	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	METHOTREXATE	37.5	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	METHOTREXATE	37.5	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 C MAI>	2	VINCRISTINE SULFATE	2	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		98	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	12	2021		RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3		3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	BLIN MRD >45kg	2	BLINATUMOMAB	133.75	258685003	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL 14 MAINT +	1	MERCAPTOPYRINE	160	258684004	12	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL 14 MAINT +	1	VINCRISTINE SULFATE	2	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	60	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	120	258684004	3	2022		RH8	10
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	120	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	120	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	20	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	40	258684004	1	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	VINCRISTINE SULFATE	2	258684004	2	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	VINCRISTINE SULFATE	2	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	VINCRISTINE SULFATE	2	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	DEXAMETHASONE	5	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	METHOTREXATE	15	258684004	12	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAIN	2	VINCRISTINE SULFATE	2	258684004	11	2021		RH8	<5
Acute myeloblastic leukaemia [AML]	C920	2		98	GILTERITINIB	2	GILTERITINIB	120	258684004	1	2022		RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3		NULL	Azacitidine	2	AZACITIDINE	130	258684004	1	2022		RH8	6
Acute myeloblastic leukaemia [AML]	C920	3		NULL	Azacitidine	2	AZACITIDINE	130	258684004	12	2021		RH8	9
Acute lymphoblastic leukaemia [ALL]	C910	3		1	Methotrexate intrathecal	2	METHOTREXATE	12	258684004	3	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	1	2022		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	80	258684004	10	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	80	258684004	11	2021		RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	120	258684004	1	2022		RH8	6
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	120	258684004	12	2021		RH8	6
Acute lymphoblastic leukaemia [ALL]	C910	3		1	UKALL2019 B MAI>	2	METHOTREXATE	20	258684004	1	2022		RH8	<5

Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	METHOTREXATE	30	258684004	3	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	VINCISTINE SULFATE	1	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	DEXAMETHASONE	5	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	VINCISTINE SULFATE	1	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit	2	AZACITIDINE	140	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML MAINT MIDOST	2	MIDOSTAURIN	50	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19DA 3+8 MIDO	1	CYTARABINE	220	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 1+4+GEMD1	2	GEMTUZUMAB OZOGAMCIN	5	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+MIDO	2	CYTARABINE	400	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	HYD AML/CML 1DAY	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	3	Cytarabine low (10to20mg/m2) P2	2	CYTARABINE	20	258684004	11	2021	RH8	10
Acute myeloblastic leukaemia [AML]	C920	3	3	VEN /LD CYT C19	2	CYTARABINE	30	258684004	1	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 MAINT +	1	MERCAPTOPYRINE	160	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 MAINT +	1	METHOTREXATE	50	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH1 -	1	PEG ASPARAGINSE ONCASPAR	1425	408102007	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	METHOTREXATE	7.5	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	MERCAPTOPYRINE	120	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	DEXAMETHASONE	5.5	258684004	3	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	10	2021	RH8	7
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit	2	VENETOCLAX	100	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit>	2	VENETOCLAX	100	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML MAINT MIDOST	2	MIDOSTAURIN	50	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 HD ARAC MI	1	MIDOSTAURIN	50	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	Cytarabine High Dose	2	CYTARABINE	2700	258684004	11	2021	RH8	6
Acute myeloblastic leukaemia [AML]	C920	3	1	Cytarabine High Dose	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	IDARUBICIN HYDROCHLORIDE	9	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	75	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	BLIN MRD >45kg	2	BLINATUMOMAB	100	258685003	3	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH1 -	1	VINCISTINE SULFATE	2	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH2 -	1	CYCLOPHOSPHAMIDE	1400	258684004	1	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH2 -	1	CYCLOPHOSPHAMIDE	1400	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH2 -	1	CYTARABINE	110	258684004	1	2022	RH8	7
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	DEXAMETHASONE	5	258684004	3	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	DEXAMETHASONE	6	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	MERCAPTOPYRINE	120	258684004	2	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	METHOTREXATE	30	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	METHOTREXATE	40	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	DEXAMETHASONE	5	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	METHOTREXATE	15	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	DEXAMETHASONE	5.5	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	DEXAMETHASONE	5.5	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	MERCAPTOPYRINE	140	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	98	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	2	98	GILTERITINIB Cy2	2	GILTERITINIB	120	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	3	2022	RH8	10
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	BLIN MRD >45kg	2	BLINATUMOMAB	100	258685003	2	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	BLINAT MRD>45kg+	2	BLINATUMOMAB	133.75	258685003	3	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH1 -	1	DAUNORUBICIN	42.5	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL 14 PH1 -	1	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	DEXAMETHASONE	6	258684004	10	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAI>	2	VINCISTINE SULFATE	2	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	MERCAPTOPYRINE	120	258684004	1	2022	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 B MAIN	2	MERCAPTOPYRINE	120	258684004	11	2021	RH8	<5
Acute lymphoblastic leukaemia [ALL]	C910	3	1	UKALL2019 C MAI>	2	METHOTREXATE	37.5	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	1	98	VICTOR VEN+ LDAC	1	CYTARABINE	34	258684004	12	2021	RH8	7
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit	2	AZACITIDINE	140	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit	2	VENETOCLAX	300	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit	2	VENETOCLAX	300	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit>	2	AZACITIDINE	140	258684004	12	2021	RH8	7
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 DA GO2	1	MIDOSTAURIN	50	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 HD ARAC MI	1	CYTARABINE	6300	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 HD ARAC MI	1	CYTARABINE	7000	258684004	12	2021	RH8	<5

Acute myeloblastic leukaemia [AML]	C920	3	1	AML19DA 3+8 MIDO	1	MIDOSTAURIN	50	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+GEMT	2	GEMTUZUMAB OZOGAMCIN	5	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Cytarabine low (10to20mg/m2) I	2	CYTARABINE	20	258684004	10	2021	RH8	20
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit	2	AZACITIDINE	130	258684004	10	2021	RH8	6
Acute myeloblastic leukaemia [AML]	C920	3	1	AML MAINT MIDOST	2	MIDOSTAURIN	50	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML Mainten MIDO	1	MIDOSTAURIN	50	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+GEMT	2	GEMTUZUMAB OZOGAMCIN	5	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	CYTARABINE	4500	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	3	Azacitidine	2	AZACITIDINE	160	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	99	Veneto + Azacit	2	VENETOCLAX	300	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	Cytarabine intrathecal	2	CYTARABINE	50	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	DEXAMETHASONE	4	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	Cytarabine intrathecal	2	CYTARABINE	50	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+GEMT	2	GEMTUZUMAB OZOGAMCIN	4.3	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	10	258684004	11	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND2	2	ARSENIC TRIOXIDE	20	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON.	2	TRETINOIN	100	258684004	3	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON+	2	ARSENIC TRIOXIDE	27	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND1	2	TRETINOIN	100	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	11	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	2	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	2	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1000	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBR/VEN*	1	IBRUTINIB	420	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	420	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	420	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	200	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	350	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	HYD AML/CML 1DY>	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	HYD AML/CML 1DY>	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	LIP DAU/CYT IND1	2	DAUNORUBICIN/CYTARABINE	280.8	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit>	2	AZACITIDINE	130	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit>	2	AZACITIDINE	140	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 1+4+GEMD1	2	DAUNORUBICIN	122.5	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	CYTARABINE	2700	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	VENETOCLAX	400	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	CYTARABINE	3300	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	DEXAMETHASONE	4	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	IDARUBICIN HYDROCHLORIDE	13	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 1+4+GEMD1	2	DAUNORUBICIN	87.5	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HD ARAC + MIDO	2	CYTARABINE	4500	258684004	1	2022	RH8	6
Acute myeloblastic leukaemia [AML]	C920	9	98	HD ARAC + MIDO	2	MIDOSTAURIN	50	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON+	2	ARSENIC TRIOXIDE	22	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON.	2	TRETINOIN	100	258684004	2	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	11	258684004	11	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	27	258684004	10	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND2	2	ARSENIC TRIOXIDE	22	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	CYTARABINE	30	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	CYTARABINE	30	258684004	10	2021	RH8	10
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	CYTARABINE	30	258684004	11	2021	RH8	10
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	VENETOCLAX	300	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 1+4+GEMD1	2	CYTARABINE	1400	258684004	3	2022	RH8	8
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+MIDO	2	DAUNORUBICIN	87.5	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+MIDO	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HD ARAC + MIDO	2	MIDOSTAURIN	50	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5

Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	22	258684004	10	2021	RH8	<5
Anaplastic large cell lymphoma, ALK-negative	C847	3	NULL	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1100	258684004	12	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	VINCISTINE SULFATE	1	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	NULL	98	VENETOCLAX-R WK3	2	VENETOCLAX	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	1	NULL	Chlorambucil	2	CHLORAMBUCIL	10	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	1	NULL	Chlorambucil	2	CHLORAMBUCIL	18	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETOCLAX-R WK1	2	VENETOCLAX	20	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+MIDO	2	DAUNORUBICIN	117.5	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	3	Azacitidine	2	AZACITIDINE	160	258684004	2	2022	RH8	7
Acute myeloblastic leukaemia [AML]	C920	3	98	HYD AML/CML 1DY>	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	99	Veneto + Azacit	2	AZACITIDINE	180	258684004	3	2022	RH8	6
Acute myeloblastic leukaemia [AML]	C920	3	99	Veneto + Azacit	2	VENETOCLAX	100	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HD ARAC + MIDO	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	1	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	22	258684004	10	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	1	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	27	258684004	10	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	24	258684004	11	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND1	2	TRETINOIN	90	258684004	11	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON+	2	TRETINOIN	100	258684004	12	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	VINCISTINE SULFATE	1	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	2	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	200	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	CYTARABINE	30	258684004	1	2022	RH8	6
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	Veneto + Azacit	2	AZACITIDINE	130	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	Veneto + Azacit	2	VENETOCLAX	100	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	CYTARABINE	3300	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	FLUDARABINE PHOSPHATE	50	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	FLUDARABINE PHOSPHATE	50	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+MIDO	2	CYTARABINE	300	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	VEN /LD CYT C19	2	CYTARABINE	36	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	VEN /LD CYT C19	2	VENETOCLAX	300	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON.	2	TRETINOIN	90	258684004	3	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON+	2	ARSENIC TRIOXIDE	22	258684004	2	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON+	2	TRETINOIN	90	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	10	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND2	2	ARSENIC TRIOXIDE	20	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON.	2	ARSENIC TRIOXIDE	22	258684004	3	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON+	2	TRETINOIN	100	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND2	2	TRETINOIN	100	258684004	11	2021	RH8	<5
Anaplastic large cell lymphoma, ALK-negative	C847	3	NULL	Brentuximab	2	BRENTUXIMAB VEDOTIN	110	258684004	1	2022	RH8	<5
Anaplastic large cell lymphoma, ALK-negative	C847	3	NULL	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	HYD AML/CML 1DY>	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML Mainten MIDO	1	MIDOSTAURIN	50	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML Mainten MIDO	1	MIDOSTAURIN	50	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 DA GO2	1	CYTARABINE	220	258684004	11	2021	RH8	20
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 DA GO2	1	DAUNORUBICIN	127.5	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 DA GO2	1	GEMTUZUMAB OZOGAMCIN	5	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 HD ARAC MI	1	CYTARABINE	6300	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19DA 3+8 MIDO	1	DAUNORUBICIN	102.5	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	Cytarabine intrathecal	2	CYTARABINE	70	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 1+4+GEMD1	2	CYTARABINE	2000	258684004	2	2022	RH8	8
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+MIDO	2	MIDOSTAURIN	50	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	FLUDARABINE PHOSPHATE	32.5	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	99	Veneto + Azacit	2	VENETOCLAX	200	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	CYTARABINE	3300	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	DEXAMETHASONE	4	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 1+4+GEMD1	2	GEMTUZUMAB OZOGAMCIN	4.3	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1500	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	1	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	22	258684004	11	2021	RH8	<5

Acute myeloblastic leukaemia [AML]	C920	1	98	VICTOR VEN+ LDAC	1	VENETOCLAX	400	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Azacididine	2	AZACITIDINE	130	258684004	2	2022	RH8	7
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Cytarabine low (10to20mg/m2) I	2	CYTARABINE	20	258684004	11	2021	RH8	8
Acute myeloblastic leukaemia [AML]	C920	3	NULL	HYD AML/CML 1DY>	2	HYDROXYCARBAMIDE	50	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit>	2	VENETOCLAX	100	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	NULL	Veneto + Azacit>	2	VENETOCLAX	100	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19 HD ARAC MI	1	CYTARABINE	7000	258684004	11	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	AML19DA 3+8 MIDO	1	CYTARABINE	200	258684004	12	2021	RH8	16
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+GEMT	2	CYTARABINE	440	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+GEMT	2	CYTARABINE	480	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+GEMT	2	DAUNORUBICIN	125	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+GEMT	2	DAUNORUBICIN	142.5	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	DA(60) 3+7+MIDO	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	DEXAMETHASONE	4	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	FLUDARABINE PHOSPHATE	65	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	1	FLAG + Idarubicin	2	IDARUBICIN HYDROCHLORIDE	18	258684004	2	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	3	Azacididine	2	AZACITIDINE	160	258684004	1	2022	RH8	6
Acute myeloblastic leukaemia [AML]	C920	3	3	Azacididine	2	AZACITIDINE	160	258684004	3	2022	RH8	10
Acute myeloblastic leukaemia [AML]	C920	3	3	Azacididine	2	AZACITIDINE	160	258684004	11	2021	RH8	6
Acute myeloblastic leukaemia [AML]	C920	3	3	VEN /LD CYT C19	2	VENETOCLAX	100	258684004	1	2022	RH8	<5
Anaplastic large cell lymphoma, ALK-negative	C847	3	NULL	Brentuximab	2	BRENTUXIMAB VEDOTIN	110	258684004	2	2022	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1100	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1100	258684004	11	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	VINCRISTINE SULFATE	1	258684004	1	2022	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	VINCRISTINE SULFATE	1	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	VINCRISTINE SULFATE	1	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	2	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	900	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETOCLAX-R WK4	2	VENETOCLAX	200	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBRUT MA	1	IBRUTINIB	420	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBRUT MA	1	IBRUTINIB	420	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	140	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	280	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	420	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	280	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	200	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	300	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	300	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX-R WK1	2	VENETOCLAX	20	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	FLUDARABINE PHOSPHATE	60	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FLAIR - IBR/VEN>	1	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	OBIN + CHLORAM	2	CHLORAMBUCIL	32	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	OBIN + CHLORAM	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin + Venet Cy2	2	VENETOCLAX	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin+Venet Cy3-6	2	VENETOCLAX	300	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	3	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON.	2	ARSENIC TRIOXIDE	27	258684004	3	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON+	2	ARSENIC TRIOXIDE	27	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND1	2	ARSENIC TRIOXIDE	24	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO IND2	2	TRETINOIN	90	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON.	2	ARSENIC TRIOXIDE	22	258684004	2	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON.	2	ARSENIC TRIOXIDE	27	258684004	2	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON+	2	ARSENIC TRIOXIDE	22	258684004	12	2021	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO IND2	2	ARSENIC TRIOXIDE	22	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	NULL	98	VENETOCLAX-R WK1	2	VENETOCLAX	20	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	1	NULL	Chlorambucil	2	CHLORAMBUCIL	18	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	2	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	3	2022	RH8	<5

Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBRUT MA	1	IBRUTINIB	420	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Imatinib 400mg	2	IMATINIB	100	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	200	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	300	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	2	2022	RH8	6
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	200	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Dasatinib	2	DASATINIB	50	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	300	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	PONATINIB - C3>	2	PONATINIB	30	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	98	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myelomonocytic leukaemia	C931	3	NULL	HYD AML/CML 1DAY	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	3	Ruxolitinib	2	RUXOLITINIB	15	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	10	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	15	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	25	258684004	11	2021	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	3	5	BEXAROTENE>	2	BEXAROTENE	225	258684004	1	2022	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	3	5	BEXAROTENE>	2	BEXAROTENE	225	258684004	2	2022	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	3	5	BEXAROTENE>	2	BEXAROTENE	225	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R GCVP	2	CYCLOPHOSPHAMIDE	1300	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	CYCLOPHOSPHAMIDE	1300	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	CYCLOPHOSPHAMIDE	1300	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	CYCLOPHOSPHAMIDE	1300	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	CYCLOPHOSPHAMIDE	1300	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R-GDP(RDE)	2	CISPLATIN	164	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	CYCLOPHOSPHAMIDE	900	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	CYCLOPHOSPHAMIDE	1200	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	8
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	280	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	420	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	420	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETO+RITUX C1	2	RITUXIMAB - RIXATHON	800	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX-R WK4	2	VENETOCLAX	200	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 1	2	FLUDARABINE PHOSPHATE	40	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	350	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	350	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	450	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	FLUDARABINE PHOSPHATE	60	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	FLUDARABINE PHOSPHATE	70	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	RITUXIMAB - RIXATHON	900	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FLAIR - IBR/VEN	1	IBRUTINIB	420	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	OBIN + CHLORAM	2	CHLORAMBUCIL	42	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	6
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R C>1	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R C>1	2	ETOPOSIDE	96	258684004	3	2022	RH8	<5

Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BEND.	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R IVAC	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	CYCLOPHOSPHAMIDE	1600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	5	R-GDP(RDE)	2	CISPLATIN	145	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1400	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C1	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETOCLAX-R WK3	2	VENETOCLAX	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETOCLAX-R WK5	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	280	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	420	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	140	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETO+RITUX C1	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	200	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	300	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX-R WK2	2	VENETOCLAX	50	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX-R WK3	2	VENETOCLAX	100	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	7
Essential (haemorrhagic) thrombocytopenia	D473	1	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	3	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	6
Essential (haemorrhagic) thrombocytopenia	D473	3	5	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	5	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	6
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	6
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	8
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	6
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	2022	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	NULL	98	VENETOCLAX-R WK2	2	VENETOCLAX	50	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1000	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1000	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1000	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	200	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	300	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C1	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBR/VEN*	1	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBRUT MA	1	IBRUTINIB	420	258684004	10	2021	RH8	<5

Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL-	2	IBRUTINIB	140	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	420	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	420	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	FCR Oral - Cycle 1	2	CYCLOPHOSPHAMIDE	550	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Imatinib 400mg	2	IMATINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Nilotinib	2	NILOTINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Nilotinib	2	NILOTINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	Imatinib 400mg	2	IMATINIB	200	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	PONATINIB - C3>	2	PONATINIB	45	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	1	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	20	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	50	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	100	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	300	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	300	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	300	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	3	98	VEN/LD CYT19>>	2	CYTARABINE	30	258684004	12	2021	RH8	10
Acute myeloblastic leukaemia [AML]	C920	9	1	FLAG + Idarubicin	2	FLUDARABINE PHOSPHATE	50	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+GEMT	2	CYTARABINE	280	258684004	1	2022	RH8	7
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+GEMT	2	DAUNORUBICIN	87.5	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	DA(60) 3+7+MIDO	2	MIDOSTAURIN	50	258684004	10	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HD ARAC + MIDO	2	CYTARABINE	4500	258684004	12	2021	RH8	6
Acute myeloblastic leukaemia [AML]	C920	9	98	HD ARAC + MIDO	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1500	258684004	3	2022	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	<5
Acute myeloblastic leukaemia [AML]	C920	9	98	VEN /LD CYT C19	2	VENETOCLAX	100	258684004	1	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON.	2	ARSENIC TRIOXIDE	22	258684004	3	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	3	1	ATRA/ATO CON+	2	TRETINOIN	90	258684004	2	2022	RH8	<5
Acute promyelocytic leukaemia [PML]	C924	9	1	ATRA/ATO CON+	2	ARSENIC TRIOXIDE	22	258684004	1	2022	RH8	<5
Anaplastic large cell lymphoma, ALK-negative	C847	3	NULL	CHOP - 21 days	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Angioimmunoblastic T-cell lymphoma	C865	3	98	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	NULL	98	VENETOCLAX-R WK4	2	VENETOCLAX	200	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	1	NULL	Chlorambucil	2	CHLORAMBUCIL	18	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	1	1	Ibrutinib	2	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	2	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	420	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	200	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	300	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	FLUDARABINE PHOSPHATE	60	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FLAIR - IBR/VEN>	1	VENETOCLAX	20	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin+Venet Cy3-6	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	PONATINIB - C3>	2	PONATINIB	30	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	PONATINIB - RDE	2	PONATINIB	30	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 1	2	CYCLOPHOSPHAMIDE	350	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	RITUXIMAB - RIXATHON	900	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	1	2022	RH8	<5

Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin + Venet Cy1	2	VENETOCLAX	20	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Nilotinib	2	NILOTINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	NULL	HYD AML/CML 1DY>	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	NULL	HYD AML/CML 7DY>	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	1	Nilotinib	2	NILOTINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Nilotinib	2	NILOTINIB	300	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	Imatinib 400mg	2	IMATINIB	400	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	9
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	2000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	99	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	99	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	6
Follicular lymphoma, unspecified	C829	1	99	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	1	99	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	OBIN MAINT	2	OBINUTUZUMAB	1000	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	Rituximab (Maintenance)	2	RITUXIMAB - RIXATHON	500	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	Rituximab (Maintenance)	2	RITUXIMAB - RIXATHON	500	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	5	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	1	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	420	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	280	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	280	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETO+RITUX C>1	2	VENETOCLAX	400	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	200	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	300	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX-R WKS	2	VENETOCLAX	400	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB	2	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	350	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	450	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	RITUXIMAB - RIXATHON	900	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	PONATINIB - C3>	2	PONATINIB	45	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	300	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	98	Nilotinib	2	NILOTINIB	150	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	99	HYD AML/CML 1DAY	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Chronic myelomonocytic leukaemia	C931	3	NULL	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	3	Ruxolitinib	2	RUXOLITINIB	15	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	5	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	20	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	20	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	20	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	20	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	20	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	25	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	9	98	Ruxolitinib	2	RUXOLITINIB	10	258684004	11	2021	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	9	98	BEXAROTENE>	2	BEXAROTENE	300	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R GCVF	2	GEMCITABINE	1600	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	88	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	150	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	150	258684004	12	2021	RH8	<5

Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	PONATINIB - C3>	2	PONATINIB	45	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	20	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE 90 CYC1	2	IMATINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	200	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Imatinib 400mg	2	IMATINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	150	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	150	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	300	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	300	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	PONATINIB - C3>	2	PONATINIB	45	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	PONATINIB - C3>	2	PONATINIB	45	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Dasatinib	2	DASATINIB	50	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE90 CYC>1	2	IMATINIB	200	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP	2	CYCLOPHOSPHAMIDE	1600	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN MAINT	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	RCEOP	2	ETOPOSIDE	150	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	140	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	99	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	CVP R	2	CYCLOPHOSPHAMIDE	1400	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	CVP R	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET	2	DABRAFENIB	150	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	TRAMETINIB	2	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	TRAMETINIB	2	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ECT - BLEOMYCIN	2	BLEOMYCIN	23750	408102007	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	45	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	300	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	450	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Imatinib 400mg	2	IMATINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Imatinib 400mg	2	IMATINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	300	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	PONATINIB - C2	2	PONATINIB	30	258684004	3	2022	RH8	<5
Chronic myelomonocytic leukaemia	C931	3	NULL	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Chronic myelomonocytic leukaemia	C931	3	98	HYD AML/CML 7DY>	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	7
Chronic myeloproliferative disease	D471	3	3	Ruxolitinib	2	RUXOLITINIB	15	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	3	Ruxolitinib	2	RUXOLITINIB	15	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	5	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	15	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	15	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	5	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	25	258684004	12	2021	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	9	98	BEXAROTENE	2	BEXAROTENE	300	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	CISPLATIN	79	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	CYTARABINE	3300	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1200	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	1	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE	2	BOSUTINIB	500	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	20	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	100	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	100	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	100	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE 90 CYC1	2	IMATINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	300	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	200	258684004	10	2021	RH8	<5

Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	200	258684004	11	2021	RH8	6
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	200	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	300	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	PONATINIB - C3>	2	PONATINIB	45	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R-GDP(RDE)	2	RITUXIMAB - RIXATHON	800	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	VINCISTINE SULFATE	1.5	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1100	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	2	2022	RH8	6
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	800	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	1	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	10
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R-	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R C>1	2	VINCISTINE SULFATE	0.81	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	CYCLOPHOSPHAMIDE	360	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	108	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	200	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	RITUXIMAB - RIXATHON	800	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPILIM RDE	2	IPILIMUMAB	225	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	6
Malignant melanoma of skin	C43X	3	NULL	TVEC	2	TALIMOGENE LAHERPAREPVEC 10*6	3	74964007	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	TVEC >1	2	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	100	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	TRAMETINIB	1.5	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	CARBOPLATIN	630	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	DEXAMETHASONE	2	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	PACLITAXEL	120	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1450	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	20	258684004	11	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	ETOPOSIDE	120	258684004	2	2022	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	IFOSFAMIDE	2640	258684004	11	2021	RH8	<5
Malignant neoplasm of floor of mouth	C04X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of floor of mouth	C04X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Dasatinib	2	DASATINIB	50	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Imatinib 400mg	2	IMATINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Imatinib 400mg	2	IMATINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	300	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	300	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	PONATINIB - C3>	2	PONATINIB	30	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	3	Ruxolitinib	2	RUXOLITINIB	15	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	10	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	15	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	20	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	FEDRATINIB	2	FEDRATINIB	400	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	20	258684004	3	2022	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	3	5	BEXAROTENE>	2	BEXAROTENE	225	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	CYTARABINE	3300	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	ETOPOSIDE	68	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R GCVF	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	88	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	ETOPOSIDE	60	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE)	2	CISPLATIN	113	258684004	3	2022	RH8	<5

Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	VINCISTINE SULFATE	1	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BENDA	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BENDA	2	POLATUZUMAB VEDOTIN	152	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BENDA	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1600	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE)	2	CISPLATIN	128	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE)	2	RITUXIMAB - RIXATHON	700	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	CISPLATIN	128	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	GEMCITABINE	1800	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	VINCISTINE SULFATE	1	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	6
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	9
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	800	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	1	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	1.5	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	12
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R-	2	CYCLOPHOSPHAMIDE	1580	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BEND.	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R IVAC	2	ETOPOSIDE	108	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R IVAC	2	IFOSFAMIDE	2640	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	CYCLOPHOSPHAMIDE	1500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	CYCLOPHOSPHAMIDE	1600	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	RITUXIMAB - RIXATHON	800	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	CISPLATIN	113	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	GEMCITABINE	2000	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	GEMCITABINE	2000	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	25	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	50	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	50	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AVELUMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL	2	AVELUMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AVELUMAB	800	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AXITINIB	5	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTINIB RDE	2	CABOZANTINIB	40	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO/IPI RCC +	2	IPILIMUMAB	55	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	600	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	800	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1200	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1600	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	70	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	2	2022	RH8	8
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	11
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	1	258684004	3	2022	RH8	<5

Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	9
Diffuse large B-cell lymphoma	C833	3	1	CVP R	2	CYCLOPHOSPHAMIDE	1100	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CVP R	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R-	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R-	2	ETOPOSIDE	96	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R C>1	2	ETOPOSIDE	96	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R IVAC	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 3/4	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	5	Busulfan Oral	2	BUSULFAN	2	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	9
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	12
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	RITUXIMAB - RIXATHON	900	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	OBIN + CHLORAM	2	OBINUTUZUMAB	900	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Obin+Venet C7-12	2	VENETOCLAX	400	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin + Venet CY2	2	VENETOCLAX	50	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin+Venet Cy3-6	2	VENETOCLAX	300	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Imatinib 400mg	2	IMATINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Imatinib 400mg	2	IMATINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	NULL	HYD AML/CML 7DY>	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	1	Nilotinib	2	NILOTINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Imatinib 400mg	2	IMATINIB	100	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Imatinib 400mg	2	IMATINIB	100	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Imatinib 400mg	2	IMATINIB	100	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	PONATINIB - C3>	2	PONATINIB	30	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	1	Nilotinib	2	NILOTINIB	150	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	700	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	100	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	500	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1400	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	VINCISTINE SULFATE	1	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	2000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	37.5	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	50	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	10	2021	RH8	<5

Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO RCC 4WK	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin+Fluorouracil 4 or 5 d 2	2	FLUOROURACIL	8200	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	CISPLATIN + FLUOROURACIL	2	FLUOROURACIL	7250	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	CIS 35 WK RDE	2	CISPLATIN	63	258684004	10	2021	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	NULL	99	CIS 35 WK RDE	2	CISPLATIN	63	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	630	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	890	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	240	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	270	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	500	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	900	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETO+RITUX C>1	2	RITUXIMAB - RIXATHON	1000	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	NULL	VENETOCLAX-R WK2	2	VENETOCLAX	50	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	FLAIR - IBRUT MA	1	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	420	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	140	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB - CLL	2	IBRUTINIB	420	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	IBRUTINIB-CLL>	2	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	200	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAIN>	2	VENETOCLAX	300	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	5	VENETOCLAX MAINT	2	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	ACALABRUTINIB>	2	ACALABRUTINIB	100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	2	CYCLOPHOSPHAMIDE	350	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	CYCLOPHOSPHAMIDE	1500	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	CYCLOPHOSPHAMIDE	1600	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	96	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE)	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	700	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	VINCRISTINE SULFATE	2	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BEND.	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1600	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1800	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	800	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	VINCRISTINE SULFATE	2	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	300	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	3	LENALID MONO	2	LENALIDOMIDE	20	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	3	LENALID MONO	2	LENALIDOMIDE	20	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	3	LENALID MONO	2	LENALIDOMIDE	20	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	5	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	100	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	CHOP R - 21 days	2	VINCRISTINE SULFATE	2	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5

Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	OBINUTUZUMAB	900	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	RCEOP	2	CYCLOPHOSPHAMIDE	600	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	20	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	50	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	50	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	2	DASATINIB	50	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE 90 CYC1	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	3	2022	RH8	7
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Imatinib 400mg	2	IMATINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	150	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	150	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE90 CYC>1	2	IMATINIB	200	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	98	HYD AML/CML 1DAY	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	98	Imatinib 400mg	2	IMATINIB	400	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	10	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	10	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	15	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	15	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	20	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	10	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	5	Busulfan Oral	2	BUSULFAN	2	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	5	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	8
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	9
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	2000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	1	99	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	1	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	82.5	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	1	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	1	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	LENALIDOMIDE	20	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA	2	OBINUTUZUMAB	1000	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN MAINT	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	75	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	75	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	PEMBRO 553 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	15
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET	2	DABRAFENIB	150	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET	2	DABRAFENIB	150	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	DABRAFENIB	150	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	DABRAFENIB	150	258684004	10	2021	RH8	7
Malignant melanoma of skin	C43X	3	NULL	ECT - BLEOMYCIN	2	BLEOMYCIN	32500	408102007	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR + BINIM	2	BINIMETINIB	45	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR + BINIM C2	2	BINIMETINIB	45	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	30	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	30	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	200	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	450	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	Ipilimumab	2	IPILIMUMAB	250	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	700	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5

Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	PACLITAXEL	300	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	CARBOPLATIN	500	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	LIPOSOMAL DOXORUBICIN	50	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	LIPOSOMAL DOXORUBICIN	50	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	CARBOPLATIN	500	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	PACLITAXEL	300	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	CARBOPLATIN	400	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	300	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	400	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	GEMCITABINE	1300	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB - RDE	NIRAPARIB	200	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >	NIRAPARIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >	NIRAPARIB	100	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	FLUDARABINE PHOSPHATE	70	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	RITUXIMAB - RIXATHON	900	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Ibrutinib	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	OBIN + CHLORAM	CHLORAMBUCIL	32	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	OBIN + CHLORAM	OBINUTUZUMAB	100	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	Obin+Venet C7-12	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETO+RITUX C>1	RITUXIMAB - RIXATHON	1100	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETOCLAX MAINT	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	99	Obin+Venet Cy3-6	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	5	VENETOCLAX MAINT	VENETOCLAX	400	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	5	VENETOCLAX MAINT	VENETOCLAX	400	258684004	10	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	5	VENETOCLAX MAINT	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB>	ACALABRUTINIB	100	258684004	2	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	FCR Oral - Cycle 1	FLUDARABINE PHOSPHATE	90	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Nilotinib	NILOTINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	1	Nilotinib	NILOTINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Nilotinib	NILOTINIB	300	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Nilotinib	NILOTINIB	300	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	CYCLOPHOSPHAMIDE	1500	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	VINCISTINE SULFATE	2	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	VINCISTINE SULFATE	2	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	NULL	98	HYDROXY 3/4 -	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	NULL	99	HYDROXY 5/2-	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 3/4 -	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 3/4 -	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 7 DAYS-	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	8
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	2000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 7 DAYS-	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAYS	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	Imatinib 400mg	IMATINIB	200	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	Nilotinib	NILOTINIB	300	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	PONATINIB - C2	PONATINIB	30	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	1	Nilotinib	NILOTINIB	300	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE	BOSUTINIB	500	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	BOSUTINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	BOSUTINIB - RDE>	BOSUTINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	DASATINIB	100	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE 90 CYC1	IMATINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	IMATINIB	200	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	IMATINIB	200	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	IMATINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	IMATINIB	400	258684004	12	2021	RH8	7
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Imatinib 400mg	IMATINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Imatinib 400mg	IMATINIB	400	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	NILOTINIB	150	258684004	11	2021	RH8	<5

Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	200	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	400	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	15	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	20	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	9	98	Ruxolitinib	2	RUXOLITINIB	5	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	9	98	Ruxolitinib	2	RUXOLITINIB	10	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	CISPLATIN	89	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R GCVP	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	150	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	VINCRISTINE SULFATE	2	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	ETOPOSIDE	80	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP - 21 days	2	VINCRISTINE SULFATE	2	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	2022	RH8	6
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	11	2021	RH8	7
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	12	2021	RH8	10
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	3	2022	RH8	6
Malignant melanoma of skin	C43X	3	NULL	NIVO SKIN 4WK	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPIL RDE -	2	Nivolumab	58	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	TVEC >1	2	TALIMOGENE LAHERPAREPVEC 10*8	1	74964007	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	1	NIVO SKIN 4WK	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	75	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	75	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	TRAMETINIB	1.5	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	11	2021	RH8	7
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	20	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	2	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	PACLITAXEL	120	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	DEXAMETHASONE	2	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	15	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	16	258684004	12	2021	RH8	<5
Malignant neoplasm of base of tongue	C01X	NULL	99	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	ETOPOSIDE	148	258684004	11	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	VDC >1	2	VINCRISTINE SULFATE	2	258684004	12	2021	RH8	<5
Malignant neoplasm of gallbladder	C23X	1	1	CAPE ADJ CHOLAN	2	CAPECITABINE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	200	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	200	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA	2	Olaparib	300	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	BEVACIZUMAB	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	BEVACIZUMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	Olaparib	300	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAPARIB Main>	2	Olaparib	300	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	OLAPARIB Main>	2	Olaparib	250	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	OLAPARIB -RDE>	2	Olaparib	250	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	4	NULL	NIRAPARIB 1st >	2	NIRAPARIB	200	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Cabazitaxel	2	CABAZITAXEL	40	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	1	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	80	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	500	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	10	2021	RH8	7
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	CYCLOPHOSPHAMIDE	1300	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5

Follicular lymphoma, unspecified	C829	3	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	99	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	DABRAFENIB	150	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	DABRAFENIB	150	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	30	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	30	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	45	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 357 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	PONATINIB - C3>	2	PONATINIB	15	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	BOSUTINIB - RDE>	2	BOSUTINIB	500	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Imatinib 400mg	2	IMATINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	PONATINIB - C3>	2	PONATINIB	30	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	98	Imatinib 400mg	2	IMATINIB	400	258684004	3	2022	RH8	<5
Chronic myelomonocytic leukaemia	C931	3	NULL	HYD AML/CML 3/4>	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	3	Ruxolitinib	2	RUXOLITINIB	15	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	5	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	10	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	15	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	20	258684004	10	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	20	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	9	98	Ruxolitinib	2	RUXOLITINIB	5	258684004	3	2022	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	3	5	BEXAROTENE>	2	BEXAROTENE	225	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	ESHAP R	2	ETOPOSIDE	68	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	88	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R-GDP(RDE)	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	15
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	9
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	20
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	8
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	2000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	1	98	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	Rituximab (Maintenance)	2	RITUXIMAB - RIXATHON	500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	12	2021	RH8	10
Diffuse large B-cell lymphoma	C833	3	1	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R-	2	VINCRISTINE SULFATE	0.81	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R C>1	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BEND.	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BENDA	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BENDA	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	CYCLOPHOSPHAMIDE	1400	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	VINCRISTINE SULFATE	2	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	96	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	VINCRISTINE SULFATE	2	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE)	2	GEMCITABINE	1500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE)	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5

Diffuse large B-cell lymphoma	C833	3	5	R-GDP(RDE)	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	5	R-GDP(RDE)	2	GEMCITABINE	2000	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	5	R-GDP(RDE)	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	500	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	VINCRIStINE SULFATE	2	258684004	3	2022	RH8	<5
Malignant neoplasm of gallbladder	C23X	1	1	CAPE ADJ CHOLAN	2	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL	2	AVELUMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4-	2	AXITINIB	5	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AXITINIB	5	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO/PII RCC +	2	Nivolumab	160	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	25	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	25	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	1	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	75	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	75	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	TRAMETINIB	1.5	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1300	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	2	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	PACLITAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm of base of tongue	C01X	NULL	99	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	2	99	AMM AND MIFAM	2	MIFAMURTIDE	4	258684004	11	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	ETOPOSIDE	120	258684004	1	2022	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	IFOSFAMIDE	2160	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	CABOZANTIN RDE >	2	CABOZANTINIB	60	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	CABOZANTIN RDE >	2	CABOZANTINIB	60	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AXITINIB	2	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL	2	AXITINIB	5	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4-	2	AVELUMAB	800	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4-	2	AVELUMAB	800	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Cabazitaxel	2	CABAZITAXEL	40	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	DEXAMETHASONE	0.5	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	120	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	26
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	27
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	40	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	10	2021	RH8	7
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	120	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	1	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5

Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	CYCLOPHOSPHAMIDE	1300	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	OBINUTUZUMAB	1000	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	OBINUTUZUMAB	1000	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	CVP R	2	CYCLOPHOSPHAMIDE	1400	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	LENALIDOMIDE	20	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	LENALIDOMIDE	20	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	R-GDP(RDE)	2	GEMCITABINE	2000	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	NULL	RCEOP	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1200	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	2	2022	RH8	6
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	11	2021	RH8	12
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R >1	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	Methotrexate intrathecal	2	METHOTREXATE	12	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BEND.	2	POLATUZUMAB VEDOTIN	128	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R CODOX M	2	DOXORUBICIN HYDROCHLORIDE	70	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R IVAC	2	CYTARABINE	3600	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	108	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	108	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1400	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BEND.	2	POLATUZUMAB VEDOTIN	152	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	Cytarabine+Methotrexate Intrat	2	METHOTREXATE	12.5	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	NULL	99	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	NULL	99	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	2000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	1	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO RCC 4WK	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	1	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin+Fluorouracil 4 or 5 d	2	CARBOPLATIN	700	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	220	258684004	11	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	CIS 35 WK RDE	2	CISPLATIN	56	258684004	11	2021	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	72	258684004	1	2022	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	72	258684004	3	2022	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	72	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	630	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	240	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	270	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	336	258684004	2	2022	RH8	<5

Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m	2	BEVACIZUMAB	450	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4-	2	AXITINIB	5	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AXITINIB	2	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AXITINIB	2	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	20	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO/IPI RCC -	2	Nivolumab	160	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO/IPI RCC +	2	IPILIMUMAB	50	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	600	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	PAZOPANIB - RDE+	2	PAZOPANIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	25	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	37.5	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC -	2	Nivolumab	160	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC +	2	Nivolumab	160	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	25	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	25	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	50	258684004	2	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	164	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine	2	CAPECITABINE	900	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	165	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	55	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	200	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	800	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	360	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	1	2022	RH8	<5
Idiopathic thrombocytopenic purpura	D693	3	98	Rituximab	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Idiopathic thrombocytopenic purpura	D693	3	98	Rituximab	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	75	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	1	99	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	DABRAFENIB	150	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	DABRAFENIB	150	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ECT - BLEOMYCIN	2	BLEOMYCIN	26250	408102007	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	45	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	200	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	Ipilimumab	2	IPILIMUMAB	250	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO MAIN 4WK>>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO SKIN 4WK	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPIL RDE -	2	IPILIMUMAB	175	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPIL RDE -	2	IPILIMUMAB	175	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPIL RDE -	2	Nivolumab	68	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	6
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	6
Malignant melanoma of skin	C43X	3	1	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET	2	TRAMETINIB	1.5	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	200	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	200	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	RITUXIMAB - RIXATHON	800	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	RITUXIMAB - RIXATHON	800	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	CISPLATIN	145	258684004	1	2022	RH8	<5

Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	CISPLATIN	145	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	CISPLATIN	145	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	GEMCITABINE	1500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1400	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BEND.	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BEND.	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	800	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	800	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE)	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	CISPLATIN	128	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	GEMCITABINE	1800	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		BEVACIZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		CARBOPLATIN	700	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		CARBOPLATIN	890	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		CARBOPLATIN	890	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		CARBOPLATIN	890	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxe(m 2		PACLITAXEL	270	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2		DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2		LIPOSOMAL DOXORUBICIN	50	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2		LIPOSOMAL DOXORUBICIN	54	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2		CARBOPLATIN	790	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	270	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	300	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	360	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	240	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	450	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1200	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1200	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2		FLUOROURACIL	500	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2		FLUOROURACIL	500	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2		IRINOTECAN HYDROCHLORIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2		FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2		OXALIPLATIN	180	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2		OXALIPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	350	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	350	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	2250	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	3150	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine + Oxaliplatin 21day 2		CAPECITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine + Oxaliplatin 21day 2		CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine + Oxaliplatin 21day 2		OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2		CETUXIMAB	700	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2		FLUOROURACIL	2500	258684004	3	2022	RH8	<5
Malignant neoplasm of thymus	C37X	3	NULL	Carboplatin + Etoposide IV 3 day 2		CARBOPLATIN	330	258684004	12	2021	RH8	<5
Malignant neoplasm of thymus	C37X	3	NULL	Carboplatin + Etoposide IV 3 day 2		ETOPOSIDE	148	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	6
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	5	Busulfan Oral	2	BUSULFAN	30	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	26
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	10
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	10	2021	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	3	99	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	99	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	99	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	6
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5

Follicular lymphoma, unspecified	C829	3	1	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	3	LENALID MONO	2	LENALIDOMIDE	20	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	5	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	NIVO H+N C19>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	CIS 35 WK RDE	2	CISPLATIN	63	258684004	2	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	3	PEMBRO H+N	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of other and unspecified parts of tongue	C02X	3	3	PEMBRO H+N	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of other and unspecified parts of tongue	C02X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	500	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	560	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	350	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	350	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	500	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	600	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	TRAMETINIB	1.5	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	Dabrafenib	2	DABRAFENIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1650	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	20	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	20	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	CARBOPLATIN	700	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	PACLITAXEL	162	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1150	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	9	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	9	1	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	20	258684004	3	2022	RH8	<5
Malignant neoplasm of base of tongue	C01X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	2	99	AMM AND MIFAM	2	MIFAMURTIDE	4	258684004	10	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	2	99	AMM AND MIFAM>	2	MIFAMURTIDE	4	258684004	12	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	3	3	Cisplatin + Doxorubicin	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	IFOSFAMIDE	2160	258684004	2	2022	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	IFOSFAMIDE	2640	258684004	10	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	VDC >1	2	DOXORUBICIN HYDROCHLORIDE	55	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AVELUMAB	800	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	VINCRISTINE SULFATE	2	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	Cytarabine+Methotrexate Intrat2	2	CYTARABINE	50	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	6
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	1	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Liposomal Doxorubicin 50mg/m22	2	LIPOSOMAL DOXORUBICIN	66	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Liposomal Doxorubicin 50mg/m22	2	LIPOSOMAL DOXORUBICIN	66	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >>	2	NIRAPARIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>	2	Olaparib	300	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	Olaparib	300	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	96	258684004	2	2022	RH8	<5

Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	144	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	144	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Treosulfan	2	TREOSULFAN	500	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	OLAPARIB -RDE>	2	Olaparib	250	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	9	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON-(C19)	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE Cy-1	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Cabazitaxel	2	CABAZITAXEL	40	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	120	258684004	2	2022	RH8	<5
Malignant neoplasm of thymus	C37X	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	148	258684004	12	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	NULL	LENVATINIB>	2	LENVATINIB - LENVIMA	4	258684004	10	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	3	CABOZ MTC -	2	CABOZANTINIB	140	258684004	11	2021	RH8	<5
Malignant neoplasm of ureter	C66X	1	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	CISPLATIN	128	258684004	3	2022	RH8	<5
Malignant neoplasm of ureter	C66X	9	98	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	500	258684004	1	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	164	258684004	1	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	164	258684004	2	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	164	258684004	3	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	725	258684004	10	2021	RH8	<5
Malignant neoplasm: Adrenal gland, unspecified	C749	3	3	Mitotane 3 - 3.5g	2	MITOTANE	500	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Fluorouracil+Mitomycin+RT (Blac 2	2	FLUOROURACIL	3950	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Fluorouracil+Mitomycin+RT (Blac 2	2	FLUOROURACIL	3950	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Fluorouracil+Mitomycin+RT (Blac 2	2	MITOMYCIN	22	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	GemCarbo Days 1+8	2	CARBOPLATIN	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	CISPLATIN	113	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	CYCLOPHOSPHAMIDE	1300	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	OBINUTUZUMAB	1000	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	RCEOP	2	ETOPOSIDE	40	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	99	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	2000	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	CVP R	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	CVP R	2	VINCISTINE SULFATE	2	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	75	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	PEMBRO 553 6WK	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	12
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	CARBOPLATIN	630	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	CARBOPLATIN	790	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	PACLITAXEL	198	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	PACLITAXEL	270	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	PACLITAXEL	300	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliavel(m 2	2	PACLITAXEL	300	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	LIPOSOMAL DOXORUBICIN	50	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	450	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	630	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	300	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	336	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	300	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	330	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	330	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	450	258684004	10	2021	RH8	<5

Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AVELUMAB	800	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4-	2	AXITINIB	2	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	20	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	PAZOPANIB - RDE+	2	PAZOPANIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	25	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	37.5	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	37.5	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	20	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTINIB RDE	2	CABOZANTINIB	40	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO RCC 4WK	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC -	2	IPILIMUMAB	50	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	25	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	6
Essential (haemorrhagic) thrombocytthaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	5	Busulfan Oral	2	BUSULFAN	30	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	5	Busulfan Oral	2	BUSULFAN	30	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	98	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	1500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytthaemia	D473	3	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	300	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1300	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1300	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Liposomal Doxorubicin 50mg/m2	2	LIPOSOMAL DOXORUBICIN	100	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >	2	NIRAPARIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA	2	BEVACIZUMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA	2	Olaparib	300	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	BEVACIZUMAB	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	Olaparib	300	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAPARIB Main	2	Olaparib	300	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAPARIB Main>	2	Olaparib	200	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAPARIB Main>	2	Olaparib	200	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	96	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	96	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	96	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	Bevacizumab 15mg/kg	2	BEVACIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	4	NULL	NIRAPARIB 1st >	2	NIRAPARIB	200	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	4	NULL	NIRAPARIB 1st >	2	NIRAPARIB	200	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	9	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	9	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	1	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	500	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	11	2021	RH8	10
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	DEXAMETHASONE	0.5	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	10	2021	RH8	6

Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	164	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	12	2021	RH8	7
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	80	258684004	12	2021	RH8	6
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	35
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMG>4	1	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET	2	TRAMETINIB	2	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	45	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	45	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	450	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPIL RDE -	2	Nivolumab	58	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET	2	DABRAFENIB	100	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	100	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	100	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	10	2021	RH8	7
Malignant melanoma of skin	C43X	3	3	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	12	2021	RH8	7
Malignant melanoma of skin	C43X	3	3	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	9	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	800	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	CARBOPLATIN	790	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	PACLITAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)	2	CISPLATIN	128	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8)	2	CISPLATIN	128	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8)	2	GEMCITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB >>	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB >>	2	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Cisplatin + Gemcitabine (D 1 & 8)	2	GEMCITABINE	1300	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	GEMCITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	NULL	Cisplatin + Gemcitabine (D 1 & 8)	2	GEMCITABINE	1600	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	260	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	GemCarbo Days 1+8	2	CARBOPLATIN	330	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	NULL	Temozolomide 150mg/m2	2	TEMOZOLOMIDE	265	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV - RDE	2	LOMUSTINE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV - RDE	2	PROCARBAZINE	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV - RDE	2	VINCRISTINE SULFATE	1.8	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	300	258684004	1	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	11	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	NIVO H+N C19	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	200	258684004	2	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	72	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	400	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	500	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	700	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	890	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	890	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	500	258684004	3	2022	RH8	<5

Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	500	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	400	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 5/2	2	HYDROXYCARBAMIDE	1500	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	29
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	7
Essential (haemorrhagic) thrombocythaemia	D473	9	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	300	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	NULL	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	3	LENALID MONO	2	LENALIDOMIDE	20	258684004	1	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	5	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA	2	OBINUTUZUMAB	1000	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	CYCLOPHOSPHAMIDE	1300	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	RCEOP	2	VINCISTINE SULFATE	1	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	LENALID MONO	2	LENALIDOMIDE	20	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	NULL	99	Enzalutamide	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	NULL	99	Enzalutamide	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	NULL	99	Enzalutamide	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	500	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Cabazitaxel	2	CABAZITAXEL	40	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Cabazitaxel	2	CABAZITAXEL	40	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	9
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	10
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	11
Malignant neoplasm of prostate	C61X	3	1	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	80	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	500	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	500	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	12
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	500	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	LOMUSTINE	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	345	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	365	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	395	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	395	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	3	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	275	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	Docetaxel	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)	2	CYCLOPHOSPHAMIDE	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)	2	EPIDUBICIN HYDROCHLORIDE	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)	2	FLUOROURACIL	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	EPIDUBICIN HYDROCHLORIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	1	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	1	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	3	2022	RH8	<5

Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	6
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Cabazitaxel	2	CABAZITAXEL	36	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	7
Malignant neoplasm of prostate	C61X	9	3	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	7
Malignant neoplasm of prostate	C61X	9	3	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm of base of tongue	C01X	NULL	99	PEMBRO H+N	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	3	3	Cisplatin + Doxorubicin	2	CISPLATIN	79	258684004	10	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	ETOPOSIDE	148	258684004	10	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	ETOPOSIDE	148	258684004	12	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	IE	2	IFOSFAMIDE	2640	258684004	12	2021	RH8	<5
Malignant neoplasm of floor of mouth	C04X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of floor of mouth	C04X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AXITINIB	5	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4-	2	AVELUMAB	800	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AVELUMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL >4+	2	AVELUMAB	800	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL>	2	AVELUMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	20	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	630	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	630	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	270	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	300	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	336	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut:2	2	CARBOPLATIN	400	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut:2	2	CARBOPLATIN	450	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut:2	2	CARBOPLATIN	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	450	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	700	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	300	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	300	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	330	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	630	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	9	98	OBIN + BENDA >1	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET	2	TRAMETINIB	2	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET	2	TRAMETINIB	2	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	TRAMETINIB	2	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	TRAMETINIB	2	258684004	10	2021	RH8	7
Malignant melanoma of skin	C43X	3	NULL	ENCOR + BINIM	2	BINIMETINIB	45	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR + BINIM	2	ENCORAFENIB	450	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR + BINIM C2	2	ENCORAFENIB	450	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	BINIMETINIB	45	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	450	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	450	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO MAIN 4WK>>	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO MAIN 4WK>>	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPIL RDE -	2	IPIILIMUMAB	225	258684004	3	2022	RH8	<5

Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPILIM RDE	2	Nivolumab	68	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPILIM RDE	2	Nivolumab	90	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine	2	CAPECITABINE	1650	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	4450	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine	2	CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine	2	CAPECITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2150	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	180	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Cabazitaxel	2	CABAZITAXEL	36	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	DEXAMETHASONE	0.5	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	120	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	120	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	120	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	26
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	1	2022	RH8	7
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	120	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	34
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	36
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	1	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	1	ENZALUTAMIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	1	METFORMIN	850	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Cabazitaxel	2	CABAZITAXEL	34	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	CYCLOPHOSPHAMIDE	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	DOCETAXEL	164	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	EC - CY1	2	EPIDUBICIN HYDROCHLORIDE	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	140	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	160	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	180	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	50	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC	2	Nivolumab	160	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC -	2	Nivolumab	160	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	37.5	258684004	10	2021	RH8	<5

Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	50	258684004	12	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	CISPLATIN + FLUOROURACIL	2	DEXAMETHASONE	2	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	220	258684004	2	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	220	258684004	12	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	CIS 35 WK RDE	2	CISPLATIN	56	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	3	PEMBRO H+N	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	NULL	99	PEMBRO H+N	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of other connective and soft tissue	C49X	3	NULL	Trabectedin	2	TRABECTEDIN	2.55	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	700	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	240	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	200	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA	2	BEVACIZUMAB	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>	2	BEVACIZUMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	Olaparib	300	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAPARIB Main>	2	Olaparib	200	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	OLAPARIB Main	2	Olaparib	250	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	OLAPARIB Main>	2	Olaparib	200	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	TRAMETINIB>	2	TRAMETINIB	1	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	TRAMETINIB>	2	TRAMETINIB	1	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	NULL	99	Enzalutamide	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	NULL	99	Enzalutamide	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	1	99	EMBARK-EN/PL+LE>	1	LEUPROLIDE	22.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	1	99	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	1	99	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	2	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	1	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	1	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	1	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	75	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	100	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	100	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	Dabrafenib	2	DABRAFENIB	75	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	9	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1300	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	MITOMYCIN	20	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	CARBOPLATIN	700	258684004	12	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	PACLITAXEL	162	258684004	10	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	NULL	WKLY PAC+CAR	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	3	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	9	1	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm of base of tongue	C01X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	2	99	PAMM AND MIFAM	2	MIFAMURTIDE	4	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	500	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	600	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3150	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3150	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3950	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	220	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	240	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	800	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	800	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK	2	FLUOROURACIL	350	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK	2	OXALIPLATIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK	2	PANITUMUMAB	440	258684004	10	2021	RH8	<5

Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	2250	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	OXALIPLATIN	120	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	PANITUMUMAB	440	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	1	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	164	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	164	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	6
Malignant neoplasm of prostate	C61X	9	3	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	TRIFLURIDINE/TIPI>	2	TRIFLURIDINE/TIPIRACIL	70	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	220	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	CYCLOPHOSPHAMIDE	1100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	DOCETAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	DOCETAXEL	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCARBO - C1	2	DOCETAXEL	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Loadr	2	CARBOPLATIN	890	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day loading dose 2	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	PACLITAXEL	144	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	CARBOPLATIN	330	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKY PAC+TRAS AD	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	336	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	336	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	630	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	790	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	790	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	890	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	336	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	336	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	LIPOSOMAL DOXORUBICIN	58	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	790	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	300	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	360	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	360	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Cabazitaxel	2	CABAZITAXEL	40	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	80	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	1	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5

Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	500	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	17
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY-1	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	DEXAMETHASONE	0.5	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	11	2021	RH8	7
Malignant neoplasm of bone and articular cartilage of other and unspecified sites	C41X	3	NULL	VDC >1	2	CYCLOPHOSPHAMIDE	1780	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVEL>	2	AXITINIB	5	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO/PI RCC +	2	Nivolumab	180	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	800	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	800	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	PAZOPANIB - RDE+	2	PAZOPANIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	PAZOPANIB - RDE+	2	PAZOPANIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	25	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	37.5	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	50	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	600	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	750	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	1500	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	1500	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	800	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	180	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	400	258684004	11	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	NULL	99	LENVATINIB>	2	LENVATINIB - LENVIMA	14	258684004	3	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	NULL	99	LENVATINIB>	2	LENVATINIB - LENVIMA	14	258684004	12	2021	RH8	<5
Malignant neoplasm of tonsil	C09X	NULL	99	Carboplatin AUC 2 - 5	2	CARBOPLATIN	200	258684004	2	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	3	3	NIVO H+N C19>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	450	258684004	10	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	450	258684004	11	2021	RH8	<5
Malignant neoplasm of ureter	C66X	9	3	ATEZOLIZUMAB	2	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKY PAC+TRAS AD>	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	8
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	CARBOPLATIN	630	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBOHP(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST	2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST	2	CAPECITABINE	2300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	164	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC	2	CYCLOPHOSPHAMIDE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC - CY1	2	CYCLOPHOSPHAMIDE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5

Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	400	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1200	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1200	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	MIRASOL PAC WKLY	1	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >	2	NIRAPARIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	200	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	OLAP/BEVA>>	2	BEVACIZUMAB	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	96	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	Bevacizumab 15mg/kg	2	BEVACIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	OLAPARIB -RDE>	2	Olaparib	250	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	TRAMETINIB>	2	TRAMETINIB	1	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	4	NULL	NIRAPARIB 1st >	2	NIRAPARIB	200	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1 2	2	CETUXIMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3150	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3500	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	260	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK	2	FLUOROURACIL	2250	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	500	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	2250	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	OXALIPLATIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	OXALIPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	PANITUMUMAB	440	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	PANITUMUMAB	440	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	700	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	800	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	250	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTINIB RDE	2	CABOZANTINIB	40	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO RCC 4WK	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	25	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	700	258684004	12	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	Carboplatin+Fluorouracil 4 or 5 d 2	2	CARBOPLATIN	790	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	220	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	NULL	99	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	630	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	790	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	240	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	336	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	450	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	890	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	890	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	25
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	80	258684004	11	2021	RH8	7
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	1	ENZALUTAMIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5

Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	6
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	7
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	2	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	148	258684004	10	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	11	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	12	2021	RH8	<5
Malignant neoplasm: Adrenal gland, unspecified	C749	3	3	MITOTANE 4.5-9.0	2	MITOTANE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Fluorouracil+Mitomycin+RT (Blac	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Fluorouracil+Mitomycin+RT (Blac	2	MITOMYCIN	18	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	GemCarbo Days 1+8	2	GEMCITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	GEMCITABINE	1800	258684004	3	2022	RH8	6
Malignant neoplasm: Bladder, unspecified	C679	2	1	Fluorouracil+Mitomycin+RT (Blac	2	FLUOROURACIL	5650	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	ATEZOLIZUMAB>	2	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	CISPLATIN	128	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	CISPLATIN	145	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	450	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	220	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Cisplatin + Gemcitabine (D 1 & 8) 2	2	CISPLATIN	113	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	330	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	2	DEXAMETHASONE	8	258684004	3	2022	RH8	12
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	144	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	WKY PAC+TRAS AD>	2	PACLITAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	FLUOROURACIL	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	FLUOROURACIL	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 8 15	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	120	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD>	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	16
Malignant neoplasm: Breast, unspecified	C509	2	1	KADCYLA ADJ ECHO	2	TRASTUZUMAB - EMTANSINE	148	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON>(C19)	2	DEXAMETHASONE	0.5	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	9
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	DEXAMETHASONE	0.5	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	3500	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	700	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	1500	258684004	1	2022	RH8	<5

Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2	FLUOROURACIL	500	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2	IRINOTECAN HYDROCHLORIDE	220	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2	IRINOTECAN HYDROCHLORIDE	400	258684004	10	2021	RH8	<5
Malignant neoplasm of thymus	C37X	3	NULL	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Malignant neoplasm of thymus	C37X	3	NULL	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	200	258684004	2	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	NULL	99	LENVATINIB>	LENVATINIB - LENVIMA	20	258684004	10	2021	RH8	<5
Malignant neoplasm of tonsil	C09X	NULL	99	Carboplatin AUC 2 - 5	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	3	3	NIVO H+N C19>	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	3	3	NIVO H+N C19>	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	3	3	NIVO H+N C19>	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	ATEZOLIZUMAB	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	100	258684004	3	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	240	258684004	10	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Adrenal gland, unspecified	C749	3	3	Mitotane 5.5 - 10g	MITOTANE	1500	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	BEVACIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	BEVACIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	BEVACIZUMAB	500	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	BEVACIZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	CARBOPLATIN	560	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	CARBOPLATIN	630	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	PACLITAXEL	216	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	PACLITAXEL	270	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	PACLITAXEL	336	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	LIPOSOMAL DOXORUBICIN	58	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	LIPOSOMAL DOXORUBICIN	58	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	CARBOPLATIN	270	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	GEMCITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide + RT	TEMOZOLOMIDE	130	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide + RT	TEMOZOLOMIDE	135	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide + RT	TEMOZOLOMIDE	145	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	TEMOZOLOMIDE	315	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	TEMOZOLOMIDE	335	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide + RT	TEMOZOLOMIDE	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	TEMOZOLOMIDE	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	LOMUSTINE	160	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	LOMUSTINE	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	LOMUSTINE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	LOMUSTINE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	PROCARBAZINE	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	VINCRISTINE SULFATE	2	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	TEMOZOLOMIDE	290	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	TEMOZOLOMIDE	345	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	3	Temozolomide 200mg/m2	DEXAMETHASONE	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	3	Temozolomide 200mg/m2	TEMOZOLOMIDE	275	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	FEC 100 X 3 - 1	CYCLOPHOSPHAMIDE	800	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ENZALUTAMIDE(C19	ENZALUTAMIDE	160	258684004	3	2022	RH8	11
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine	CAPECITABINE	1600	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	OXALIPLATIN	165	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	165	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1650	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	200	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1300	258684004	1	2022	RH8	<5

Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	280	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1 2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2	FLUOROURACIL	500	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2	FLUOROURACIL	550	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	KADCYLA ADJ>1	TRASTUZUMAB - EMTANSINE	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHESGO -	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHESGO*	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	DOCETAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	CARBOPLATIN	790	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	CARBOPLATIN	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	PACLITAXEL	162	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	CARBOPLATIN	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	PACLITAXEL	162	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	FLUOROURACIL	1100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOADJ TPH(sc)>	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	KADCYLA ADJ>1	TRASTUZUMAB - EMTANSINE	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)+	CARBOPLATIN	630	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc 2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc 2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC 1	CARBOPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC 1	PACLITAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE(C19)	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Cabazitaxel	CABAZITAXEL	36	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	DOCETAXEL	120	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	ENZALUTAMIDE	80	258684004	3	2022	RH8	6
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	ENZALUTAMIDE	120	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	ENZALUTAMIDE	80	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	ENZALUTAMIDE	160	258684004	3	2022	RH8	42
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	ENZALUTAMIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	7
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Cabazitaxel	CABAZITAXEL	36	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERON>(C19)	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE-	DEXAMETHASONE	0.5	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE(C19)	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	CISPLATIN	128	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	CISPLATIN	145	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	GEMCITABINE	1600	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	GEMCITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	GEMCITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8)2	GEMCITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB >>	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB>	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB>	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB>	ATEZOLIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	GEMCITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	GEMCITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	CISPLATIN	128	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	GemCarbo Days 1+8	CARBOPLATIN	330	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	GemCarbo Days 1+8	GEMCITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV	PROCARBAZINE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV	VINCRISTINE SULFATE	2	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Liposomal Doxorubicin 50mg/m2 2	LIPOSOMAL DOXORUBICIN	66	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >	NIRAPARIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB 1st >	NIRAPARIB	200	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	NIRAPARIB	200	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Treosulfan	TREOSULFAN	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	Bevacizumab 15mg/kg	BEVACIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	9	NULL	Bevacizumab 7.5mg/kg	BEVACIZUMAB	450	258684004	11	2021	RH8	<5

Malignant neoplasm of prostate	C61X	NULL	99	Enzalutamide	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	2	1	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	2	1	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	500	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	108	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	80	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	80	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	FLUOROURACIL	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	CAPE ADJ BREAST	2	CAPECITABINE	1650	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	CAPE ADJ BREAST	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	CAPE ADJ BREAST	2	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	DOCETAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	DOCETAXEL	164	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	EC	2	CYCLOPHOSPHAMIDE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	EC	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	750	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor	2	FLUOROURACIL	700	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor	2	FLUOROURACIL	3500	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	220	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan 14day	2	IRINOTECAN HYDROCHLORIDE	280	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	OXALIPLATIN	150	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	700	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	4450	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	240	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	300	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	360	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	900	258684004	11	2021	RH8	<5
Malignant neoplasm of thymus	C37X	3	NULL	Carboplatin + Etoposide IV 3 day	2	CARBOPLATIN	330	258684004	1	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	3	CABOZ MTC -	2	CABOZANTINIB	140	258684004	2	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	NULL	99	Carboplatin AUC 2 - 5	2	CARBOPLATIN	200	258684004	3	2022	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ATEZO/NAB PAC>	2	PACLITAXEL ALBUMIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	TRASTUZUMAB DERUXTECAN	280	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	TRASTUZUMAB DERUXTECAN	280	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU-ECHO	2	DEXAMETHASONE	2	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EXEMESTANE	25	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	1	2022	RH8	7
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	1	2022	RH8	6

Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	2	2022	RH8	6
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	TRIFLURID/TIPIR	2	TRIFLURIDINE/TIPIRACIL	70	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	800	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV - RDE	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 150mg/m2	2	TEMOZOLOMIDE	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	315	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	315	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	335	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 150mg/m2	2	TEMOZOLOMIDE	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	DEXAMETHASONE	6	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	LOMUSTINE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	VINCISTINE SULFATE	2	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	345	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	395	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	3	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	275	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	Docetaxel	2	DOCETAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	Docetaxel	2	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	RIBO & LETROZ 2	2	RIBOCICLIB	600	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	1	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	80	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	500	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	11
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	9
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	500	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	DEXAMETHASONE	0.5	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Cabazitaxel	2	CABAZITAXEL	36	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	1	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIDUBICIN HYDROCHLORIDE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	650	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIDUBICIN HYDROCHLORIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIDUBICIN HYDROCHLORIDE	180	258684004	11	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ>1	2	TRASTUZUMAB - EMTANSINE	220	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	CYCLOPHOSPHAMIDE	1100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	DOCETAXEL	148	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCARBO - C1	2	CARBOPLATIN	560	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint 2	2	CARBOPLATIN	890	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint 2	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint 2	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	GEMCITABINE	1400	258684004	10	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	270	258684004	10	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	CISPLATIN	145	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	GEMCITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	GemCarbo Days 1+8	2	CARBOPLATIN	360	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	GemCarbo Days 1+8	2	GEMCITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	CISPLATIN	128	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8) 2	2	GEMCITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Fluorouracil+Mitomycin+RT (Blac 2	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Fluorouracil+Mitomycin+RT (Blac 2	2	MITOMYCIN	24	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB>	2	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	330	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	NULL	Cisplatin + Gemcitabine (D 1 & 8) 2	2	CISPLATIN	113	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	NULL	Cisplatin + Gemcitabine (D 1 & 8) 2	2	GEMCITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day) 2	2	CISPLATIN	128	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	EXEMESTANE	25	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	10	2021	RH8	6
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >3	2	RIBOCICLIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >3	2	RIBOCICLIB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO + FULVEST	2	RIBOCICLIB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	WK THP>(SC)	2	DOCETAXEL	40	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>	2	ABEMACICLIB	50	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1350	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1350	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1650	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	650	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	220	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	350	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	PANITUMUMAB	700	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine	2	CAPECITABINE	2500	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	250	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	4450	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	4450	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	250	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	400	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	900	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMJ>4	1	ENZALUTAMIDE	120	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Cabazitaxel	2	CABAZITAXEL	44	258684004	1	2022	RH8	<5

Malignant neoplasm of prostate	C61X	9	NULL	Cabazitaxel	2	CABAZITAXEL	44	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERON>(C19)	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE RDE	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	164	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	6
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	9
Malignant neoplasm of prostate	C61X	9	3	ENZALUTAMIDE(C19	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	7
Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY-1	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	PACLITAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	CARBOPLATIN	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	CARBOPLATIN	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	PACLITAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	PACLITAXEL	144	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBOHP(SC)	2	CARBOPLATIN	700	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST1	2	CAPECITABINE	1900	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST1	2	CAPECITABINE	2400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel + Trastuzumab (Load)	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel + Trastuzumab (Maint)	2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC - CY1	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	CYCLOPHOSPHAMIDE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	CYCLOPHOSPHAMIDE	1100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	CYCLOPHOSPHAMIDE	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	CYCLOPHOSPHAMIDE	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO*	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)>	2	DOCETAXEL	96	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	148	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	164	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	164	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	ZOLEDRONIC ACID ADJ	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Load)	2	DOCETAXEL	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	DOCETAXEL	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	650	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	750	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	DEXAMETHASONE	2	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	335	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	350	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	350	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	390	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	3	3	EVEROLIMUS SEGA>	2	EVEROLIMUS	5	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	DEXAMETHASONE	6	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	LOMUSTINE	160	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	LOMUSTINE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	VINCRISTINE SULFATE	1.6	258684004	10	2021	RH8	<5

Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	260	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	345	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	365	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1650	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	2	PACLITAXEL	96	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	2	PACLITAXEL	120	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LULV >2	2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PLASMAMATCH E>	1	AZD6738	160	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	2	RIBOCICLIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ 2	2	RIBOCICLIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	SACITUZ GOVIT>	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	SACITUZ GOVIT>	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (1st cycle)	2	TRASTUZUMAB - EMTANSINE	280	258684004	11	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	NULL	99	LENVATINIB>	2	LENVATINIB - LENVIMA	14	258684004	2	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	NULL	99	LENVATINIB>	2	LENVATINIB - LENVIMA	14	258684004	11	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	3	CABOZ MTC -	2	CABOZANTINIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	3	1	CIS 35 WK RDE	2	CISPLATIN	70	258684004	12	2021	RH8	<5
Malignant neoplasm of tonsil	C09X	3	3	NIVO H+N C19>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	270	258684004	10	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	GEMCITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm of ureter	C66X	9	3	ATEZOLIZUMAB>	2	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	330	258684004	10	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	500	258684004	12	2021	RH8	<5
Malignant neoplasm: Adrenal gland, unspecified	C749	3	3	MITOTANE 4.5-9.0	2	MITOTANE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Adrenal gland, unspecified	C749	3	3	MITOTANE 4.5-9.0	2	MITOTANE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	CISPLATIN	128	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	CISPLATIN	145	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Fluorouracil+Mitomycin+RT (Blac 2	2	MITOMYCIN	22	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	99	Capecitabine	2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine	2	CAPECITABINE	1400	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine	2	CAPECITABINE	1500	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3150	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	220	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	280	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	PAN/OX/MDG 2WK>	2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	700	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	220	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	FLUOROURACIL	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	132	258684004	3	2022	RH8	6
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	12	2021	RH8	8
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD>	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	750	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	CYCLOPHOSPHAMIDE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCARBO	2	CARBOPLATIN	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	12	2021	RH8	8
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	CARBOPLATIN	330	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	395	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	Docetaxel	2	DOCETAXEL	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)	2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	CYCLOPHOSPHAMIDE	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	FLUOROURACIL	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)>	2	DOCETAXEL	88	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	164	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	EC - CY1	2	CYCLOPHOSPHAMIDE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	ATEZOLIZUMAB	2	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB >>	2	ATEZOLIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB>	2	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	330	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	GEMCITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	NULL	Cisplatin + Gemcitabine (D 1 & 8)	2	CISPLATIN	128	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	260	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV	2	LOMUSTINE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV - RDE	2	PROCARBAZINE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide + RT	2	TEMOZOLOMIDE	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 150mg/m2	2	TEMOZOLOMIDE	295	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	285	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	285	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	315	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	350	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	390	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide + RT	2	TEMOZOLOMIDE	150	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	800	258684004	2	2022	RH8	<5

Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	250	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	750	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	IRINOTECAN HYDROCHLORIDE	240	258684004	3	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	3	CABOZ MTC -	CABOZANTINIB	140	258684004	12	2021	RH8	<5
Malignant neoplasm of tonsil	C09X	3	1	CIS 35 WK RDE	CISPLATIN	70	258684004	10	2021	RH8	<5
Malignant neoplasm of tonsil	C09X	3	3	NIVO H+N C19>	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm of ureter	C66X	1	1	Cisplatin + Gemcitabine (D 1 & 8)2	GEMCITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	GEMCITABINE	1600	258684004	2	2022	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	GEMCITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	GEMCITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Paclitaxel (3 week)2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	725	258684004	12	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	1	1	GemCarbo Days 1+8	CARBOPLATIN	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	GEMCITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	ATEZOLIZUMAB >>	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	CARBOPLATIN	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	GEMCITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Cisplatin + Gemcitabine (D 1 & 8)2	GEMCITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Fluorouracil+Mitomycin+RT (Blac 2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Fluorouracil+Mitomycin+RT (Blac 2	MITOMYCIN	24	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB >>	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Cisplatin + Gemcitabine (D 1 & 8)2	CISPLATIN	89	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Cisplatin + Gemcitabine (D 1 & 8)2	CISPLATIN	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	GEMCITABINE	1400	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	NULL	Cisplatin + Gemcitabine (D 1 & 8)2	CISPLATIN	113	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	CISPLATIN	128	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	GemCarbo Days 1+8	GEMCITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	TEMOZOLOMIDE	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	TEMOZOLOMIDE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	TEMOZOLOMIDE	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	3	3	EVEROLIMUS SEGA>	EVEROLIMUS	5	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	PROCARBAZINE	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	PROCARBAZINE	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	PROCARBAZINE	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	VINCRISTINE SULFATE	1.6	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	VINCRISTINE SULFATE	2	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	TEMOZOLOMIDE	365	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	TEMOZOLOMIDE	395	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	Docetaxel	DOCETAXEL	148	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	FEC 100 X 3 - 1	EPIRUBICIN HYDROCHLORIDE	160	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)	EPIRUBICIN HYDROCHLORIDE	50	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)	DOCETAXEL	96	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)	DOCETAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	DOCETAXEL	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	DOCETAXEL	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	PACLITAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	PACLITAXEL	162	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID HER -	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	CARBOPLATIN	630	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	CARBOPLATIN	630	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel + Trastuzumab (Maint)2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC	EPIRUBICIN HYDROCHLORIDE	140	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC	EPIRUBICIN HYDROCHLORIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC - CY1	CYCLOPHOSPHAMIDE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	CYCLOPHOSPHAMIDE	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	CYCLOPHOSPHAMIDE	1100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	EPIRUBICIN HYDROCHLORIDE	220	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	FLUOROURACIL	750	258684004	10	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	FLUOROURACIL	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	FLUOROURACIL	1100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHEGSO -	2	ZOLEDRONIC ACID ADJ	3.5	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	1	2022	RH8	9
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST	2	ABEMACICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	2650	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	2650	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Docetaxel	2	DOCETAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHEGSO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHEGSO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHEGSO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Vinorelbine (oral)	2	VINORELBINE	110	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	3.3	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	29
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	790	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	790	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	CARBOPLATIN	890	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO - C1	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO - C1	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	2	PACLITAXEL	162	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	2	CYCLOPHOSPHAMIDE	1100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEO TCARBHP(SC)+	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOAJD TPH(SC)	2	DOCETAXEL	164	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	WKLY CARBO+PACL	2	CARBOPLATIN	120	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	9
Malignant neoplasm: Breast, unspecified	C509	1	98	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	10	2021	RH8	8
Malignant neoplasm: Breast, unspecified	C509	1	98	WKY PAC+TRAS AD>	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	CYCLOPHOSPHAMIDE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	220	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	120	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	3.5	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	EC POST CARB+PAC	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHEGSO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	PCV - RDE	2	LOMUSTINE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide + RT	2	TEMOZOLOMIDE	130	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	285	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	350	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	3	2022	RH8	<5

Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	VINCRIStINE SULFATE	1.6	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	345	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	3	Temozolomide 150mg/m2	2	TEMOZOLOMIDE	275	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	FEC 100 X 3 - 1	2	FLUOROURACIL	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)	2	CYCLOPHOSPHAMIDE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	FLUOROURACIL	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)	2	DOCETAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ TPH(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	450	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	790	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEOADJ TPH(SC)	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEOADJ TPH(sc)>	2	DOCETAXEL	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO	2	CARBOPLATIN	360	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	2	PACLITAXEL	162	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC1	2	CARBOPLATIN	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	CYCLOPHOSPHAMIDE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	CYCLOPHOSPHAMIDE	1100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	CYCLOPHOSPHAMIDE	1100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	2	EPIRUBICIN HYDROCHLORIDE	220	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	1100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ	2	TRASTUZUMAB - EMTANSINE	320	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ>1	2	TRASTUZUMAB - EMTANSINE	320	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCARBO	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCARBO	2	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Loadir	2	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Loadir	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	220	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Load)	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Load)	2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	240	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	900	258684004	12	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	9	NULL	Vinorelbine (oral)	2	VINORELBINE	140	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	WK THP>(SC)	2	DOCETAXEL	60	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	WK THP>(SC)	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	Capecitabine	2	CAPECITABINE	1950	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & FULV	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	NLMT-ARMC>	1	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	NLMT-ARMC>	1	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Carboplatin + Vinorelbine Oral	2	VINORELBINE	90	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Carboplatin + Vinorelbine Oral	2	VINORELBINE	110	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	128	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	2	99	GemCarbo Days 1+8	2	CARBOPLATIN	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	2	99	GemCarbo Days 1+8	2	GEMCITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATE BEV CAR TAX>	2	CARBOPLATIN	270	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)+	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	DOCETAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC 1	2	CARBOPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC 1	2	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	3.5	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ATEZO MAINTEN-	2	ATEZOLIZUMAB	840	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	CAPECITABINE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2300	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CARBO BR CA	2	CARBOPLATIN	450	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	DEXAMETHASONE	2	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	TRASTUZUMAB DERUXTECAN	280	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU-ECHO	2	DEXAMETHASONE	2	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Eribulin	2	ERIBULIN	2.02	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EVEROLIMUS	7.5	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	CAPE ADJ BREAST	2	CAPECITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	CYCLOPHOSPHAMIDE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	DOCETAXEL	132	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	164	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Load)	2	DOCETAXEL	164	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	700	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEAD FEC(FECTPH)	2	CYCLOPHOSPHAMIDE	1100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEAD FEC(FECTPH)	2	FLUOROURACIL	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	WKLY CARBO+PACL	2	CARBOPLATIN	120	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO AD PHESGO -	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	CARBOPLATIN	630	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBOHP(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ATEZO/NAB PAC>	2	ATEZOLIZUMAB	840	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	500	258684004	11	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU-ECHO	2	TRASTUZUMAB DERUXTECAN	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EVEROLIMUS	5	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EVEROLIMUS	7.5	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EVEROLIMUS	7.5	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EXEMESTANE	25	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PAC ALB>	2	PACLITAXEL ALBUMIN BOUND	450	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ	2	TRASTUZUMAB - EMTANSINE	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ>1	2	TRASTUZUMAB - EMTANSINE	320	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	CYCLOPHOSPHAMIDE	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	DOCETAXEL	148	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day loading dose	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	11
Malignant neoplasm: Breast, unspecified	C509	1	1	WKY PAC+TRAS AD	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	DOCETAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBOHP(SC)	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC	2	CYCLOPHOSPHAMIDE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	FLUOROURACIL	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHESGO -	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	CARBOPLATIN	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKY PAC+TRAS AD>	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	11
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST1	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel + Trastuzumab (Maint'	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC	2	EPIRUBICIN HYDROCHLORIDE	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC - CY1	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	PEMETREXED	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	PEMETREXED	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMETREXED	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	240	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Vinorelbine Oral	2	CARBOPLATIN	270	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DABR+TRAM>(C19)	2	TRAMETINIB	2	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DABR+TRAM>(C19)	2	TRAMETINIB	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DABRAF+TRAM(C19)	2	TRAMETINIB	2	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DOCET/NINTED	2	DOCETAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DOCET/NINTED	2	NINTEDANIB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1500	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	80	258684004	1	2022	RH8	6
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL+	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL+	2	PACLITAXEL	270	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 +	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 +	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	POMETREXED	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	POMETREXED	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	POMETREXED	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	POMETREXED	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	POMETREXED	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	POMETREXED	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	6
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBROLIZ>	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Pemetrexed	2	POMETREXED	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	148	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	162	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >1	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >	2	RIBOCICLIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV 2	2	RIBOCICLIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	SACITUZ GOVIT	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	THP (SC)	2	DOCETAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	THP (SC)	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	THP (SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab 21 day loading dose	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (1st cycle)	2	TRASTUZUMAB - EMTANSINE	280	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EXEMESTANE	25	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHEGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHEGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	2	2022	RH8	9
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	162	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	EXEMESTANE	25	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	EXEMESTANE	25	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >	2	RIBOCICLIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (1st cycle)	2	TRASTUZUMAB - EMTANSINE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	280	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Vinorelbine (oral)	2	VINORELBINE	140	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Vinorelbine (oral)	2	VINORELBINE	140	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	WK THP (SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	CAPE/TRAS>	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Docetaxel	2	DOCETAXEL	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Docetaxel	2	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	2	PACLITAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	2	2022	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	CYCLOPHOSPHAMIDE	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	FLUOROURACIL	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	FLUOROURACIL	1100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHEGSO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHEGSO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	8
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHEGSO*	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	144	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	WKY PAC+TRAS AD>	2	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	WKY PAC+TRAS AD>	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHEGSO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD	2	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	3.5	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHEGSO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHEGSO*	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)+	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	148	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	CISPLATIN	45	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	70	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	70	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	60	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	80	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	PEMETREX LUNG 1	2	PEMETREXED	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	ATE BEV CAR TAX>	2	BEVACIZUMAB	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>	2	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO CARBO+ETOP	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1350	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1650	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2300	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	1.63	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ	2	PALBOCICLIB	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	75	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	3	2022	RH8	6
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	10	2021	RH8	6
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO + LETROZ>1	2	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PLASMAMATCH E>	1	Olaparib	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	12	2021	RH8	8

Malignant neoplasm: Breast, unspecified	C509	4	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	DEXAMETHASONE	1	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 7 day	2	PACLITAXEL	84	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	ANASTROZOLE	1	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ	2	RIBOCICLIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	10	2021	RH8	6
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	220	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	99	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	99	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>	2	ABEMACICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	DEXAMETHASONE	1	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Docetaxel	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	2	ERIBULIN	2.2	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	148	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	CARBOPLATIN	500	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEOADJ TPH(sc)>	2	DOCETAXEL	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEOADJ TPH(sc)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	2	CARBOPLATIN	220	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	2	CARBOPLATIN	270	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEAD FEC(FECTPH)	2	EPIRUBICIN HYDROCHLORIDE	220	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	WKLY CARBO+PACL	2	CARBOPLATIN	160	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	CAPE ADJ BREAST	2	CAPECITABINE	2150	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	2	2022	RH8	6
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	3.5	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	CYCLOPHOSPHAMIDE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	FLUOROURACIL	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD	2	PACLITAXEL	144	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD>	2	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	3	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	3.5	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	10	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ>1	2	TRASTUZUMAB - EMTANSINE	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	CYCLOPHOSPHAMIDE	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TCH (21 day Trastuzumab) Maint 2	2	CARBOPLATIN	890	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day loading dose 2	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	PACLITAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	PACLITAXEL	144	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	CARBOPLATIN	270	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PACL	2	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKY PAC+TRAS AD>	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST	2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	CAPE ADJ BREAST	2	CAPECITABINE	1950	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	164	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	ANASTROZOLE	1	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Vinorelbine (oral)	2	VINORELBINE	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	OSIMERT ADJ>	2	Osimertinib	40	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	OSIMERT ADJ>	2	Osimertinib	40	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	PEM CAR TAXOL	2	PACLITAXEL	270	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZ BEV CAR TAX	2	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZ BEV CAR TAX	2	BEVACIZUMAB	700	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Erlotinib	2	ERLOTINIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB >	2	Osimertinib	80	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB >	2	Osimertinib	80	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19	2	Osimertinib	80	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	40	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMB +	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMB +	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	DEXAMETHASONE	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	4	3	Crizotinib	2	CRIZOTINIB	250	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO+	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABRAF+TRAM(C19)	2	DABRAFENIB	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DOCET/NINTED	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEM CAR TAXOL	2	PACLITAXEL	10	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	98	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	99	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Cisplatin 7 day	1	CISPLATIN	56	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	FEC 100	2	FLUOROURACIL	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	FEC 100	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO T CARBOHP(SC)	2	DOCETAXEL	132	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PACL	2	PACLITAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PACL	2	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PACL	2	PACLITAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	CAPECITABINE	1000	258684004	3	2022	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARB+ETOP>	2	CARBOPLATIN	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	560	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	Pemetrexed	700	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	Pemetrexed	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	Pemetrexed	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	Pemetrexed	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	CYCLOPHOSPHAMIDE	1100	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	DOXORUBICIN HYDROCHLORIDE	60	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	ANASTROZOLE	1	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	ANASTROZOLE	1	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Vinorelbine (oral)	2	VINORELBINE	90	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	WK THP (SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	WK THP>(SC)	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	630	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Carboplatin + Vinorelbine Oral	2	CARBOPLATIN	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	90	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	OSIMERT ADJ>	2	Osimertinib	40	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	164	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	PEM CAR TAXOL	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2300	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2300	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EVEROLIMUS	5	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EXEMESTANE	25	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	11	2021	RH8	6
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	132	258684004	12	2021	RH8	9
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	162	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV	2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1150	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	550	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	650	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	3150	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	4450	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	280	258684004	2	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	320	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Oxaliplatin + Modified de Gramo 2	OXALIPLATIN	135	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1650	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	Osimertinib	40	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	Osimertinib	80	258684004	2	2022	RH8	6
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	Osimertinib	80	258684004	10	2021	RH8	8
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL	PACLITAXEL	336	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL+	PACLITAXEL	336	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL+	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	CARBOPLATIN	630	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 +	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	PEMETREXED	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMETREX LUNG 1	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	164	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Vinorelbine Oral 2	VINORELBINE	80	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	99	Cetuximab + Oxaliplatin + MdG h.2	CETUXIMAB	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX	CETUXIMAB	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX>	CETUXIMAB	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX>	ENCORAFENIB	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	280	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	5000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	OXALIPLATIN	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	TRIFLURIDINE/TIPIRACIL	65	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	375	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	2250	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	3950	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Vinorelbine Oral 2	VINORELBINE	90	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day) 2	ETOPOSIDE	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day) 2	ETOPOSIDE	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day) 2	ETOPOSIDE	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day) 2	ETOPOSIDE	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO) 2	VINORELBINE	60	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	DURVAL>(C19)	DURVALUMAB	1500	258684004	11	2021	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	DEXAMETHASONE	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	PEMETREXED	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	PEMETREXED	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	PEMETREXED	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	PEMETREXED	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	450	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATE BEV CAR TAX>	2	PACLITAXEL	270	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>	2	ATEZOLIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>>	2	ATEZOLIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	CAV	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATE BEV CAR TAX>	2	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZ BEV CAR TAX	2	PACLITAXEL	270	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO - NSCLC>	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARBO+ETOP	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARBO+ETOP	2	CARBOPLATIN	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARBO+ETOP	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	360	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	DOXORUBICIN HYDROCHLORIDE	60	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ	2	RIBOCICLIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >	2	RIBOCICLIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO + FULVEST	2	RIBOCICLIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	SACITUZ GOVIT>	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Vinorelbine (oral)	2	VINORELBINE	140	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	Docetaxel	2	DOCETAXEL	164	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV	2	PALBOCICLIB	75	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	2	RIBOCICLIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	2	RIBOCICLIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	SACITUZ GOVIT>	2	SACITUZUMAB GOVITECAN	930	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day loading dose<2	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day maintenanc<2	2	TRASTUZUMAB	600	258684004	1	2022	RH8	7
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day maintenanc<2	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	440	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	2250	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	3150	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	PANITUMUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	RALT/OXALI-MET>	2	OXALIPLATIN	110	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	55	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	40	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	80	258684004	3	2022	RH8	8
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL+	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 -	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	POMETREXED	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	POMETREXED	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	POMETREXED	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	POMETREXED	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	POMETREXED	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Pemetrexed	2	DEXAMETHASONE	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Pemetrexed	2	DEXAMETHASONE	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Erlotinib	2	ERLOTINIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Erlotinib	2	ERLOTINIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ERLOTINIB 2MTH+	2	ERLOTINIB	50	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB >	2	Osimertinib	80	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	80	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	80	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMB +	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMB +	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	POMETREX LUNG 1	2	POMETREXED	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	DEXAMETHASONE	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	DEXAMETHASONE	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	POMETREXED	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Topotecan (oral)	2	TOPOTECAN	3.25	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	POMETREXED	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CARBO/PACL	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABRAF+TRAM(C19)	2	TRAMETINIB	2	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DOCET/NINTED	2	NINTEDANIB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	ECT - BLEOMYCIN	2	BLEOMYCIN	23750	408102007	3	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Liposomal Doxorubicin 50mg/m2	2	LIPOSOMAL DOXORUBICIN	76	258684004	1	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Trabectedin	2	TRABECTEDIN	2.35	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	2	CARBOPLATIN	360	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	2	CISPLATIN	89	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	790	258684004	10	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	890	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	336	258684004	12	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	3	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	1	Imatinib 400mg	2	IMATINIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	1	Imatinib 400mg	2	IMATINIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	1	Imatinib 400mg	2	IMATINIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	2	IMATINIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Nasal cavity	C300	2	NULL	CISPLATIN + FLUOROURACIL	2	DEXAMETHASONE	2	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	NULL	99	OX/CAP B 80	2	CAPECITABINE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	99	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	4	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	4	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	4	NULL	Paclitaxel 7 day	2	PACLITAXEL	108	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>1	2	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	ANASTROZOLE	1	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	2	2022	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	9	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Vinorelbine Oral	2	CARBOPLATIN	270	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	450	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	450	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZ BEV CAR TAX	2	BEVACIZUMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>>	2	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO MAIN SC	2	ATEZOLIZUMAB	1680	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Erlotinib	2	ERLOTINIB	50	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Erlotinib	2	ERLOTINIB	50	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ERLOTINIB 2MTH+	2	ERLOTINIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ERLOTINIB 2MTH+	2	ERLOTINIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB >	2	OSimertinib	80	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB >	2	Osimertinib	80	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19	2	Osimertinib	40	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	Pemetrexed	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	Pemetrexed	500	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	Pemetrexed	750	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMBRO 428 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMBROLIZ>>	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	99	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ-	2	CARBOPLATIN	330	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	950	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	550	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	3500	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	2	CETUXIMAB	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	2	IRINOTECAN HYDROCHLORIDE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3950	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	NULL	99	OX/CAP B 80	2	OXALIPLATIN	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	NULL	99	OX/CAP> B 80	2	OXALIPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	DOCETAXEL	60	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	FLUOROURACIL	3150	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	OXALIPLATIN	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	CARBOPLATIN	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	CARBOPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	CARBOPLATIN	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	84	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	108	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	88	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	96	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	108	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	5650	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	CAPECITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	CISPLATIN	145	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	PEMETREXED	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	ATEZ MAIN SC>	2	ATEZOLIZUMAB	1680	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	GemCarbo Days 1+8	2	GEMCITABINE	1300	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	4	3	Crizotinib	2	CRIZOTINIB	250	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO+	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	Carboplatin + Vinorelbine Oral	2	VINORELBINE	80	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEM CAR TAXOL	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMETREXED	500	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME 1	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMBRO 531 6WK	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Cisplatin 7 day	2	CISPLATIN	70	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGO W CISP/PEM>	1	CISPLATIN	63	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab(Kadcyla?) (1st cycle)	2	TRASTUZUMAB - EMTANSINE	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab(Kadcyla?) (Mainten2	2	TRASTUZUMAB - EMTANSINE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab(Kadcyla?) (Mainten2	2	TRASTUZUMAB - EMTANSINE	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Vinorelbine (oral)	2	VINORELBINE	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	WK THP>(SC)	2	DOCETAXEL	60	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & FULV >1	2	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	NLMT-ARMC>	1	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Carboplatin + Vinorelbine Oral	2	CARBOPLATIN	360	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Carboplatin + Vinorelbine Oral	2	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	OSIMERT ADJ>	2	Osimertinib	40	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	OSIMERT ADJ>	2	Osimertinib	40	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	110	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATE BEV CA TAX>>	2	BEVACIZUMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATE BEV CAR TAX>	2	BEVACIZUMAB	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	KADCYLA ADJ ECHO	2	ZOLEDRONIC ACID ADJ	3	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)+	2	CARBOPLATIN	890	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)+	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	DOCETAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEOADJ TPH(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEOADJ TPH(sc)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO	2	DOCETAXEL	108	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PAC 1	2	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	WKLY CARBO+PACL	2	CARBOPLATIN	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	CYCLOPHOSPHAMIDE	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	2	CYCLOPHOSPHAMIDE	1100	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ	2	BEVACIZUMAB	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ	2	PACLITAXEL	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ-	2	BEVACIZUMAB	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ-	2	PACLITAXEL	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ>	2	PACLITAXEL	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	650	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	3150	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	3950	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	360	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	650	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	3950	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	750	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	TRASTUZUMAB-ONTRUZANT	651	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	CAPECITABINE	2150	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	CISPLATIN	145	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	CISPLATIN	164	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	TRASTUZUMAB-ONTRUZANT	504	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	TRASTUZUMAB-ONTRUZANT	588	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	TRASTUZUMAB-ONTRUZANT	588	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	280	258684004	12	2021	RH8	<5

Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP B 80	2	CAPECITABINE	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP B 80	2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> A 100	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CAPECITABINE	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CAPECITABINE	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	2	CARBOPLATIN	160	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan 14day	2	IRINOTECAN HYDROCHLORIDE	164	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	3500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine	2	CAPECITABINE	1950	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2150	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	1150	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARB+ETOP>	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARBO+ETOP	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	PEMETREXED	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	CARBOPLATIN	360	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	3	2022	RH8	6
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DABR+TRAM>(C19)	2	DABRAFENIB	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DABRAF+TRAM(C19)	2	DABRAFENIB	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	40	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	40	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	4450	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	550	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	3500	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	10	2021	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	2150	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	99	Cetuximab + Oxaliplatin + MdG l 2	OXALIPLATIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	78	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	96	258684004	1	2022	RH8	8
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Cisplatin +Fluorouracil (3 wk) 2	CISPLATIN	40	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Cisplatin +Fluorouracil (3 wk) 2	CISPLATIN	56	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	750	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP> B 80	2	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	NIVO - OESO>>	2	480	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	OX/CAP C 60	2	135	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	1700	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	1700	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	1	99	Gemcitabine 1000mg/m2 D1 8 1'2	GEMCITABINE	1600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	2	220	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	2	1100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEAD FEC(FECTPH)	2	220	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEAD FEC(FECTPH)	2	1100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEO AD PHEGSO	2	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOADJ TPH(SC)	2	164	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	WKLY CARBO+PACL	2	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	KADCYLA ADJ>1	2	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	560	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	630	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	96	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc	2	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC 1	2	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC L	2	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC L	2	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ATEZO/NAB PAC>	2	840	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ATEZO/NAB PAC>*	2	840	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	IRINOTECAN HYDROCHLORIDE	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 1	2	650	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	FLUOROURACIL	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	FLUOROURACIL	450	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	FLUOROURACIL	2500	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	FLUOROURACIL	3500	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	3500	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	75	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPIR	2	65	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPIR	2	70	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	2	1150	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1150	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1250	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1250	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1300	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	40	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	560	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	2	400	258684004	3	2022	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	PEMETREXED	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	PEMETREXED	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBROLIZ>	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Vinorelbine Oral	2	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	CISPLATIN	70	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	132	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	113	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	164	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	80	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX>	2	CETUXIMAB	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX>	2	ENCORAFENIB	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramo 2	2	FLUOROURACIL	2500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	550	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	3500	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	PEMB 6WK COLREC	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	PEMB 6WK COLREC	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	65	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	65	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	65	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX	2	IRINOTECAN HYDROCHLORIDE	260	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	FLUOROURACIL	3150	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	IRINOTECAN HYDROCHLORIDE	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	650	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	OXALIPLATIN	165	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	DOCETAXEL	108	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	FLUOROURACIL	5650	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	OXALIPLATIN	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1500	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP C 60	2	OXALIPLATIN	135	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZ MAIN SC+	2	ATEZOLIZUMAB	1680	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZ - NSCLC>	2	ATEZOLIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Erlotinib	2	ERLOTINIB	50	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	DEXAMETHASONE	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	PEMETREXED	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	ATEZ MAIN SC+	2	ATEZOLIZUMAB	1680	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	ATEZO MAIN SC	2	ATEZOLIZUMAB	1680	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	4	3	Crizotinib	2	CRIZOTINIB	250	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO+	2	CARBOPLATIN	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO+	2	PEMETREXED	750	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CARBO/PACL	2	CARBOPLATIN	360	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CARBO/PACL	2	PACLITAXEL	270	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	Carboplatin + Vinorelbine Oral	2	VINORELBINE	80	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABR+TRAM>(C19)	2	DABRAFENIB	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABR+TRAM>(C19)	2	TRAMETINIB	2	258684004	2	2022	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMBRO428 6WK C1	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	99	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	270	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Carboplatin + Paclitaxel (weekly)	1	PACLITAXEL	108	258684004	10	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Cisplatin 7 day	2	CISPLATIN	50	258684004	1	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGO W CISP/PEM>	1	CISPLATIN	70	258684004	1	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGOT PEMBRO 3W	1	PEMBROLIZUMAB/PLACEBO	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGOT W CISP/PEM	1	CISPLATIN	70	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ	2	CARBOPLATIN	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ>	2	BEVACIZUMAB	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	700	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	700	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	3950	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	BLEOMYCIN	30000	408102007	3	2022	RH8	6
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	CISPLATIN	113	258684004	2	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	890	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	560	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	Bendamustine+Rituximab (1st Cc	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	Ibrutinib	2	IBRUTINIB	560	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT MAINT	2	IBRUTINIB	560	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT MAINT	2	RITUXIMAB	1400	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT>1	2	RITUXIMAB - RIXATHON	800	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	700	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIVO - MESO C19	2	Nivolumab	480	258684004	11	2021	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	IPILIMUMAB	75	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	IPILIMUMAB	75	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	IPILIMUMAB	75	258684004	10	2021	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	BLEOMYCIN	18750	408102007	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DACARBAZINE	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPIR	2	TRIFLURIDINE/TIPIRACIL	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	1	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	1450	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	250	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	1100	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	1100	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	375	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	4450	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	2250	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ATEZO/NAB PAC>*	2	PACLITAXEL ALBUMIN	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	CAPECITABINE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	500	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	DS8201-A-U301>	1	DS-8201A	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	DEXAMETHASONE	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	3	2022	RH8	8

Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	2	PACLITAXEL	162	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ 2	2	RIBOCICLIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2150	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	375	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	2500	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	2500	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX	2	CETUXIMAB	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	ENCORAFENIB	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	3950	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	240	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	2	CETUXIMAB	700	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	650	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	650	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	550	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	135	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine	2	CAPECITABINE	1950	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	SACITUZ GOVIT>	2	SACITUZUMAB GOVITECAN	720	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab 21 day maintenano 2	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten 2	2	TRASTUZUMAB - EMTANSINE	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Vinorelbine (oral)	2	VINORELBINE	140	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Vinorelbine (oral)	2	VINORELBINE	140	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	Docetaxel	2	DOCETAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	WK THP>(SC)	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	50	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	CAPE/TRAS>	2	CAPECITABINE	500	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2300	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	1.63	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	1.63	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	1.63	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	1.63	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX	2	ENCORAFENIB	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	3500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	3150	258684004	1	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	OXALIPLATIN	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK	PANITUMUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	2	PAN/IRI/MDG 2WK>	FLUOROURACIL	3950	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Irinotecan + Modified De Gramor2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	CARBOPLATIN	330	258684004	12	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	Carboplatin AUC 6 - 10	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	DEXAMETHASONE	2	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	Carboplatin + Paclitaxel (3 week)	PACLITAXEL	336	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	DOCETAXEL	220	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel + Trastuzumab (Load)	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel + Trastuzumab (Maint)	DOCETAXEL	148	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	EC - CY1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	EPIRUBICIN HYDROCHLORIDE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	EPIRUBICIN HYDROCHLORIDE	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	FLUOROURACIL	1100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHESGO -	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHESGO -	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	DEXAMETHASONE	8	258684004	2	2022	RH8	8
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 8 15	PACLITAXEL	144	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Trastuzumab 21 day maintenanc	TRASTUZUMAB	600	258684004	11	2021	RH8	9
Malignant neoplasm: Breast, unspecified	C509	1	98	WKY PAC+TRAS AD	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ZOLE ACID HER -	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	VINBLASTINE SULFATE	6	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	VINBLASTINE SULFATE	6	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	VINBLASTINE SULFATE	11	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	VINBLASTINE SULFATE	12	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	E-BEACOPP RDE	DOXORUBICIN HYDROCHLORIDE	65	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP (RDE)	CISPLATIN	164	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	2	GDP>1 (RDE)	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP>1 (RDE)	GEMCITABINE	2200	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	PROCARBAZINE	250	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	9	1	GDP (RDE)	CISPLATIN	128	258684004	3	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	9	1	GDP (RDE)	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	DARATUMUMAB SC>9	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	LENALID (19)>	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	Melphalan oral	MELPHALAN	14	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE 2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	CAR LEN DEX	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	BORTEZOMIB	2.75	258684004	10	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	MET PHESGO >	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	PACLITAXEL	96	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	PACLITAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	PALBOCICLIB	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	RIBOCICLIB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	RIBOCICLIB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	RIBOCICLIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	RIBOCICLIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	RIBOCICLIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	RIBOCICLIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	RIBOCICLIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	RIBOCICLIB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >3	RIBOCICLIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	SACITUZ GOVIT>	SACITUZUMAB GOVITECAN	930	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day maintenanc	TRASTUZUMAB	600	258684004	11	2021	RH8	6

Malignant neoplasm: Breast, unspecified	C509	1	99	Docetaxel	2	DOCETAXEL	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	EPIDRUBICIN HYDROCHLORIDE	220	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	FLUOROURACIL	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100	2	FLUOROURACIL	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	TRAS SC MAIN-ADJ	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	3.3	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	2	2022	RH8	9
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	CARBOPLATIN	450	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	CARBOPLATIN	890	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO	2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	TCARBO	2	DOCETAXEL	148	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	250	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	DEXAMETHASONE	2	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	IXAZOMIB/PLACEBO	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA-(C19	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA-(C19	2	IXAZOMIB	2.3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA-(C19	2	IXAZOMIB	2.3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA-(C19	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2)	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2)	2	LENALIDOMIDE	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	BORTEZOMIB	1.6	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN 1	1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE 2	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE>1	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE>1	2	BORTEZOMIB	2.75	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	3	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	3	LEN/DEX/IXA	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>+	2	CETUXIMAB	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>+	2	ENCORAFENIB	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	2500	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	260	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	550	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	2800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK	2	FLUOROURACIL	650	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK	2	FLUOROURACIL	3950	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	FLUOROURACIL	650	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	FLUOROURACIL	650	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	FLUOROURACIL	3950	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	750	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine	2	CAPECITABINE	2450	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	225	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	200	258684004	3	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	225	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	2150	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	280	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	99	Cetuximab + Oxaliplatin + MdG Iv2	FLUOROURACIL	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	99	Cetuximab + Oxaliplatin + MdG Iv2	FLUOROURACIL	3500	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	650	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	NIVO MSI>C19	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	NIVO MSI>C19	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	3	ATTEND MAINTEN	ATEZOLIZUMAB/PLACEBO	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	1	Imatinib 400mg	IMATINIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	1	Imatinib 400mg	IMATINIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	IMATINIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	IMATINIB - (GLIVEC)	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	2	1	Imatinib 400mg	IMATINIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	IMATINIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Nasal cavity	C300	2	NULL	CISPLATIN + FLUOROURACIL	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	NULL	99	OX/CAP> B 80	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	FLUOROURACIL	3500	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	OXALIPLATIN	110	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	84	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	120	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	DOCETAXEL	88	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	ZOLE ACID HER -	ZOLEDRONIC ACID ADJ	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	CYCLOPHOSPHAMIDE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	EPIRUBICIN HYDROCHLORIDE	130	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	EC POST CARB+PAC	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	CYCLOPHOSPHAMIDE	1100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	EPIRUBICIN HYDROCHLORIDE	220	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOADJ TPH(sc)>	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOADJ TPH(sc)>	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	WKLY CARBO+PACL	PACLITAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	CAPE ADJ BREAST	CAPECITABINE	2150	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	KADCYLA ADJ>1	TRASTUZUMAB - EMTANSINE	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO AD PHESGO	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO AD PHESGO -	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO AD PHESGO -	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO AD PHESGO -	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)+	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	DOCETAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten2	TRASTUZUMAB - EMTANSINE	220	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten2	TRASTUZUMAB - EMTANSINE	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	ABEMACICLIB	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	CAPECITABINE	1450	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Docetaxel	DOCETAXEL	96	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	ERIBULIN	1.76	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	ERIBULIN	2.02	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 7 day	PACLITAXEL	108	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 7 day	PACLITAXEL	108	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 7 day	PACLITAXEL	108	258684004	12	2021	RH8	6
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Paclitaxel 80mg/m2 day 1 8 15	PACLITAXEL	96	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	PALBOCICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	PALBOCICLIB	75	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	PALBOCICLIB	75	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	PALBOCICLIB	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	PALBOCICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	3	POM/DEX>	POMALIDOMIDE	3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	CYCLOPHOSPHAMIDE	500	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	THALIDOMIDE	50	258684004	3	2022	RH8	<5

Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	THALIDOMIDE	50	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 1	DEXAMETHASONE	20	258684004	2	2022	RH8	8
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD- Cyc 8	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	DARATUMUMAB >25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	11
Multiple myeloma	C900	3	5	ISA/POM/DEX	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	650	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	POMALIDOMIDE	2	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	POMALIDOMIDE	2	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	POMALIDOMIDE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBOHP(SC)	CARBOPLATIN	630	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc	ZOLEDRONIC ACID ADJ	3.5	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PACL	CARBOPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	ZOLEDRONIC ACID ADJ	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ABEM & FULVEST>>	ABEMACICLIB	50	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	CAPECITABINE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CAPE + PHESGO >1	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	CAPECITABINE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	CAPECITABINE	2000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	CAPECITABINE	2300	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	DS8201-A-U301>	DS-8201A	330	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EC	EPIRUBICIN HYDROCHLORIDE	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	DEXAMETHASONE	2	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	DEXAMETHASONE	2	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	TRASTUZUMAB DERUXTECAN	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	TRASTUZUMAB DERUXTECAN	280	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	FLUOROURACIL	3950	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	PANITUMUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	RALT/OXALI-MET>	RALTITREXED	3.5	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPIR	TRIFLURIDINE/TIPIRACIL	60	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	98	Irinotecan + Modified De Gramor	IRINOTECAN HYDROCHLORIDE	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Doxorubicin 75mg/m2	DOXORUBICIN HYDROCHLORIDE	90	258684004	2	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Doxorubicin 75mg/m2	DOXORUBICIN HYDROCHLORIDE	120	258684004	10	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	PACLITAXEL	270	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	PACLITAXEL	270	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	PACLITAXEL	336	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	Carboplatin AUC 6 - 10	CARBOPLATIN	790	258684004	10	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	CISPLATIN	79	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	CISPLATIN	89	258684004	2	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	DEXAMETHASONE	2	258684004	2	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	ATTEND MAINTEN	ATEZOLIZUMAB/PLACEBO	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	Carboplatin + Paclitaxel (3 week)	PACLITAXEL	336	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	NIVO MSI>C19	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	NIVO MSI>C19	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU-ECHO	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU-ECHO	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	MET PHESGO >	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PAC ALB	PACLITAXEL ALBUMIN BOUND	450	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Paclitaxel 7 day	PACLITAXEL	162	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >1	PALBOCICLIB	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	EXEMESTANE	25	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ	RIBOCICLIB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >3	RIBOCICLIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >3	RIBOCICLIB	400	258684004	12	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >3	2	RIBOCICLIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO & LETROZ >3	2	RIBOCICLIB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV 2	2	RIBOCICLIB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	SACITUZ GOVIT	2	SACITUZUMAB GOVITECAN	721	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	SACITUZ GOVIT>	2	SACITUZUMAB GOVITECAN	720	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	240	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	3	2022	RH8	6
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	11	2021	RH8	7
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>(C19	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (C19)	2	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2)2	4	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2)2	5	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2)2	10	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2)2	25	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	MYL XI LEN MAIN>	1	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	POMALIDOMIDE	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD (28DAY)	2	THALIDOMIDE	100	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	1.8	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	3	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	2	1	Imatinib 400mg	2	IMATINIB	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	2	IMATINIB	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	DOCETAXEL	72	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	DOCETAXEL	72	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	FLUOROURACIL	3500	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	84	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	96	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	96	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	CAPECITABINE	2150	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	TRASTUZUMAB-ONTRUZANT	651	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma2	2	TRASTUZUMAB-ONTRUZANT	504	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	650	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	FEC 100	2	CYCLOPHOSPHAMIDE	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1350	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1650	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2300	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	2.64	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	2	PACLITAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Paclitaxel 7 day	2	PACLITAXEL	144	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	IRINOTECAN HYDROCHLORIDE	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX	CETUXIMAB	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	ENCOR + CETUX	ENCORAFENIB	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	FLUOROURACIL	450	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	260	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	3500	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	PEMB 6WK COLREC	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	PEMB 6WK COLREC	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	TRIFLURIDINE/TIPIRACIL	60	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	1	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab 21 day maintenanc	TRASTUZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	630	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	630	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	NLMT-ARM C	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	NLMT-ARMC>	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	NLMT-ARMC>	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	DURVAL>(C19)	DURVALUMAB	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	Cisplatin + Vinorelbine (PO)	CISPLATIN	145	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	ALECTINIB	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE>	ALECTINIB	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATE BEV CAR TAX>	PACLITAXEL	216	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO - NSCLC	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARB+ETOP>	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARB+ETOP>	ETOPOSIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	DOCETAXEL	96	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	FLUOROURACIL	4450	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	FLUOROURACIL	5650	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	FLUOROURACIL	6400	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	OXALIPLATIN	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	OXALIPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Carboplatin + Paclitaxel (weekly)	CARBOPLATIN	240	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	OXALIPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP B 80	CAPECITABINE	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> A 100	CAPECITABINE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	OXALIPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Trastuzumab 21 day maintenanc	TRASTUZUMAB-ONTRUZANT	588	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Trastuzumab 21 day maintenanc	TRASTUZUMAB-ONTRUZANT	588	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	CISPLATIN	79	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	CISPLATIN	89	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	400	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	CYCLOPHOSPHAMIDE	250	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 1	BORTEZOMIB	2.75	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 2	BORTEZOMIB	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 3	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD-Cyccs 4-7	BORTEZOMIB	2.75	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD-Cyccs 4-7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	DARATUMUMAB SC12	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS MAIN	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT	IXAZOMIB	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	IXAZOMIB	4	258684004	3	2022	RH8	<5

Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	ISATUXIMAB	600	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	ISATUXIMAB	600	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA(C19)	2	IXAZOMIB	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	1500	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	280	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	NIVO - OESO>>	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP A 100	2	OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	2	CAPECITABINE	1150	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CISPLATIN	89	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	220	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	2	CARBOPLATIN	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	78	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	2	PACLITAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Cisplatin +Fluorouracil (3 wk) 2	2	FLUOROURACIL	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	EPIRUBICIN HYDROCHLORIDE	60	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP B 80	2	CAPECITABINE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP> B 80	2	OXALIPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab 21 day loading dose 2	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten 2	2	TRASTUZUMAB - EMTANSINE	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten 2	2	TRASTUZUMAB - EMTANSINE	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	1450	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Capecitabine	2	CAPECITABINE	2650	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	2	ERIBULIN	1.76	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	2	ERIBULIN	2.02	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	2	ERIBULIN	2.02	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	2	ERIBULIN	2.2	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	ANASTROZOLE	1	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	3	2022	RH8	6
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	WK THP (SC)	2	DOCETAXEL	60	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	POMETREXED	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	POMETREXED	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	VINCISTINE SULFATE	1.4	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DOCET/NINTED	2	DOCETAXEL	96	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DOCET/NINTED	2	DOCETAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DOCET/NINTED	2	DOCETAXEL	164	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	40	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	80	258684004	11	2021	RH8	8
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL	2	CARBOPLATIN	630	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL+	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PACLITAXEL	270	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PACLITAXEL	270	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 +	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	6
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	2	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1450	258684004	1	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	CAPECITABINE	2150	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	120	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	OXALIPLATIN	280	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	2250	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	2250	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	2500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	IRINOTECAN HYDROCHLORIDE	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	220	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	ETOPOSIDE	220	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	160	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	270	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP> B 80	CAPECITABINE	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP> B 80	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	Docetaxel 75mg/m2 (21 day)	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	NIVO - OESO>>	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	BEVACIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	BEVACIZUMAB	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	BEVACIZUMAB	1700	258684004	12	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	BEVACIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	1	99	Gemcitabine 1000mg/m2 D1 8 1!2	GEMCITABINE	1600	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	IRINOTECAN HYDROCHLORIDE	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	PACLITAXEL ALBUMIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	PACLITAXEL ALBUMIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C227	3	NULL	ATEZ/BEV HCC+	BEVACIZUMAB	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC>	LENVATINIB - LENVIMA	12	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	IRINOTECAN HYDROCHLORIDE	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	IRINOTECAN HYDROCHLORIDE	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	IRINOTECAN HYDROCHLORIDE	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	FOLFOX - RDE	FLUOROURACIL	3500	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	FOLFOX - RDE	OXALIPLATIN	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	PACLITAXEL ALBUMIN	170	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	GEMCITABINE	1300	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	GEMCITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	GEMCITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	IRINOTECAN HYDROCHLORIDE	148	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	FLUOROURACIL	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	FLUOROURACIL	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	OXALIPLATIN	250	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	BEP500 AD(3DAYS)	ETOPOSIDE	360	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	CISPLATIN	100	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	DEXAMETHASONE	4.0	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	APIXABAN	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (C19)	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	DEXAMETHASONE	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	DEXAMETHASONE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE	BORTEZOMIB	2.25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE 2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	APIXABAN	2.5	258684004	1	2022	RH8	<5

Multiple myeloma	C900	3	98	VTD - RDE>1	2	BORTEZOMIB	2.25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	BORTEZOMIB	2.25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD(28 DA)>	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	Capecitabine	2	CAPECITABINE	1950	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	NULL	99	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	128	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	99	PEM CAR TAXOL	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	2	99	GemCarbo Days 1+8	2	CARBOPLATIN	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	2	99	GemCarbo Days 1+8	2	GEMCITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ALECTINIB - RDE	2	ALECTINIB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATE BEV CA TAX>>	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	CARBOPLATIN	450	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	POMETREXED	750	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2)	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 2	2	BORTEZOMIB	1.05	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	1.15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE	2	CISPLATIN	9	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	IXAZOMIB	3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	LENALID (19)>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2)	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2)	2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Melphalan IV High dose	2	MELPHALAN	185	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	POM/DEX>	2	POMALIDOMIDE	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	ETOPOSIDE	320	258684004	2	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	240	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	NULL	Ibrutinib	2	IBRUTINIB	560	258684004	2	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	560	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	560	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT - 6	2	IBRUTINIB	560	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT MAINT	2	IBRUTINIB	560	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT MAINT	2	RITUXIMAB	1400	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT>1	2	IBRUTINIB	560	258684004	10	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	500	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	POMETREXED	750	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IFI MESO Cy>	2	IPILIMUMAB	85	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IFI MESO Cy>	2	Nivolumab	360	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIVO - MESO C19	2	Nivolumab	480	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIVO - MESO C19	2	Nivolumab	480	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IFI MESO Cy>	2	IPILIMUMAB	75	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	BLEOMYCIN	20000	408102007	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	VINBLASTINE SULFATE	11	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	2	CHLORAMBUCIL	10	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP (RDE	2	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	300	258684004	2	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	375	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>+	2	CETUXIMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	5000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	550	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	FLUOROURACIL	650	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	PANITUMUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	60	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPIR	2	TRIFLURIDINE/TIPIRACIL	55	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP>1 (RDE)	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	2	VINBLASTINE SULFATE	4.8	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 1	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 3	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 3	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD-Cycs 4-7	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	LENALID (19)>	2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	NULL	LENALID (19)>	2	LENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	APIXABAN	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	NULL	Melphalan oral	2	MELPHALAN	14	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE 2	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	THALIDOMIDE	100	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	LENA MONO	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	THALIDOMIDE	50	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	THALIDOMIDE	50	258684004	11	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	225	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1300	258684004	10	2021	RH8	6
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1600	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1600	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1600	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	FLUOROURACIL	3150	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	OXALIPLATIN	110	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	3500	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	3950	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	DOCETAXEL	88	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	OXALIPLATIN	150	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	2	TRASTUZUMAB-ONTRUZANT	504	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	EPIDUBICIN HYDROCHLORIDE	100	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP A 100	2	CAPECITABINE	1150	258684004	10	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP C 60	2	CAPECITABINE	650	258684004	10	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	3	OX/CAP A 100	2	OXALIPLATIN	250	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	ETOPOSIDE	360	258684004	2	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	890	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPIR	2	TRIFLURIDINE/TIPIRACIL	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	CARBOPLATIN	790	258684004	12	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	3	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	9	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	360	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	Carboplatin + Etoposide IV 3 day 2	2	ETOPOSIDE	220	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	NIVO - AD OES>	2	Nivolumab	480	258684004	2	2022	RH8	<5

Malignant neoplasm: Oesophagus, unspecified	C159	1	1	NIVO - AD OES>	2	Nivolumab	480	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	PACLITAXEL	108	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	88	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	88	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	108	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN 1	1	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN 1	1	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE 2	2	THALIDOMIDE	100	258684004	11	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	11	2021	RH8	10
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q RDE>1	2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q RDE>1	2	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	2	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	2	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	10	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	12	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab (1st Cc	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	CYTARABINE	3600	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	THIOTEPA	54	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc	2	BENDAMUSTINE HYDROCHLORIDE	112.5	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	5650	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	165	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	CISPLATIN	164	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	CISPLATIN	164	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	CISPLATIN	164	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	TRASTUZUMAB-ONTRUZANT	882	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	1450	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CISPLATIN	145	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CISPLATIN	145	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	DEXAMETHASONE	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	TRASTUZUMAB-ONTRUZANT	441	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	IXAZOMIB	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA	2	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	DEXAMETHASONE	2	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	IXAZOMIB	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	7.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	POMALIDOMIDE	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN 1	1	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE 2	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50	2	CYCLOPHOSPHAMIDE	500	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50	2	THALIDOMIDE	50	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	2	2022	RH8	<5

NULL	C569	3	1	ACE (germ cell)	2	ETOPOSIDE	164	258684004	1	2022	RH8	<5
Other lymphoid leukaemia	C917	3	5	ORAL MTX - RDE	2	METHOTREXATE	10	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cemiplimab	2	CEMPIPLIMAB	350	258684004	11	2021	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cemiplimab>>	2	CEMPIPLIMAB	350	258684004	1	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>+	2	AVELUMAB	800	258684004	10	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4+	2	AVELUMAB	800	258684004	1	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4+	2	AVELUMAB	800	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	Cemiplimab>>	2	CEMPIPLIMAB	350	258684004	10	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	Vismodegib	2	VISMONDEGIB	150	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>	2	CEMPIPLIMAB	350	258684004	1	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>>	2	CEMPIPLIMAB	350	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	5	Busulfan Oral	2	BUSULFAN	2	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	5	RUX COMP PV	2	RUXOLITINIB	10	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	5	RUX COMP PV	2	RUXOLITINIB	10	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	6
Polycythaemia vera	D45X	3	98	MITH HYDROX 3/4-	1	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	Pemetrexed	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	Pemetrexed	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	Pemetrexed	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 428 6WK	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 428 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	6
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	10
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBROLIZ>>	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Pemetrexed	2	Pemetrexed	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	330	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	330	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	450	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	CISPLATIN	70	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	CISPLATIN	100	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	2	BORTEZOMIB	1.45	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	2	BORTEZOMIB	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 8	2	BORTEZOMIB	1.3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	2.5	258684004	11	2021	RH8	7
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	2.5	258684004	12	2021	RH8	7
Multiple myeloma	C900	3	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	10
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	650	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	650	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	1	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LENA MONO>	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	Pemetrexed	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	Pemetrexed	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	CARBOPLATIN	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	Pemetrexed	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	Pemetrexed	900	258684004	1	2022	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMETREXED	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	630	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Vinorelbine Oral	2	VINORELBINE	90	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	VINCRISTINE SULFATE	1.4	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19>	2	Osimertinib	80	258684004	12	2021	RH8	7
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	CARBOPLATIN	560	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PACLITAXEL	336	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PEMBROLIZUMAB	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 -	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMETREXED	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMETREXED	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	7
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day	2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	164	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	CISPLATIN	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	113	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	DEXAMETHASONE	4	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	DEXAMETHASONE	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	PEMETREXED	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	79	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	DEXAMETHASONE	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	450	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATE BEV CAR TAX>	2	CARBOPLATIN	630	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZ BEV CAR TAX	2	ATEZOLIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO CARBO+ETOP	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO CARBO+ETOP	2	ETOPOSIDE	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB >	2	Osimertinib	80	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMB +	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMETREX LUNG 1	2	DEXAMETHASONE	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	PEMETREXED	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Topotecan (oral)	2	TOPOTECAN	3.25	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	ATEZO MAIN SC	2	ATEZOLIZUMAB	1680	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	Carboplatin + Etoposide IV 3 day	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	4	3	Crizotinib	2	CRIZOTINIB	250	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	RUX COMP PV	2	RUXOLITINIB	10	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	98	RUX COMP PV	2	RUXOLITINIB	10	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	9	98	RUX COMP PV	2	RUXOLITINIB	15	258684004	3	2022	RH8	<5
Sickle-cell disorders	D57X	3	98	HYDROX SCD 1 DY-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	CVP R	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	CVP R	2	VINCRISTINE SULFATE	1	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1200	258684004	12	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	VINCRISTINE SULFATE	2	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	VINCRISTINE SULFATE	2	258684004	11	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	VINCRISTINE SULFATE	2	258684004	12	2021	RH8	<5
Unifocal Langerhans-cell histiocytosis	C966	3	1	LCH STR 1 CON	2	VINBLASTINE SULFATE	10	258684004	12	2021	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Ibrutinib	2	IBRUTINIB	420	258684004	2	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Ibrutinib	2	IBRUTINIB	420	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 10mg (Cycle 1 to 2):1	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5

Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	Melphalan oral	MELPHALAN	14	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	POMALIDOMIDE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	BORTEZOMIB	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	DEXAMETHASONE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 1	BORTEZOMIB	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 1	DEXAMETHASONE	20	258684004	12	2021	RH8	6
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	1	98	Rituximab (Maintenance)	RITUXIMAB	1400	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	1	98	Rituximab (Maintenance)	RITUXIMAB	1400	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	1	98	Rituximab (Maintenance)	RITUXIMAB	1400	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	IBRUTINIB	140	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	IBRUTINIB	280	258684004	2	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	IBRUTINIB	420	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	RITUXIMAB	1400	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	RITUXIMAB	1400	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	RITUXIMAB	1400	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT	IBRUTINIB	560	258684004	2	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT - 6	RITUXIMAB - RIXATHON	800	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT MAINT	IBRUTINIB	560	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	9	98	Ibrutinib	IBRUTINIB	560	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	PEMETREXED	750	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	PEMETREXED	800	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	PEMETREXED	1000	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	PEMETREXED	1000	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	IPILIMUMAB	85	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	Nivolumab	360	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIVO - MESO C19	Nivolumab	480	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VJ - Cyc 3	DEXAMETHASONE	20	258684004	1	2022	RH8	6
Multiple myeloma	C900	3	98	DARATUMUMAB SC>9	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	CISPLATIN	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	DOXORUBICIN HYDROCHLORIDE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	ETOPOSIDE	80	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	THALIDOMIDE	100	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS FIT	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNF1 >	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNF1 >	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	ISATUXIMAB	600	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	POMALIDOMIDE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	IXAZOMIB	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	APIXABAN	2.5	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP A 100	CAPECITABINE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> A 100	OXALIPLATIN	135	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	CAPECITABINE	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	CAPECITABINE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	CAPECITABINE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	CAPECITABINE	1000	258684004	1	2022	RH8	<5

Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	220	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	EPIDRUBICIN HYDROCHLORIDE	60	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP> B 80	2	CAPECITABINE	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	NIVO - OESO>>	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	OX/CAP C 60	2	CAPECITABINE	650	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	ATEZOLIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	BEVACIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	ATEZOLIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC	2	LENVATINIB - LENVIMA	12	258684004	11	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC>=	2	LENVATINIB - LENVIMA	12	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	7.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Muk9 main\$Cdar-1	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	1	BORTEZOMIB (MUK 9)	1.2	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	1	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	MUK9maint sc da	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE	2	BORTEZOMIB	2.25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE	2	THALIDOMIDE	50	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD(28 DAY)>	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	BLEOMYCIN	18750	408102007	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DACARBAZINE	700	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	VINBLASTINE SULFATE	12	258684004	3	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	2	CHLORAMBUCIL	10	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	2	PROCARBAZINE	200	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	2	PROCARBAZINE	200	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	E-BEACOPP RDE	2	CYCLOPHOSPHAMIDE	2260	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	2	VINBLASTINE SULFATE	4.8	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 3	2	BORTEZOMIB	2.75	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	DARATUMUMAB SC>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	NULL	LENALID (19)>	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	Melphalan oral	2	MELPHALAN	14	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE 2	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	CAR LEN DEX	2	CARFILZOMIB	40	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATE BEV CAR TAX>	2	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>	2	ATEZOLIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO CARBO+ETOP	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO CARBO+ETOP	2	ETOPOSIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	40	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	80	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	80	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	80	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMB +	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	ATEZ MAIN SC>	2	ATEZOLIZUMAB	1680	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	ATEZO MAIN SC	2	ATEZOLIZUMAB	1680	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	99	GemCarbo Days 1+8	2	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	500	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	PEMETREXED	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	Carboplatin + Vinorelbine Oral	2	VINORELBINE	80	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 3	2	BORTEZOMIB	1.15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	IXAZOMIB	3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	DEXAMETHASONE	2.0	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (19)>	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (19)>	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN	1	CYCLOPHOSPHAMIDE	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	4	3	Crizotinib	2	CRIZOTINIB	250	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO	2	PEMETREXED	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	PEMETREXED	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABR+TRAM-(C19)	2	DABRAFENIB	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DOCET/NINTED	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMETREXED	500	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	99	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	99	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	NULL	Carboplatin + Paclitaxel (3 week):2	2	CARBOPLATIN	330	258684004	11	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	NULL	Carboplatin + Paclitaxel (3 week):2	2	PACLITAXEL	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Carboplatin + Paclitaxel (weekly):1	1	CARBOPLATIN	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Carboplatin + Paclitaxel (weekly):1	1	PACLITAXEL	108	258684004	11	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGO W CISP/PEM>	1	PEMBROLIZUMAB/PLACEBO	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGOT PEMBRO 3W	1	PEMBROLIZUMAB/PLACEBO	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGOT W CISP/PEM	1	PEMBROLIZUMAB/PLACEBO	200	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN 1	1	CYCLOPHOSPHAMIDE	500	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE 2	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE>1	2	THALIDOMIDE	100	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 1	2	BORTEZOMIB	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 1	2	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 1	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 1	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	LENALID 5Q RDE>1	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	LENALID 5Q RDE>1	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	150	258684004	1	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D>1	2	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D>1	2	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q RDE>1	2	LENALIDOMIDE	5	258684004	10	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q RDE>1	2	LENALIDOMIDE	5	258684004	12	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	98	Azacitidine	2	AZACITIDINE	120	258684004	1	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	98	Azacitidine	2	AZACITIDINE	120	258684004	2	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	99	Azacitidine	2	AZACITIDINE	150	258684004	1	2022	RH8	6
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	3	Azacitidine	2	AZACITIDINE	130	258684004	12	2021	RH8	7
Multiple myeloma	C900	1	98	CAR LEN DEX	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainScdar>1	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainScdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainScdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainScdar>1	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	1.8	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5

Multiple myeloma	C900	3	NULL	FITNESS FRAIL	1	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	IXAZOMIB/PLACEBO	3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	LLENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	LLENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	LLENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>75>	1	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>75>	1	IXAZOMIB	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	DEXAMETHASONE	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LLENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LLENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LLENALIDOMIDE	15	258684004	2	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC>=	2	LENVATINIB - LENVIMA	12	258684004	2	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC>=	2	LENVATINIB - LENVIMA	12	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	FLUOROURACIL	2250	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	FOLFOX - RDE	2	OXALIPLATIN	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1800	258684004	12	2021	RH8	6
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	225	258684004	12	2021	RH8	6
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1300	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1600	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1600	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	FLUOROURACIL	3950	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	IRINOTECAN HYDROCHLORIDE	200	258684004	2	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	VINCRISTINE SULFATE	2	258684004	1	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	CYTARABINE	1800	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	CYTARABINE	3600	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	CYTARABINE	3600	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc 2	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
NULL	C569	3	1	ACCELERATED EP	2	CISPLATIN	100	258684004	11	2021	RH8	<5
Other lymphoid leukaemia	C917	3	5	ORAL MTX - RDE	2	METHOTREXATE	10	258684004	11	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	NULL	Cemiplimab	2	CEMIPLIMAB	350	258684004	12	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	Vismodegib	2	VISMONDEGIB	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABR+TRAM>(C19)	2	TRAMETINIB	2	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABRAF+TRAM(C19)	2	DABRAFENIB	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABRAF+TRAM(C19)	2	TRAMETINIB	2	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DOCET/NINTED	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	NINTEDANIB MONO	2	NINTEDANIB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME -	2	PEMETREXED	500	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMETREXED	500	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	PACLITAXEL	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Cisplatin 7 day	2	CISPLATIN	70	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	650	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	3500	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	3500	258684004	11	2021	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	3950	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	FLUOROURACIL	550	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGOT W CISP/PEM	PEMBROLIZUMAB/PLACEBO	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	9	NULL	CAR/PAC/BEVACIZ>	CARBOPLATIN	330	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	700	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	700	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	CETUXIMAB	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	550	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	650	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	FLUOROURACIL	3950	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	IRINOTECAN HYDROCHLORIDE	240	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	IRINOTECAN HYDROCHLORIDE	360	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	FLUOROURACIL	3150	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1 2	IRINOTECAN HYDROCHLORIDE	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	FLUOROURACIL	750	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	FLUOROURACIL	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor2	IRINOTECAN HYDROCHLORIDE	320	258684004	1	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>	CEMPIIMAB	350	258684004	12	2021	RH8	<5
Other specified types of T/NK-cell lymphoma	C86X	3	1	SMILE	IFOSFAMIDE	3200	258684004	12	2021	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C84A	3	NULL	CVP	VINCRISTINE SULFATE	1	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	NULL	99	HYDROXY 7 DAYS	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	NULL	99	HYDROXY 7 DAYS	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	NULL	Busulfan Oral	BUSULFAN	2	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	NULL	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	NULL	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	NULL	HYDROXY 5/2-	HYDROXYCARBAMIDE	1500	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	5	Busulfan Oral	BUSULFAN	30	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	5	RUX COMP PV	RUXOLITINIB	10	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	5	RUX COMP PV	RUXOLITINIB	10	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 7 DAYS-	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	6
Polycythaemia vera	D45X	3	98	HYDROXY 7 DAYS-	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	6
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	OXALIPLATIN	110	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	FLUOROURACIL	650	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	FLUOROURACIL	3950	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	IRINOTECAN HYDROCHLORIDE	260	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	IRINOTECAN HYDROCHLORIDE	280	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	1	99	OX/CAP A 100	CAPECITABINE	1150	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	DOCETAXEL	88	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	DOCETAXEL	96	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	CISPLATIN	164	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	EPIRUBICIN HYDROCHLORIDE	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	OXALIPLATIN	250	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP A 100	CAPECITABINE	1150	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP A 100	OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	CAPECITABINE	1150	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	3	OX/CAP A 100	CAPECITABINE	1150	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	3	OX/CAP> A 100	CAPECITABINE	1150	258684004	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	1	Carboplatin AUC 6 - 10	CARBOPLATIN	900	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 7 DAYS-	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	6
Polycythaemia vera	D45X	3	98	RUX COMP PV	RUXOLITINIB	10	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	CVP R	CYCLOPHOSPHAMIDE	1100	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	Bendamustine+Rituximab(Sub Cc 2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	VINCRISTINE SULFATE	2	258684004	10	2021	RH8	<5

Waldenström macroglobulinaemia	C880	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	10	2021	RH8	<5
Waldenström macroglobulinaemia	C880	3	98	DRC CATCH UP RIT	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Bendamustine+Rituximab (1st Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Ibrutinib	2	IBRUTINIB	420	258684004	1	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Ibrutinib	2	IBRUTINIB	420	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan 14day	2	IRINOTECAN HYDROCHLORIDE	164	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine	2	CAPECITABINE	1950	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	4450	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	4450	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	320	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine	2	CAPECITABINE	2150	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2150	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2200	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	99	Cetuximab + Oxaliplatin + MdG h 2	2	FLUOROURACIL	3950	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1150	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	900	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	550	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	2500	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	135	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	135	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	BEP500 AD(3DAYS)	2	BLEOMYCIN	30000	408102007	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	BEP500 AD(3DAYS)	2	CISPLATIN	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	Carboplatin AUC 6 - 10	2	CARBOPLATIN	770	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	Carboplatin AUC 6 - 10	2	CARBOPLATIN	970	258684004	1	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	Carboplatin AUC 6 - 10	2	CARBOPLATIN	1270	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	BLEOMYCIN	30000	408102007	2	2022	RH8	7
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	CISPLATIN	113	258684004	3	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week) 2	2	PACLITAXEL	240	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	NULL	Ibrutinib	2	IBRUTINIB	560	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	ENRICH-RITUX	1	RITUXIMAB	1400	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	1	2022	RH8	<5

Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	Bendamustine+Rituximab (1st Cc 2	1	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	1	IBRUTINIB	420	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	10	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	750	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Melphalan oral	2	MELPHALAN	12	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	POMALIDOMIDE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN 1	1	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE>1	2	DEXAMETHASONE	2.0	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	3	LEN/DEX/IXA	2	APIXABAN	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	CYCLOPHOSPHAMIDE	500	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)Vd - Cyc 2	2	BORTEZOMIB	2.75	258684004	3	2022	RH8	6
Multiple myeloma	C900	3	5	D(sc)Vd - Cyc 3	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)Vd - Cyc 3	2	BORTEZOMIB	3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)Vd-Cycs 4-7	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)Vd-Cycs 4-7	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	700	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	700	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	750	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	65	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPIR	2	TRIFLURIDINE/TIPIRACIL	60	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	2	CAPECITABINE	1500	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	CETUXIMAB	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	CETUXIMAB	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	5000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	IRINOTECAN HYDROCHLORIDE	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	CETUXIMAB	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	3950	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1150	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1150	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	3950	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1 2	2	CETUXIMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1 2	2	IRINOTECAN HYDROCHLORIDE	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Irinotecan + Modified De Gramor 2	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	550	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	550	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	800	258684004	1	2022	RH8	<5

Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	2	IPILIMUMAB	75	258684004	11	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	2	IPILIMUMAB	100	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIVO - MESO C19	2	Nivolumab	480	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DACARBAZINE	700	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DACARBAZINE	700	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	2	VINBLASTINE SULFATE	10	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	E-BEACOPP RDE	2	ETOPOSIDE	400	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP>1 (RDE)	2	CISPLATIN	164	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	2	CHLORAMBUCIL	10	258684004	3	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	Melphalan oral	2	MELPHALAN	14	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	1	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	1	Melphalan IV High dose	2	MELPHALAN	400	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE	2	THALIDOMIDE	50	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE-1	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD (28DAY)	2	BORTEZOMIB	2.75	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	450	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	900	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	2	FLUOROURACIL	650	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	60	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	250	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	98	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Doxorubicin 75mg/m2	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	GEM/DOC STS 2ND>	2	DOCETAXEL	164	258684004	10	2021	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Liposomal Doxorubicin 50mg/m2	2	LIPOSOMAL DOXORUBICIN	76	258684004	2	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Trabectedin	2	TRABECTEDIN	2.75	258684004	2	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	135	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	1150	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day	2	CAPECITABINE	1450	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	165	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day	2	OXALIPLATIN	280	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	CETUXIMAB	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	2250	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	FLUOROURACIL	4450	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw	2	IRINOTECAN HYDROCHLORIDE	440	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	900	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	1100	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	850	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	850	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	IXAZOMIB	2.3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5

Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	6	258684004	10	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar-1	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	250	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	IXAZOMIB	3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>75>	1	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA(C19)	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA(C19)	2	IXAZOMIB	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	APIXABAN	5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	DEXAMETHASONE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	CYCLOPHOSPHAMIDE	500	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	NIVO MSI>C19	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	2	1	Imatinib 400mg	2	IMATINIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	2	IMATINIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Nasal cavity	C300	2	NULL	CISPLATIN + FLUOROURACIL	2	CISPLATIN	145	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	NIVO - AD OES>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	NIVO - OESO	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	PACLITAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	88	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	88	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	96	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	4450	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	CAPECITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	CAPECITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa2	2	TRASTUZUMAB-ONTRUZANT	588	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma2	2	CISPLATIN	145	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	4450	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	440	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX	2	CETUXIMAB	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	ENCORAFENIB	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	ENCORAFENIB	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>	2	ENCORAFENIB	300	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX>+	2	ENCORAFENIB	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	650	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	2500	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo2	2	FLUOROURACIL	550	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo2	2	FLUOROURACIL	3150	258684004	2	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo 2	FLUOROURACIL	3150	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>(C19	IXAZOMIB	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LENA MONO>	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	MYL XI LEN MAIN>	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	MYL XI LEN MAIN>	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD (28DAY)	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	BORTEZOMIB	1.8	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	BORTEZOMIB	2	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	CYCLOPHOSPHAMIDE	500	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	CYCLOPHOSPHAMIDE	500	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)Vd - Cyc 3	BORTEZOMIB	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	DARATUMUMAB SC12	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	CISPLATIN	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	CYCLOPHOSPHAMIDE	800	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	FLUDARABINE PHOSPHATE	60	258684004	1	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FCR Oral - Cycle 2 onwards	FLUDARABINE PHOSPHATE	60	258684004	12	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	FLAIR-IBR/VEN	IBRUTINIB	420	258684004	3	2022	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	3	98	VENETO+RITUX C>1	VENETOCLAX	400	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB	ACALABRUTINIB	100	258684004	11	2021	RH8	<5
Chronic lymphocytic leukaemia of B-cell type	C911	9	98	ACALABRUTINIB>	ACALABRUTINIB	100	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Nilotinib	NILOTINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	NULL	99	Nilotinib	NILOTINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	1	Nilotinib	NILOTINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Imatinib 400mg	IMATINIB	100	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Imatinib 400mg	IMATINIB	100	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Nilotinib	NILOTINIB	300	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	1	98	Nilotinib	NILOTINIB	300	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	NULL	Imatinib 400mg	IMATINIB	400	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	DASATINIB	20	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	DASATINIB	50	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Dasatinib	DASATINIB	100	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE 90 CYC1	IMATINIB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma 2	TRASTUZUMAB-ONTRUZANT	588	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	CAPECITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	OXALIPLATIN	135	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP B 80	CAPECITABINE	1150	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	CAPECITABINE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	CAPECITABINE	1150	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	OXALIPLATIN	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day 2	CARBOPLATIN	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	96	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Cisplatin +Fluorouracil (3 wk)	FLUOROURACIL	2250	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	90	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	CISPLATIN	100	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE	THALIDOMIDE	50	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE 2	THALIDOMIDE	100	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	3	LEN/DEX/IXA	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	3	POM/DEX>	DEXAMETHASONE	30	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	3	POM/DEX>	POMALIDOMIDE	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	CYCLOPHOSPHAMIDE	500	258684004	3	2022	RH8	<5

Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	THALIDOMIDE	50	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 1	BORTEZOMIB	2.75	258684004	2	2022	RH8	8
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	6
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	BORTEZOMIB	2.75	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD- Cyc 8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD- Cyc 8	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	BORTEZOMIB	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX	POMALIDOMIDE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	PAN/IRI/MDG 2WK>	PANITUMUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPI>	TRIFLURIDINE/TIPIRACIL	55	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Capecitabine (14 day) + Irinoteca 2	CAPECITABINE	1450	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	9	3	Capecitabine (14 day) + Irinoteca 2	IRINOTECAN HYDROCHLORIDE	320	258684004	11	2021	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Doxorubicin 75mg/m2	DOXORUBICIN HYDROCHLORIDE	90	258684004	3	2022	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	GEM/DOC STS 2ND>	GEMCITABINE	1400	258684004	10	2021	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Trabectedin	TRABECTEDIN	2.75	258684004	1	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	DEXAMETHASONE	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	RT+CISP >CAR/PAC	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	IMATINIB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	IMATINIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	IMATINIB	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	IMATINIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	3	NULL	Imatinib 400mg	IMATINIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	CARBOPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly) 2	PACLITAXEL	96	258684004	11	2021	RH8	6
Multiple myeloma	C900	3	98	DT-PACE RDE>	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO>	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO>	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO>	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	DEXAMETHASONE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	650	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	700	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	850	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	POMALIDOMIDE	2	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	POMALIDOMIDE	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	DEXAMETHASONE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	LENALIDOMIDE	15	258684004	10	2021	RH8	7
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	LENALIDOMIDE	10	258684004	3	2022	RH8	<5

Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	MYL XI LEN MAIN>	1	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	MYL XI LEN MAIN>	1	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	THALIDOMIDE	200	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)2	2	THALIDOMIDE	200	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	100	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	200	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 1	2	BORTEZOMIB	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 3	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	2.75	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT	1	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT	1	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	IXAZOMIB	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	2	IXAZOMIB	4	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	96	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	4450	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	5000	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	6400	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	165	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	165	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	1300	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CISPLATIN	79	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CISPLATIN	145	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	TRASTUZUMAB-ONTRUZANT	588	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	2	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	7.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	7.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	MELPHALAN	400	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	THALIDOMIDE	200	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5

Multiple myeloma	C900	3	99	LENA MONO	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	EPIRUBICIN HYDROCHLORIDE	60	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP B 80	2	OXALIPLATIN	180	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	NIVO - QESO>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	ATEZOLIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	BEVACIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	BEVACIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	BEVACIZUMAB	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	FLUOROURACIL	2250	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	FLUOROURACIL	2250	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	OXALIPLATIN	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	OXALIPLATIN	110	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1400	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 1!2	2	GEMCITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX	2	FLUOROURACIL	3950	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	IRINOTECAN HYDROCHLORIDE	260	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	OXALIPLATIN	150	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	650	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	3950	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Carboplatin + Paclitaxel (weekly)	2	PACLITAXEL	66	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Carboplatin + Paclitaxel (weekly)	2	PACLITAXEL	66	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	650	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	1500	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	75	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	135	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	250	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP B 80	2	OXALIPLATIN	250	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	2	CAPECITABINE	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP> B 80	2	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	220	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Cisplatin +Fluorouracil (3 wk)	2	FLUOROURACIL	2250	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	OX/CAP> B 80	2	CAPECITABINE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	NIVO - QESO>>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	ATEZOLIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	BEVACIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	TRASTUZUMAB-ONTRUZANT	651	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	3	OX/CAP> A 100	2	OXALIPLATIN	250	258684004	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	BLEOMYCIN	30000	408102007	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	560	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	560	258684004	2	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	560	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	Ibrutinib	2	IBRUTINIB	560	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT MAINT	2	RITUXIMAB	1400	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT>1	2	IBRUTINIB	560	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT>1	2	IBRUTINIB	560	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT>1	2	RITUXIMAB - RIXATHON	800	258684004	12	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	500	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	10	2021	RH8	<5
Mesothelioma, unspecified	C459	9	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	BLEOMYCIN	20000	408102007	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	MELPHALAN	320	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	1	BORTEZOMIB (MUK 9)	1.2	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	1	BORTEZOMIB (MUK 9)	1.2	258684004	12	2021	RH8	<5

Multiple myeloma	C900	3	98	MUK9 SC DARA P2>	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	THALIDOMIDE	150	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	99	Melphalan IV High dose	2	MELPHALAN	340	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2!>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2!>	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2!>	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 2	2	BORTEZOMIB	2	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 3	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 2	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 3	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD-Cycs 4-7	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE	2	ETOPOSIDE	36	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75	1	IXAZOMIB	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	IXAZOMIB	3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (19)>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (C19)	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (C19)	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2!>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2!>	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2!>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	Melphalan IV High dose	2	MELPHALAN	165	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	BEVACIZUMAB	1700	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	BEVACIZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	BEVACIZUMAB	1700	258684004	12	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC>=	2	LENVATINIB - LENVIMA	12	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	1	99	Gemcitabine 1000mg/m2 D1 8 1!>	2	GEMCITABINE	1600	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	FLUOROURACIL	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	FLUOROURACIL	3150	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	OXALIPLATIN	75	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	FOLFOX - RDE	2	FLUOROURACIL	3950	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	FOLFOX - RDE	2	OXALIPLATIN	165	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1400	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	GEMCITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	225	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	OXALIPLATIN	110	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	650	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	3500	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	FLUOROURACIL	3950	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	IRINOTECAN HYDROCHLORIDE	280	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	IRINOTECAN HYDROCHLORIDE	280	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DACARBAZINE	700	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	2	VINBLASTINE SULFATE	10	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP>1 (RDE)	2	CISPLATIN	164	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 1	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	DARATUMUMAB SC	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	NULL	DARATUMUMAB SC>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	Lenalidomide 25mg (Cycle 1 to 2!>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	NULL	Lenalidomide 25mg (Cycle 1 to 2!>	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	1	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	THALIDOMIDE	100	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5

Multiple myeloma	C900	1	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD (28DAY)	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	98	VTD (28DAY)	2	THALIDOMIDE	50	258684004	1	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL	1	APIXABAN	2.5	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	IRINOTECAN HYDROCHLORIDE	280	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	OXALIPLATIN	150	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	OXALIPLATIN	165	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	OXALIPLATIN	165	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	1	99	OX/CAP A 100	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	1	99	OX/CAP> A 100	2	CAPECITABINE	1150	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	1	99	OX/CAP> A 100	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	FLUOROURACIL	2500	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	OXALIPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	2	1	FLOT	2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	80	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	EPIRUBICIN HYDROCHLORIDE	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	OXALIPLATIN	250	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP A 100	2	OXALIPLATIN	180	258684004	10	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP B 80	2	CAPECITABINE	500	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	CAPECITABINE	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	CAPECITABINE	1150	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN	1	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE	2	BORTEZOMIB	2.75	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE	2	THALIDOMIDE	50	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE 2	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	LENALID 5Q RDE>1	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	LENALID 5Q RDE>1	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	120	258684004	12	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	150	258684004	12	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D>1	2	LENALIDOMIDE	5	258684004	12	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	99	Azacitidine	2	AZACITIDINE	150	258684004	10	2021	RH8	7
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	3	Azacitidine	2	AZACITIDINE	130	258684004	1	2022	RH8	6
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	9	3	Azacitidine	2	AZACITIDINE	130	258684004	3	2022	RH8	7
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	1	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	11	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	12	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD-Cycc 4-7	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75	1	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75	1	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	LENALID (C19)	2	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	POM/DEX>	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN	1	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 2	2	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5

Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	OXALIPLATIN	135	258684004	2	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	3	OX/CAP> A 100	2	CAPECITABINE	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	BEP500 AD(3DAYS)	2	BLEOMYCIN	30000	408102007	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	BEP500 AD(3DAYS)	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	99	Carboplatin AUC 6 - 10	2	CARBOPLATIN	1020	258684004	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	CISPLATIN	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	ETOPOSIDE	360	258684004	3	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	890	258684004	2	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week)	2	PACLITAXEL	240	258684004	2	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	1	Cisplatin 7 day	2	CISPLATIN	70	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	2	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	Bendamustine+Rituximab (1st Cc	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	1	IBRUTINIB	420	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	1	IBRUTINIB	420	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	R-IBRUT>1	2	RITUXIMAB - RIXATHON	800	258684004	11	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	700	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	800	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	900	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	IXAZOMIB	3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>75>	1	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA(C19)	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA(C19)	2	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	IXAZOMIB	2.3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	IXAZOMIB	2.3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19)	2	LENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2)	2	DEXAMETHASONE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN 1	1	CYCLOPHOSPHAMIDE	500	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE 2	2	BORTEZOMIB	2.75	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	MATRIX	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	VINCRISTINE SULFATE	2	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	CYTARABINE	3600	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	RITUXIMAB - RIXATHON	700	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	THIOTEPA	54	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	R Chlorambucil	2	CHLORAMBUCIL	18	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
NULL	C569	3	1	ACCELERATED EP	2	CISPLATIN	100	258684004	12	2021	RH8	<5
NULL	C569	3	1	ACCELERATED EP	2	ETOPOSIDE	440	258684004	11	2021	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cisplatin +Fluorouracil (2 wk)	2	CISPLATIN	185	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cisplatin +Fluorouracil (2 wk)	2	FLUOROURACIL	9250	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cisplatin +Fluorouracil (2 wk)	2	FLUOROURACIL	9250	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4-	2	AVELUMAB	800	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4-	2	AVELUMAB	800	258684004	11	2021	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>	2	CEMPIPLIMAB	350	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>	2	CEMPIPLIMAB	350	258684004	10	2021	RH8	<5
Other specified types of T/NK-cell lymphoma	C86X	3	1	SMILE>1	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	10	2021	RH8	13
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	150	258684004	11	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	99	Azacitidine	2	AZACITIDINE	150	258684004	2	2022	RH8	7
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	VINCRISTINE SULFATE	2	258684004	12	2021	RH8	<5

Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc 2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc 2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	CYCLOPHOSPHAMIDE	2000	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	R Chlorambucil	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Other autoimmune haemolytic anaemias	D591	3	NULL	Rituximab	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cisplatin +Fluorouracil (2 wk)	CISPLATIN	185	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4-	AVELUMAB	800	258684004	1	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4+	AVELUMAB	800	258684004	11	2021	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	CYCLOPHOSPHAMIDE	1100	258684004	3	2022	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	VINCRISTINE SULFATE	2	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	NULL	99	HYDROXY 7 DAYS	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	6
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAYS	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 5/2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 5/2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 7 DAYS-	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	5	Busulfan Oral	BUSULFAN	30	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	3	5	RUX COMP PV	RUXOLITINIB	10	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	5	RUX COMP PV	RUXOLITINIB	10	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	Busulfan Oral	BUSULFAN	30	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 3/4 -	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	98	MITH HYDROX 3/4-	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	MITHRI RUXOL >	RUXOLITINIB	15	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	99	HYDROXY 1 DAY-	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	9	98	RUX COMP PV	RUXOLITINIB	15	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	9	98	RUX COMP PV	RUXOLITINIB	15	258684004	12	2021	RH8	<5
Sickle-cell disorders	D57X	3	98	HYDROX SCD 1 DY-	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	CVP R	CYCLOPHOSPHAMIDE	1100	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	3	Bortezomib + Cyclophos + Dex	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD- Cyc 8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	BORTEZOMIB	1.3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	DARATUMUMAB >25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	11
Multiple myeloma	C900	3	5	DARATUMUMAB >25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	10
Multiple myeloma	C900	3	5	ISA/POM/DEX	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX	ISATUXIMAB	750	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	DEXAMETHASONE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	650	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	700	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	ISATUXIMAB	900	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	POMALIDOMIDE	2	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	APIXABAN	2.5	258684004	11	2021	RH8	6
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	Nivolumab	360	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	BLEOMYCIN	20000	408102007	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	BLEOMYCIN	20000	408102007	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	DOXORUBICIN HYDROCHLORIDE	50	258684004	3	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	CHLVPP	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP (RDE	GEMCITABINE	2200	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	CHLORAMBUCIL	10	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	9	1	GDP (RDE	GEMCITABINE	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5

Multiple myeloma	C900	1	NULL	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	2.75	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD-Cycs 4-7	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	NULL	LENALID (19)>	2	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE CYC 5	2	BORTEZOMIB	1.45	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	3	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	3	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	CAR LEN DEX	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	CHLORAMBUCIL	16	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1200	258684004	11	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1300	258684004	2	2022	RH8	<5
Waldenström macroglobulinaemia	C880	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	1	2022	RH8	<5
Waldenström macroglobulinaemia	C880	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	12	2021	RH8	7
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD (28DAY)	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	VTD (28DAY)	2	THALIDOMIDE	50	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	DEXAMETHASONE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)2	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	1.8	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 3	2	BORTEZOMIB	2.75	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 3	2	BORTEZOMIB	2.75	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 3	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	98	CAR LEN DEX	2	CARFILZOMIB	54	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	98	VTD (28DAY)	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 main\$Cdar>1	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	250	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL	1	DEXAMETHASONE	2	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	IXAZOMIB/PLACEBO	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	POMALIDOMIDE	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	POMALIDOMIDE	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE>1	2	THALIDOMIDE	100	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	3	LEN/DEX/IXA	2	IXAZOMIB	4	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	Cemiplimab>	2	CEMPIPLIMAB	350	258684004	10	2021	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>	2	CEMPIPLIMAB	350	258684004	11	2021	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>>	2	CEMPIPLIMAB	350	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>>	2	CEMPIPLIMAB	350	258684004	12	2021	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	2	CYCLOPHOSPHAMIDE	1100	258684004	2	2022	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	2	CYCLOPHOSPHAMIDE	1100	258684004	12	2021	RH8	<5

Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	2	VINCRIStINE SULFATE	1	258684004	1	2022	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	2	VINCRIStINE SULFATE	2	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	NULL	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	98	Busulfan Oral	2	BUSULFAN	22	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	MITHRI RUXOL >	1	RUXOLITINIB	15	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	MITHRI RUXOL >>	1	RUXOLITINIB	15	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	98	RUX COMP PV	2	RUXOLITINIB	10	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	9	98	RUX COMP PV	2	RUXOLITINIB	15	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1200	258684004	10	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1300	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	CYCLOPHOSPHAMIDE	500	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	THALIDOMIDE	50	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	3	2022	RH8	6
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	700	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	700	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	2	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	IXAZOMIB	2.3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	IXAZOMIB	2.3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD-Cycs 4-7	2	DEXAMETHASONE	20	258684004	2	2022	RH8	6
Multiple myeloma	C900	3	98	DT-PACE RDE>	2	CYCLOPHOSPHAMIDE	800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	2	ETOPOSIDE	80	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS FIT	1	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS FIT	1	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS MAIN	1	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	IXAZOMIB	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	ISATUXIMAB	550	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	POMALIDOMIDE	3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA(C19)	2	LENALIDOMIDE	2	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19)	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19)	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19)	2	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LENA MONO>	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5

Multiple myeloma	C900	3	5	LENALID (19)>	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2!2	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2!2	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2!2	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2!2	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Melphalan oral	2	MELPHALAN	12	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX	2	POMALIDOMIDE	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	POMALIDOMIDE	3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	VTD (28DAY)	2	BORTEZOMIB	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	BORTEZOMIB	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	200	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	250	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)Vd - Cyc 1	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)Vd - Cyc 3	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)Vd-Cyccs 4-7	2	BORTEZOMIB	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)Vd-Cyccs 4-7	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)Vd-Cyccs 4-7	2	DEXAMETHASONE	20	258684004	3	2022	RH8	6
Multiple myeloma	C900	3	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	DT-PACE RDE>	2	THALIDOMIDE	200	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS MAIN	1	IXAZOMIB/PLACEBO	2.3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	POMALIDOMIDE	3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (C19)	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (C19)	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2!2	2	LENALIDOMIDE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	MELPHALAN	400	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Muk9 mainSCdar-1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	MUK9maint sc da	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX	2	POMALIDOMIDE	2	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE 2	2	BORTEZOMIB	2.25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE CYC 5	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	BORTEZOMIB	2.25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD(28 DAY)>	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	1.8	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	200	258684004	1	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	200	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	300	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	300	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Imatinib 400mg	2	IMATINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	150	258684004	2	2022	RH8	<5

Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	5	Nilotinib	2	NILOTINIB	200	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Dasatinib	2	DASATINIB	50	258684004	10	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE 90 CYC1	2	IMATINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	2	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	IMAT RDE90 CYC>1	2	IMATINIB	400	258684004	12	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	300	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	Nilotinib	2	NILOTINIB	400	258684004	3	2022	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	3	98	PONATINIB - C2	2	PONATINIB	30	258684004	11	2021	RH8	<5
Chronic myeloid leukaemia [CML], BCR/ABL-positive	C921	9	98	BOSUTINIB - RDE	2	BOSUTINIB	200	258684004	12	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	7.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Melphalan IV High dose	2	MELPHALAN	275	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Muk9 mainSCdar>1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX>	2	DEXAMETHASONE	40	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX>	2	POMALIDOMIDE	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE 2	2	THALIDOMIDE	100	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE CYC 5	2	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE CYC 5	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	BORTEZOMIB	2.25	258684004	10	2021	RH8	7
Multiple myeloma	C900	3	98	VTD - RDE>1	2	BORTEZOMIB	2.25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	1.8	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 3	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 8	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE	2	CYCLOPHOSPHAMIDE	360	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	3	IXAZOMIB	3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	IXAZOMIB	3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (19)>	2	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	DEXAMETHASONE	20	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	THALIDOMIDE	100	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 1	2	BORTEZOMIB	2	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 1	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	D(sc)VD - Cyc 3	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE>	2	CYCLOPHOSPHAMIDE	480	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75	1	LENALIDOMIDE	25	258684004	10	2021	RH8	<5

Multiple myeloma	C900	9	98	FITNESS>75>	1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	5	258684004	2	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	5	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	5	Ruxolitinib	2	RUXOLITINIB	10	258684004	3	2022	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	20	258684004	11	2021	RH8	<5
Chronic myeloproliferative disease	D471	3	98	Ruxolitinib	2	RUXOLITINIB	25	258684004	1	2022	RH8	<5
Cutaneous T-cell lymphoma, unspecified	C848	3	5	BEXAROTENE>	2	BEXAROTENE	225	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	ETOPOSIDE	88	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	VINCRISTINE SULFATE	2	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	1	1	RCEOP	2	VINCRISTINE SULFATE	2	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1300	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	12	2021	RH8	7
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1600	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	POM/DEX	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN 1	1	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	Z-Dex.	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)V/D - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	120	258684004	3	2022	RH8	6
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	1	2022	RH8	8
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	2	2022	RH8	11
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	LENALID 5Q RDE>1	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	150	258684004	10	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D>1	2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D>1	2	LENALIDOMIDE	5	258684004	10	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	98	Azacitidine	2	AZACITIDINE	120	258684004	12	2021	RH8	7
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	99	Azacitidine	2	AZACITIDINE	150	258684004	12	2021	RH8	7
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	9	3	Azacitidine	2	AZACITIDINE	130	258684004	11	2021	RH8	7
Non-Hodgkin lymphoma, unspecified	C859	2	3	R Chlorambucil	2	CHLORAMBUCIL	12	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	2	3	R Chlorambucil	2	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	RITUXIMAB - RIXATHON	900	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	THIOTEPA	54	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	RITUXIMAB - RIXATHON	800	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc 2	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc 2	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	POM/DEX	2	POMALIDOMIDE	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE>1	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE>1	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5

Multiple myeloma	C900	9	99	D(sc)VD - Cyc 1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	150	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D	2	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q 28D>1	2	LENALIDOMIDE	5	258684004	11	2021	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	LENALID 5Q RDE>1	2	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	98	Azacitidine	2	AZACITIDINE	120	258684004	3	2022	RH8	6
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	9	3	Azacitidine	2	AZACITIDINE	130	258684004	2	2022	RH8	7
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	9	3	Azacitidine	2	AZACITIDINE	130	258684004	10	2021	RH8	7
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	10	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1400	258684004	12	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	11	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	2	3	R Chlorambucil	2	CHLORAMBUCIL	16	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab (1st Cc2	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc2	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc2	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	CYCLOPHOSPHAMIDE	2000	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	CYCLOPHOSPHAMIDE	2000	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	CYTARABINE	4500	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	CYTARABINE	1800	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX - CYC>1	2	THIOTEPA	28	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc2	2	BENDAMUSTINE HYDROCHLORIDE	112.5	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc2	2	DEXAMETHASONE	8	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc2	2	RITUXIMAB - RIXATHON	100	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	R Chlorambucil	2	RITUXIMAB - RIXATHON	100	258684004	3	2022	RH8	<5
NULL	C569	3	1	ACCELERATED EP	2	ETOPOSIDE	440	258684004	12	2021	RH8	<5
Other malignant neoplasms of skin	C44X	NULL	99	Cemiplimab>	2	CEMPIIMAB	350	258684004	12	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	NULL	Cemiplimab>	2	CEMPIIMAB	350	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc2	2	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc2	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	99	Bendamustine+Rituximab(Sub Cc2	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
NULL	C37X	3	3	CAPE + TEMOZOL	2	CAPECITABINE	650	258684004	1	2022	RH8	<5
NULL	C569	3	1	ACE (germ cell)	2	DACTINOMYCIN	0.5	258684004	1	2022	RH8	<5
Other lymphoid leukaemia	C917	3	5	ORAL MTX - RDE	2	METHOTREXATE	10	258684004	1	2022	RH8	<5
Other lymphoid leukaemia	C917	3	5	ORAL MTX - RDE	2	METHOTREXATE	10	258684004	3	2022	RH8	<5
Other lymphoid leukaemia	C917	3	5	ORAL MTX - RDE	2	METHOTREXATE	10	258684004	12	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	NULL	Cemiplimab>>	2	CEMPIIMAB	350	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4-	2	AVELUMAB	800	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4-	2	AVELUMAB	800	258684004	10	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	AVELUMAB>4-	2	AVELUMAB	800	258684004	12	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	Vismodegib	2	VISMONEGIB	150	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>	2	CEMPIIMAB	350	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>>	2	CEMPIIMAB	350	258684004	10	2021	RH8	<5
Other specified types of T/NK-cell lymphoma	C86X	3	1	SMILE	2	PEGASPARGASE (Oncaspar)	5250	408102007	12	2021	RH8	<5
Polycythaemia vera	D45X	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	NULL	99	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	NULL	99	HYDROXY 7 DAYS	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	1	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	8
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	1	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	1	2022	RH8	10
Diffuse large B-cell lymphoma	C833	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	2	2022	RH8	13
Diffuse large B-cell lymphoma	C833	3	1	DA-EPOCH R C>1	2	VINCISTINE SULFATE	0.81	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	POLATUZ R-BENDA	2	POLATUZUMAB VEDOTIN	128	258684004	10	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	CYCLOPHOSPHAMIDE	1600	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	108	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	RCEOP	2	ETOPOSIDE	200	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE)	2	GEMCITABINE	2000	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	1	R-GDP(RDE) >	2	GEMCITABINE	2000	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	11	2021	RH8	<5

Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	VINCRIStINE SULFATE	1	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	VINCRIStINE SULFATE	1	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	CVP R	2	VINCRIStINE SULFATE	1	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	3	98	POLATUZ R-BENDA	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1800	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	800	258684004	12	2021	RH8	<5
Other malignant neoplasms of skin	C44X	3	3	Vismodegib	2	VISMONDEGIB	150	258684004	11	2021	RH8	<5
Other specified types of T/NK-cell lymphoma	C86X	3	1	SMILE	2	DEXAMETHASONE	40	258684004	12	2021	RH8	<5
Other specified types of T/NK-cell lymphoma	C86X	3	1	SMILE>1	2	ETOPOSIDE	200	258684004	3	2022	RH8	<5
Peripheral T-cell lymphoma, not elsewhere classified	C844	3	NULL	CVP	2	VINCRIStINE SULFATE	2	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	NULL	99	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	NULL	Busulfan Oral	2	BUSULFAN	30	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	NULL	HYDROXY 7 DAYS	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	6
Polycythaemia vera	D45X	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	98	RUX COMP PV	2	RUXOLITINIB	10	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	99	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	9	98	RUX COMP PV	2	RUXOLITINIB	15	258684004	10	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	CHLORAMBUCIL	16	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	RITUXIMAB - RIXATHON	600	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	CYCLOPHOSPHAMIDE	1200	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	VINCRIStINE SULFATE	2	258684004	2	2022	RH8	<5
Waldenström macroglobulinaemia	C880	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	2	2022	RH8	<5
Waldenström macroglobulinaemia	C880	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	3	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Bendamustine+Rituximab (1st Cc	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	5	Busulfan Oral	2	BUSULFAN	30	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	6
Polycythaemia vera	D45X	3	98	RUX COMP PV	2	RUXOLITINIB	10	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	Bendamustine+Rituximab(Sub Cc	2	BENDAMUSTINE HYDROCHLORIDE	140	258684004	10	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	Bendamustine+Rituximab(Sub Cc	2	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Ibrutinib	2	IBRUTINIB	420	258684004	10	2021	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Bendamustine+Rituximab(Sub Cc	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	Methotrexate intrathecal	2	METHOTREXATE	12.5	258684004	3	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE)	2	GEMCITABINE	1800	258684004	12	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	1	R-GDP(RDE) >	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	CYCLOPHOSPHAMIDE	1500	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	2	2022	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	11	2021	RH8	<5
Diffuse large B-cell lymphoma	C833	9	99	CHOP R - 21 days	2	VINCRIStINE SULFATE	2	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	NULL	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	2000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	1	NULL	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	6
Essential (haemorrhagic) thrombocythaemia	D473	3	NULL	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	6
Essential (haemorrhagic) thrombocythaemia	D473	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	5	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocythaemia	D473	3	98	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	12	2021	RH8	<5

Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 1 DAYS	2	HYDROXYCARBAMIDE	500	258684004	1	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	12
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	7
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	3	2022	RH8	25
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	20
Essential (haemorrhagic) thrombocytopenia	D473	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	2000	258684004	10	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	9	98	HYDROXY 3/4	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	9	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	9	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Essential (haemorrhagic) thrombocytopenia	D473	9	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	1	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	5	LENALID MONO	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	5	Rituximab (Maintenance)	2	RITUXIMAB	1400	258684004	12	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	Bendamustine+Rituximab(Sub Cc	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	CHOP R - 21 days	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + BENDA >1	2	OBINUTUZUMAB	1000	258684004	3	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN + CVP>	2	VINCRISTINE SULFATE	2	258684004	11	2021	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	OBIN MAINT>	2	OBINUTUZUMAB	1000	258684004	2	2022	RH8	<5
Follicular lymphoma, unspecified	C829	3	98	RCEOP	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	75	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	DABRAFENIB	150	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	1	1	DABRAF AND TRAM>	2	TRAMETINIB	2	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	1	1	PEMBRO 553 6WK	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	17
Malignant melanoma of skin	C43X	1	1	PEMBRO 553 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	21
Malignant melanoma of skin	C43X	1	1	PEMBRO 553 6WK	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	23
Malignant melanoma of skin	C43X	1	1	PEMBRO 553 6WK	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	16
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	TRAMETINIB	2	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	DABRAF + TRAMET>	2	TRAMETINIB	2	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR + BINIM	2	ENCORAFENIB	450	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	200	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	ENCOR+ BINIM C>2	2	ENCORAFENIB	450	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO MAIN 4WK>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO MAIN 4WK>>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO MAIN 4WK>1	2	Nivolumab	480	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVO SKIN 4WK>>	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	NIVOL/IPILIM RDE	2	IPILIMUMAB	300	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	3	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	8
Malignant melanoma of skin	C43X	3	1	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	DABRAFENIB	75	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	TRAMETINIB	1.5	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	DABRAF + TRAMET>	2	TRAMETINIB	1.5	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	Dabrafenib	2	DABRAFENIB	75	258684004	11	2021	RH8	<5
Malignant melanoma of skin	C43X	3	3	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant melanoma of skin	C43X	3	3	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant melanoma of skin	C43X	9	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	<5
Malignant melanoma of skin	C43X	9	NULL	PEMBRO 366 6WK	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	NULL	99	MITOMYCIN + CAPECITABINE	2	CAPECITABINE	1800	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	CARBOPLATIN	790	258684004	10	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	2	258684004	10	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	DEXAMETHASONE	2	258684004	11	2021	RH8	<5
Malignant neoplasm of anus and anal canal	C21X	2	99	WKLY PAC+CAR	2	PACLITAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm of base of tongue	C01X	NULL	99	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of base of tongue	C01X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of bone and articular cartilage of limbs	C40X	3	3	Cisplatin + Doxorubicin	2	DOXORUBICIN HYDROCHLORIDE	30	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	NULL	Sunitinib	2	SUNITINIB	25	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AXITINIB	2	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	AXIT + AVE >4>>	2	AXITINIB	5	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	20	258684004	1	2022	RH8	<5

Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTIN RDE >	2	CABOZANTINIB	20	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	CABOZANTINIB RDE	2	CABOZANTINIB	20	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC 4WK>>	2	Nivolumab	480	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO RCC MAIN <<	2	Nivolumab	480	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	NIVO/IPI RCC -	2	IPILIMUMAB	50	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	800	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Pazopanib	2	PAZOPANIB	800	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	PAZOPANIB - RDE+	2	PAZOPANIB	800	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	37.5	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	3	3	Sunitinib	2	SUNITINIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANT - RDE>	2	CABOZANTINIB	20	258684004	1	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	CABOZANTIN RDE >	2	CABOZANTINIB	40	258684004	10	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC	2	IPILIMUMAB	50	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC -	2	IPILIMUMAB	50	258684004	12	2021	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	NIVO/IPI RCC +	2	IPILIMUMAB	50	258684004	2	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	50	258684004	3	2022	RH8	<5
Malignant neoplasm of kidney, except renal pelvis	C64X	9	3	Sunitinib	2	SUNITINIB	50	258684004	11	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	CISPLATIN + FLUOROURACIL	2	CISPLATIN	145	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	CISPLATIN + FLUOROURACIL	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	1	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	NULL	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	200	258684004	1	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	Carboplatin AUC 2 - 5	2	CARBOPLATIN	220	258684004	3	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	1	CIS 35 WK RDE	2	CISPLATIN	63	258684004	1	2022	RH8	<5
Malignant neoplasm of oropharynx	C10X	3	3	PEMBRO H+N+	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm of other and unspecified parts of mouth	C06X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	72	258684004	2	2022	RH8	<5
Malignant neoplasm of other connective and soft tissue	C49X	3	NULL	Trabectedin	2	TRABECTEDIN	2.8	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	400	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	700	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin + Paclitaxel (3 week)2	2	PACLITAXEL	270	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	400	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	500	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	BEVACIZUMAB	600	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	630	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	700	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	790	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	790	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	CARBOPLATIN	890	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	300	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Bevacizumab+Carbo+Pacliaxel(m 2	2	PACLITAXEL	336	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	CARBOPLATIN	400	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	LIPOSOMAL DOXORUBICIN	50	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Liposomal Doxorut 2	2	LIPOSOMAL DOXORUBICIN	58	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	700	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	790	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	890	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	PACLITAXEL	336	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	PACLITAXEL	336	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	300	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	330	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	330	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	360	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	450	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	500	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Carboplatin AUC 6 - 10	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	240	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	240	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	450	258684004	10	2021	RH8	<5

Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1300	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	1	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	MIRASOL PAC WKLY	1	PACLITAXEL	129	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	NIRAPARIB> - RDE	2	NIRAPARIB	200	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	144	258684004	2	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	144	258684004	11	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	PAC WKLY (3WKS)	2	PACLITAXEL	162	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	Paclitaxel 80mg/m2 day 1 8 15	2	PACLITAXEL	96	258684004	10	2021	RH8	<5
Malignant neoplasm of ovary	C56X	3	NULL	WKLY CARBOPLATIN	2	CARBOPLATIN	140	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	Bevacizumab 15mg/kg	2	BEVACIZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm of ovary	C56X	3	3	TRAMETINIB>	2	TRAMETINIB	1	258684004	12	2021	RH8	<5
Malignant neoplasm of ovary	C56X	9	NULL	Bevacizumab 7.5mg/kg	2	BEVACIZUMAB	450	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	1	99	EMBARK-EN/PL+LE>	1	ENZALUTAMIDE/PLACEBO	160	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	2	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERON-(C19)	2	ABIRATERONE ACETATE	500	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE RDE	2	DEXAMETHASONE	0.5	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	500	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Cabazitaxel	2	CABAZITAXEL	40	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	Enzalutamide	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	120	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	1	2022	RH8	11
Malignant neoplasm of prostate	C61X	3	NULL	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	8
Malignant neoplasm of prostate	C61X	3	3	ABIRATERON-(C19)	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	14
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	12	2021	RH8	19
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	12	2021	RH8	11
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	7
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ABIRATERONE RDE-	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Cabazitaxel	2	CABAZITAXEL	36	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Cabazitaxel	2	CABAZITAXEL	40	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	120	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	148	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	120	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	3	2022	RH8	35
Malignant neoplasm of prostate	C61X	3	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	30
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	40	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	40	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	28
Malignant neoplasm of prostate	C61X	3	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	12	2021	RH8	37
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMG>4	1	ABIRATERONE ACETATE	500	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE -ARMG>4	1	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	3	STAMPEDE- ARMK>4	1	METFORMIN	850	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ABIRATERONE RDE	2	ABIRATERONE ACETATE	1000	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	3	99	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	500	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	NULL	Cabazitaxel	2	CABAZITAXEL	34	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	132	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERON-(C19)	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Abiraterone	2	ABIRATERONE ACETATE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE CY>1	2	DEXAMETHASONE	0.5	258684004	10	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ABIRATERONE(C19)	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	164	258684004	1	2022	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	80	258684004	12	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	Enzalutamide	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	<5
Malignant neoplasm of prostate	C61X	9	3	ENZALUTAMIDE(C19)	2	ENZALUTAMIDE	160	258684004	11	2021	RH8	7

Malignant neoplasm of prostate	C61X	9	99	ABIRATERONE CY>1	2	ABIRATERONE ACETATE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine	2	CAPECITABINE	1400	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	4450	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	NULL	99	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	4450	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	1	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	1	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine	2	CAPECITABINE	1450	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	2	99	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	250	258684004	10	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	3150	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	800	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	5000	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	NULL	Oxaliplatin + Modified de Gramo 2	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	1	Capecitabine	2	CAPECITABINE	1650	258684004	2	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	750	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	1500	258684004	1	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Cetuximab + FOLFIRI cycle1 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	2800	258684004	3	2022	RH8	<5
Malignant neoplasm of rectum	C20X	3	3	Irinotecan + Modified De Gramor2	2	FLUOROURACIL	5000	258684004	11	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	NULL	99	LENVATINIB>	2	LENVATINIB - LENVIMA	14	258684004	1	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	3	CABOZ MTC -	2	CABOZANTINIB	140	258684004	1	2022	RH8	<5
Malignant neoplasm of thyroid gland	C73X	3	3	CABOZ MTC.	2	CABOZANTINIB	140	258684004	10	2021	RH8	<5
Malignant neoplasm of thyroid gland	C73X	9	3	CABOZ MTC -	2	CABOZANTINIB	140	258684004	10	2021	RH8	<5
Malignant neoplasm of tonsil	C09X	NULL	99	Carboplatin AUC 2 - 5	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm of tonsil	C09X	3	1	CIS 35 WK RDE	2	CISPLATIN	70	258684004	11	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	450	258684004	12	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	GEMCITABINE	1400	258684004	11	2021	RH8	<5
Malignant neoplasm of ureter	C66X	3	3	GemCarbo Days 1+8	2	GEMCITABINE	1800	258684004	10	2021	RH8	<5
Malignant neoplasm of ureter	C66X	9	98	Cisplatin + Gemcitabine (D 1 & 8)2	2	CISPLATIN	145	258684004	3	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	500	258684004	2	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	NULL	Carboplatin + Paclitaxel (3 week)2	2	CARBOPLATIN	560	258684004	10	2021	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	725	258684004	1	2022	RH8	<5
Malignant neoplasm, primary site unknown, so stated	C800	3	3	Carboplatin + Etoposide IV 3 day 2	2	CARBOPLATIN	725	258684004	11	2021	RH8	<5
Malignant neoplasm: Adrenal gland, unspecified	C749	3	3	MITOTANE 4.5-9.0	2	MITOTANE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	2	1	Cisplatin + Gemcitabine (D 1 & 8)2	2	CISPLATIN	145	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	NULL	GemCarbo Days 1+8	2	GEMCITABINE	1600	258684004	12	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	1	Fluorouracil+Mitomycin+RT (Blac 2	2	FLUOROURACIL	5000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	ATEZOLIZUMAB>	2	ATEZOLIZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	2000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	3	3	GemCarbo Days 1+8	2	CARBOPLATIN	300	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	NULL	Cisplatin + Gemcitabine (D 1 & 8)2	2	GEMCITABINE	1600	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	2	CISPLATIN	128	258684004	11	2021	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	260	258684004	1	2022	RH8	<5
Malignant neoplasm: Bladder, unspecified	C679	9	3	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	260	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 150mg/m2	2	TEMOZOLOMIDE	250	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	285	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	315	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	350	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	355	258684004	10	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	98	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	1	99	Temozolomide 200mg/m2	2	TEMOZOLOMIDE	240	258684004	11	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV	2	LOMUSTINE	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV	2	PROCARBAZINE	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV	2	VINCISTINE SULFATE	2	258684004	12	2021	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	LOMUSTINE	160	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	LOMUSTINE	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	100	258684004	3	2022	RH8	<5
Malignant neoplasm: Brain, unspecified	C719	9	NULL	PCV - RDE	2	PROCARBAZINE	200	258684004	12	2021	RH8	<5

Malignant neoplasm: Brain, unspecified	C719	9	3	Temozolomide 200mg/m2	2	DEXAMETHASONE	2	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	Docetaxel	2	DOCETAXEL	148	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	NULL	99	RIBO & LETROZ	2	RIBOCICLIB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ FEC(FECTPH)>	2	CYCLOPHOSPHAMIDE	800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	ADJ PHESGO*	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	CAPE ADJ BREST	2	CAPECITABINE	1500	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	CAPE ADJ BREST	2	CAPECITABINE	1650	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	CYCLOPHOSPHAMIDE	1100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Cyclophosphamide + Docetaxel	2	DOCETAXEL	148	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	148	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel	2	DOCETAXEL	148	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Docetaxel + Trastuzumab (Maint)	2	DOCETAXEL	240	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	CYCLOPHOSPHAMIDE	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	800	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100	2	FLUOROURACIL	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	700	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	FEC 100 X 3 - 1	2	FLUOROURACIL	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	KADCYLA ADJ	2	TRASTUZUMAB - EMTANSINE	220	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	NEO AD PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	NEO AD PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	3	2022	RH8	6
Malignant neoplasm: Breast, unspecified	C509	1	1	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	162	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	CYCLOPHOSPHAMIDE	1400	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	DOCETAXEL	120	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	TC(BREAST) - C1	2	DOCETAXEL	132	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	2	2022	RH8	7
Malignant neoplasm: Breast, unspecified	C509	1	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	240	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKLY CARBO+PAC 1	2	CARBOPLATIN	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	1	WKY PAC+TRAS AD>	2	PACLITAXEL	132	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	ADJ TCARBHP(SC)>	2	DOCETAXEL	132	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	148	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Docetaxel	2	DOCETAXEL	180	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	EPIRUBICIN HYDROCHLORIDE	220	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100	2	FLUOROURACIL	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHESGO	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	NEO AD PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	132	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	144	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	98	WKY PAC+TRAS AD	2	PACLITAXEL	132	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ADJ PHESGO*	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	CYCLOPHOSPHAMIDE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	FEC 100 X 3 - 1	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	Paclitaxel 80mg/m2 day 1 & 15	2	PACLITAXEL	120	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	WKY PAC+TRAS AD>	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	1	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	10	2021	RH8	8
Malignant neoplasm: Breast, unspecified	C509	2	1	EC POST CARB+PAC	2	CYCLOPHOSPHAMIDE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO AD PHESGO -	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	148	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBHP(SC)>	2	DOCETAXEL	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	DOCETAXEL	148	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	NEO TCARBOHP(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	12	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	2	1	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	3	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NAD FEC(FECTPH)>	2	FLUOROURACIL	1100	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEAD FEC(FECTPH)	2	CYCLOPHOSPHAMIDE	1100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOADJ TPH(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	98	NEOADJ TPH(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	CAPE ADJ BREST	2	CAPECITABINE	2150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	KADCYLA ADJ ECHO	2	TRASTUZUMAB - EMTANSINE	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBHP(SC)>	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBOHP(SC)	2	CARBOPLATIN	890	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBOHP(SC)	2	DOCETAXEL	132	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	NEO TCARBOHP(SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	WKLY CARBO+PAC 1	2	PACLITAXEL	132	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID	2	ZOLEDRONIC ACID ADJ	3.5	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	3.5	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	2	99	ZOLE ACID HER -	2	ZOLEDRONIC ACID ADJ	4	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1150	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	1300	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Capecitabine	2	CAPECITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	CARBO BR CA	2	CARBOPLATIN	450	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU >	2	DEXAMETHASONE	2	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	ENHERTU-ECHO	2	TRASTUZUMAB DERUXTECAN	280	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	EVERO + EXEMES>1	2	EVEROLIMUS	7.5	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >1	2	PALBOCICLIB	100	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >1	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	RIBO and FULV ON	2	RIBOCICLIB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	SACITUZ GOVIT>	2	DEXAMETHASONE	8	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	THP (SC)	2	PERTUZUMAB/TRASTUZUMAB	1800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	FEC 100	2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	WK THP (SC)	2	DOCETAXEL	40	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	1	WK THP (SC)	2	DOCETAXEL	40	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1300	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1350	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1350	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	1650	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Capecitabine	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Eribulin	2	ERIBULIN	1.63	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	MET PHESGO >	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	10	2021	RH8	8
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & FULV >2	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>1	2	PALBOCICLIB	125	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO & LETROZ>2	2	PALBOCICLIB	125	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	PALBO + LETROZ	2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	RIBO & LETROZ >	2	RIBOCICLIB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	220	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	3	3	Trastuzumab(Kadcyla?) (Mainten	2	TRASTUZUMAB - EMTANSINE	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST	2	DEXAMETHASONE	1	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>	2	ABEMACICLIB	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	ABEMACICLIB	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	ABEM & FULVEST>>	2	DEXAMETHASONE	1	258684004	3	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Eribulin	2	ERIBULIN	2.2	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	75	258684004	10	2021	RH8	<5

Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & FULV >2	2	PALBOCICLIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	PALBO & LETROZ>2	2	PALBOCICLIB	100	258684004	10	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab 21 day loading dose2	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	1	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	2	2022	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	NULL	Trastuzumab 21 day maintenanc	2	TRASTUZUMAB	600	258684004	11	2021	RH8	<5
Malignant neoplasm: Breast, unspecified	C509	9	3	PALBO & LETROZ	2	PALBOCICLIB	125	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Carboplatin + Vinorelbine Oral	2	VINORELBINE	110	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	128	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	90	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	DURVAL>(C19)	2	DURVALUMAB	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	1	1	OSIMERTINIB ADI>	2	Osimertinib	40	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZ BEV CAR TAX	2	CARBOPLATIN	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	ATEZO CARBO+ETOP	2	ETOPOSIDE	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO	2	PEMETREXED	800	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	CARBOPLATIN	500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	CARBOPLATIN	560	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	PEMBROLIZUMAB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO+	2	PEMETREXED	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAR PEM PEMBRO>	2	PEMETREXED	700	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Etoposide IV 3 day	2	ETOPOSIDE	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	450	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	Carboplatin + Pemetrexed	2	CARBOPLATIN	560	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	CYCLOPHOSPHAMIDE	1100	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	CAV	2	VINCISTINE SULFATE	1.4	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	DABR+TRAM>(C19)	2	DABRAFENIB	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	GemCarbo Days 1+8	2	CARBOPLATIN	300	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19	2	Osimertinib	80	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	OSIMERTINIB C19	2	Osimertinib	80	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PACLITAXEL	336	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM CAR TAXOL>	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEM MAIN 200 -	2	PEMBROLIZUMAB	200	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB +	2	PEMBROLIZUMAB	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME -	2	PEMETREXED	1000	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	PEMETREXED	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMB+PEME 1	2	PEMETREXED	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 428 6WK	2	PEMBROLIZUMAB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK	2	PEMBROLIZUMAB	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	3	2022	RH8	9
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	NULL	PEMETREX LUNG 1	2	PEMETREXED	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Etoposide (3 day)	2	ETOPOSIDE	200	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	CISPLATIN	128	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	50	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Cisplatin + Vinorelbine (PO)	2	VINORELBINE	70	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Docetaxel 75mg/m2 (21 day)	2	DOCETAXEL	108	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	PEMETREX LUNG 1	2	DEXAMETHASONE	4	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	DEXAMETHASONE	4	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	DEXAMETHASONE	4	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	1	Pemetrexed	2	PEMETREXED	800	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ALECTINIB - RDE	2	ALECTINIB	450	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZ BEV CAR TAX	2	CARBOPLATIN	890	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZ BEV CAR TAX	2	PACLITAXEL	336	258684004	11	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	ATEZO - NSCLC>>	2	ATEZOLIZUMAB	1200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	CAV	2	CYCLOPHOSPHAMIDE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	CAV	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19	2	Osimertinib	80	258684004	2	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19	2	Osimertinib	80	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	40	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	40	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	40	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	OSIMERTINIB C19>	2	Osimertinib	80	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	PEMBRO 531 6WK>	2	PEMBROLIZUMAB	400	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	3	3	Pemetrexed	2	PEMETREXED	800	258684004	2	2022	RH8	<5

Malignant neoplasm: Bronchus or lung, unspecified	C349	4	3	Crizotinib	2	CRIZOTINIB	250	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO	2	PEMBROLIZUMAB	200	258684004	1	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	CAR PEM PEMBRO>	2	CARBOPLATIN	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABR+TRAM>(C19)	2	DABRAFENIB	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	DABR+TRAM>(C19)	2	TRAMETINIB	2	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	NINTEDANIB MONO	2	NINTEDANIB	200	258684004	3	2022	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	NULL	PEMB+PEME +	2	PEMETREXED	500	258684004	12	2021	RH8	<5
Malignant neoplasm: Bronchus or lung, unspecified	C349	9	99	ALECTINIB - RDE>	2	ALECTINIB	600	258684004	10	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	Carboplatin + Paclitaxel (weekly)	1	CARBOPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGO W CISP/PEM>	1	CISPLATIN	63	258684004	2	2022	RH8	<5
Malignant neoplasm: Cervix uteri, unspecified	C539	3	1	ENGOT W CISP/PEM	1	CISPLATIN	63	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Capecitabine	2	CAPECITABINE	2300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	550	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	650	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	3950	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	360	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	750	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	NULL	99	Irinotecan + Modified De Gramor 2	2	FLUOROURACIL	4450	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	750	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	750	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine	2	CAPECITABINE	2450	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine	2	CAPECITABINE	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1250	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1650	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	1	99	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1800	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	2150	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	98	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	2	99	Cetuximab + Oxaliplatin + MdG lv 2	2	FLUOROURACIL	700	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1450	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	200	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	1000	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	900	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	135	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	Oxaliplatin + Modified de Gramo 2	2	OXALIPLATIN	165	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	NULL	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	75	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	1	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine	2	CAPECITABINE	1500	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	CAPECITABINE	1300	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Capecitabine + Oxaliplatin 21day 2	2	OXALIPLATIN	165	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	CETUXIMAB	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	400	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	2250	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	2250	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	FLUOROURACIL	2500	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	280	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle 2 onw 2	2	IRINOTECAN HYDROCHLORIDE	360	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	CETUXIMAB	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	FLUOROURACIL	700	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Cetuximab + FOLFIRI cycle1	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	2022	RH8	<5

Malignant neoplasm: Colon, unspecified	C189	3	3	ENCOR + CETUX->	2	CETUXIMAB	900	258684004	11	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	400	258684004	12	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	650	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	FLUOROURACIL	700	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Irinotecan + Modified De Gramor	2	IRINOTECAN HYDROCHLORIDE	400	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	550	258684004	2	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	FLUOROURACIL	2250	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	135	258684004	3	2022	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	Oxaliplatin + Modified de Gramo	2	OXALIPLATIN	150	258684004	10	2021	RH8	<5
Malignant neoplasm: Colon, unspecified	C189	3	3	TRIFLURID/TIPI>	2	TRIFLURIDINE/TIPIRACIL	55	258684004	12	2021	RH8	<5
Malignant neoplasm: Connective and soft tissue, unspecified	C499	3	NULL	Trabectedin	2	TRABECTEDIN	2.75	258684004	3	2022	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	2	CARBOPLATIN	330	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	1	1	CAR/PACLITAX	2	PACLITAXEL	270	258684004	12	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	NULL	NIVO MSI>C19	2	Nivolumab	480	258684004	11	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	3	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	10	2021	RH8	<5
Malignant neoplasm: Endometrium	C541	3	3	ATTEND MAINTEN	2	ATEZOLIZUMAB/PLACEBO	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	2	IMATINIB	300	258684004	2	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	2	IMATINIB	400	258684004	1	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	2	IMATINIB - (GLIVEC)	300	258684004	3	2022	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	1	99	Imatinib 400mg	2	IMATINIB - (GLIVEC)	300	258684004	12	2021	RH8	<5
Malignant neoplasm: Ill-defined sites within the digestive system	C269	2	1	Imatinib 400mg	2	IMATINIB	400	258684004	2	2022	RH8	<5
Malignant neoplasm: Nasal cavity	C300	2	NULL	CISPLATIN + FLUOROURACIL	2	FLUOROURACIL	7250	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	FLOT	2	OXALIPLATIN	120	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	1	1	NIVO - AD OES	2	Nivolumab	480	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	200	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	PACLITAXEL	84	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	Carboplatin + Paclitaxel (weekly)	2	PACLITAXEL	96	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	DOCETAXEL	108	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	4450	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	5000	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	2	1	FLOT	2	FLUOROURACIL	5000	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	TRASTUZUMAB-ONTRUZANT	735	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	1450	258684004	11	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	TRASTUZUMAB-ONTRUZANT	378	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	TRASTUZUMAB-ONTRUZANT	588	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	750	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	EOX	2	OXALIPLATIN	250	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	NULL	OX/CAP B 80	2	OXALIPLATIN	165	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CAPECITABINE	800	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CAPECITABINE	1000	258684004	10	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CAPECITABINE	1000	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Capecitabine + Cisplatin	2	CISPLATIN	70	258684004	12	2021	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	1	Carboplatin + Paclitaxel (weekly)	2	CARBOPLATIN	240	258684004	3	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	CAPECITABINE	1000	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	CISPLATIN	70	258684004	1	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	3	3	ECX	2	CISPLATIN	100	258684004	2	2022	RH8	<5
Malignant neoplasm: Oesophagus, unspecified	C159	9	NULL	OX/CAP C 60	2	DEXAMETHASONE	2	258684004	10	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEV HCC+	2	ATEZOLIZUMAB	1200	258684004	11	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	BEVACIZUMAB	1200	258684004	12	2021	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	ATEZ/BEVA HCC -	2	BEVACIZUMAB	1500	258684004	3	2022	RH8	<5
Malignant neoplasm: Other specified carcinomas of liver	C227	3	NULL	LENVATINIB HCC>	2	LENVATINIB - LENVIMA	12	258684004	11	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Folfirinox	2	OXALIPLATIN	75	258684004	10	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	FOLFOX - RDE	2	FLUOROURACIL	3950	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	GEMCIT/ABRAXANE	2	PACLITAXEL ALBUMIN	170	258684004	1	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 !:2	2	GEMCITABINE	1300	258684004	11	2021	RH8	7
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	Gemcitabine 1000mg/m2 D1 8 !:2	2	GEMCITABINE	1600	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX	2	OXALIPLATIN	150	258684004	12	2021	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	NULL	mFOLFIRINOX>	2	FLUOROURACIL	2500	258684004	3	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	IRINOTECAN HYDROCHLORIDE	260	258684004	2	2022	RH8	<5
Malignant neoplasm: Pancreas, unspecified	C259	3	99	Folfirinox	2	OXALIPLATIN	150	258684004	3	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Cape+Cisplatin+Trastuzumab Loa	2	CISPLATIN	164	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	Cape+Cisplatin+Trastuzumab Ma	2	CAPECITABINE	2000	258684004	12	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1000	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	EOX	2	CAPECITABINE	1500	258684004	12	2021	RH8	<5

Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP B 80	2	OXALIPLATIN	180	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	CAPECITABINE	1150	258684004	11	2021	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	OXALIPLATIN	180	258684004	1	2022	RH8	<5
Malignant neoplasm: Stomach, unspecified	C169	3	NULL	OX/CAP> A 100	2	OXALIPLATIN	225	258684004	3	2022	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	1040	258684004	10	2021	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	1	1	Carboplatin AUC 6 - 10	2	CARBOPLATIN	1070	258684004	11	2021	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	BLEOMYCIN	30000	408102007	12	2021	RH8	<5
Malignant neoplasm: Testis, unspecified	C629	3	1	BEP 3 day	2	ETOPOSIDE	320	258684004	1	2022	RH8	<5
Malignant neoplasm: Vulva, unspecified	C519	3	NULL	Carboplatin + Paclitaxel (3 week)	2	CARBOPLATIN	890	258684004	11	2021	RH8	<5
Mantle cell lymphoma	C831	3	NULL	Ibrutinib	2	IBRUTINIB	560	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	ENRICH-RITUX	1	RITUXIMAB	1400	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	140	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	5	Ibrutinib	2	IBRUTINIB	280	258684004	12	2021	RH8	<5
Mantle cell lymphoma	C831	3	98	ENRICH-RITUX+I	1	RITUXIMAB	1400	258684004	3	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	Ibrutinib	2	IBRUTINIB	560	258684004	1	2022	RH8	<5
Mantle cell lymphoma	C831	3	98	Ibrutinib	2	IBRUTINIB	560	258684004	10	2021	RH8	<5
Mantle cell lymphoma	C831	9	98	Ibrutinib	2	IBRUTINIB	560	258684004	3	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	DEXAMETHASONE	4	258684004	1	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	Carboplatin + Pemetrexed	2	PEMETREXED	900	258684004	2	2022	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	2	IPILIMUMAB	85	258684004	11	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIV/IPI MESO Cy>	2	Nivolumab	360	258684004	11	2021	RH8	<5
Mesothelioma, unspecified	C459	3	NULL	NIVO - MESO C19	2	Nivolumab	480	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	BLEOMYCIN	20000	408102007	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	10	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	ABVD	2	VINBLASTINE SULFATE	12	258684004	11	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	E-BEACOPP RDE	2	PROCARBAZINE	200	258684004	2	2022	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	1	GDP>1 (RDE)	2	GEMCITABINE	2200	258684004	12	2021	RH8	<5
Mixed cellularity (classical) Hodgkin lymphoma	C812	3	98	CHLVPP	2	PROCARBAZINE	250	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 2	2	BORTEZOMIB	2.75	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	NULL	D(sc)VD-Cycs 4-7	2	BORTEZOMIB	2.75	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	NULL	Melphalan oral	2	MELPHALAN	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE	2	BORTEZOMIB	2.75	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE 2	2	THALIDOMIDE	100	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	1	1	VTD - RDE>1	2	BORTEZOMIB	2.75	258684004	12	2021	RH8	6
Multiple myeloma	C900	1	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	1	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	BORTEZOMIB	2.75	258684004	11	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	1	98	VTD(28 DAY)>	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	2	98	Muk9 mainSCdar>1	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	1.8	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	150	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	DARATUMUMAB	2	DARATUMUMAB	1200	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL	1	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	DEXAMETHASONE	2	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS FRAIL>	1	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	IXAZOMIB/PLACEBO	3	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	IXAZOMIB/PLACEBO	3	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	IXAZOMIB/PLACEBO	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS MAIN	1	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	FITNESS>	1	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	2.5	258684004	2	2022	RH8	<5

Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	APIXABAN	5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	IXAZOMIB	2.3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	LEN/DEX/IXA>(C19	2	IXAZOMIB	2.3	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	DEXAMETHASONE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	DEXAMETHASONE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	NULL	Melphalan oral	2	MELPHALAN	8	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	NULL	Melphalan oral	2	MELPHALAN	12	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	POMALIDOMIDE	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	NULL	POM/DEX>	2	POMALIDOMIDE	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	CYCLOPHOSPHAMIDE	500	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN	1	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	RADA VCD+LEN 1	1	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE	2	BORTEZOMIB	2.75	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	NULL	VTD - RDE>1	2	BORTEZOMIB	2.75	258684004	2	2022	RH8	6
Multiple myeloma	C900	3	3	POM/DEX>	2	DEXAMETHASONE	30	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	CYCLOPHOSPHAMIDE	500	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	CTD Attenuated (Thalidomide 50 2	2	THALIDOMIDE	50	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD - Cyc 3	2	DEXAMETHASONE	20	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD- Cyc 8	2	BORTEZOMIB	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	D(sc)VD-Cycs 4-7	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	9
Multiple myeloma	C900	3	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	11
Multiple myeloma	C900	3	5	ISA/POM/DEX	2	ISATUXIMAB	750	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	40	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	650	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	ISATUXIMAB	850	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	2	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	ISA/POM/DEX>	2	POMALIDOMIDE	4	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA	2	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>	2	LENALIDOMIDE	25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>(C19	2	DEXAMETHASONE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LEN/DEX/IXA>(C19	2	LENALIDOMIDE	7.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LENA MONO>	2	LENALIDOMIDE	5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LENA MONO>	2	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	LENA MONO>	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	DEXAMETHASONE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	LENALID (19)>	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	15	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	15	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	5	Lenalidomide 25mg (Cycle 1 to 2:2	2	LENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	Melphalan oral	2	MELPHALAN	12	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX	2	POMALIDOMIDE	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	5	POM/DEX>	2	POMALIDOMIDE	4	258684004	3	2022	RH8	<5

Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	BORTEZOMIB	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	DEXAMETHASONE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)>	2	THALIDOMIDE	200	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)2	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	5	VTD(28 DAY)2	2	BORTEZOMIB	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	250	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	250	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	CYCLOPHOSPHAMIDE	500	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	Bortezomib + Cyclophos + Dex	2	DEXAMETHASONE	40	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 1	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 2	2	BORTEZOMIB	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 2	2	BORTEZOMIB	2.75	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	D(sc)VD - Cyc 3	2	BORTEZOMIB	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	DARATUMUMAB SC>9	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS	1	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS FIT	1	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	APIXABAN	2.5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	10	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	FITNESS UNFIT >	1	LENALIDOMIDE	10	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	DEXAMETHASONE	20	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	ISATUXIMAB	600	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	ISA/POM/DEX>	2	POMALIDOMIDE	3	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA(C19)	2	DEXAMETHASONE	40	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>	2	IXAZOMIB	4	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	LEN/DEX/IXA>(C19)	2	LENALIDOMIDE	10	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	98	LENALID (19)>	2	LENALIDOMIDE	5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	5	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	Muk9 mainSCdar>1	2	LENALIDOMIDE	10	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX>	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX>	2	POMALIDOMIDE	4	258684004	1	2022	RH8	<5
Multiple myeloma	C900	3	98	POM/DEX>	2	POMALIDOMIDE	4	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE 2	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE 2	2	BORTEZOMIB	2.25	258684004	11	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE CYC 5	2	BORTEZOMIB	2	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE CYC 5	2	THALIDOMIDE	200	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD - RDE>1	2	THALIDOMIDE	150	258684004	12	2021	RH8	<5
Multiple myeloma	C900	3	98	VTD (28DAY)	2	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	3	98	VTD(28 DAY)2	2	BORTEZOMIB	2.75	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	Bortezomib + Cyclophos + Dex	2	BORTEZOMIB	2.25	258684004	2	2022	RH8	<5
Multiple myeloma	C900	3	99	LENA MONO>	2	LENALIDOMIDE	10	258684004	10	2021	RH8	<5
Multiple myeloma	C900	3	99	Melphalan IV High dose	2	DEXAMETHASONE	8	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2)2	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	3	Lenalidomide 25mg (Cycle 1 to 2)2	2	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	5	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	DARATUMUMAB >25	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE	2	DOXORUBICIN HYDROCHLORIDE	13	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE	2	THALIDOMIDE	100	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE>	2	DOXORUBICIN HYDROCHLORIDE	13	258684004	2	2022	RH8	<5

Multiple myeloma	C900	9	98	DT-PACE RDE>	2	ETOPOSIDE	52	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	DT-PACE RDE>	2	THALIDOMIDE	100	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	FITNESS>75>	1	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	IXAZOMIB	2.3	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	LEN/DEX/IXA>	2	LENALIDOMIDE	15	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	APIXABAN	2.5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	LENA MONO>	2	LENALIDOMIDE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	LENALID (19)>	2	DEXAMETHASONE	40	258684004	1	2022	RH8	<5
Multiple myeloma	C900	9	98	LENALID (C19)	2	APIXABAN	2.5	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (C19)	2	LENALIDOMIDE	25	258684004	10	2021	RH8	<5
Multiple myeloma	C900	9	98	LENALID (C19)	2	LENALIDOMIDE	25	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	APIXABAN	2.5	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	DEXAMETHASONE	10	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	98	Lenalidomide 25mg (Cycle 1 to 2):2	2	LENALIDOMIDE	5	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	Melphalan oral	2	MELPHALAN	8	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN	1	BORTEZOMIB	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN	1	LENALIDOMIDE	25	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	RADA VCD+LEN 1	1	APIXABAN	2.5	258684004	3	2022	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE 2	2	APIXABAN	2.5	258684004	11	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE>1	2	BORTEZOMIB	2.75	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	VTD - RDE>1	2	DEXAMETHASONE	20	258684004	12	2021	RH8	<5
Multiple myeloma	C900	9	98	Z-Dex.	2	IDARUBICIN HYDROCHLORIDE	20	258684004	2	2022	RH8	<5
Multiple myeloma	C900	9	99	D(sc)VD - Cyc 2	2	DEXAMETHASONE	20	258684004	3	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	120	258684004	2	2022	RH8	<5
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	NULL	Azacitidine	2	AZACITIDINE	130	258684004	12	2021	RH8	13
Myelodysplastic and myeloproliferative disease, not elsewhere classified	C946	3	5	Azacitidine	2	AZACITIDINE	120	258684004	10	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	10	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	NULL	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	11	2021	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	1	CHOP R - 21 days	2	RITUXIMAB - RIXATHON	700	258684004	3	2022	RH8	<5
Nodular lymphocyte predominant Hodgkin lymphoma	C810	3	1	CHOP R - 21 days	2	VINCISTINE SULFATE	2	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab (1st Cc2	2	RITUXIMAB - RIXATHON	600	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc2	2	DEXAMETHASONE	8	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	NULL	Bendamustine+Rituximab(Sub Cc2	2	RITUXIMAB - RIXATHON	600	258684004	3	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	CYCLOPHOSPHAMIDE	1800	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	RITUXIMAB - RIXATHON	900	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	RITUXIMAB - RIXATHON	900	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	CVP R	2	VINCISTINE SULFATE	2	258684004	11	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	RITUXIMAB - RIXATHON	600	258684004	10	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	1	MATRIX	2	RITUXIMAB - RIXATHON	800	258684004	2	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab (1st Cc2	2	RITUXIMAB - RIXATHON	600	258684004	12	2021	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc2	2	BENDAMUSTINE HYDROCHLORIDE	82.5	258684004	1	2022	RH8	<5
Non-Hodgkin lymphoma, unspecified	C859	3	98	Bendamustine+Rituximab(Sub Cc2	2	RITUXIMAB - RIXATHON	700	258684004	1	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	NULL	Cemiplimab>	2	CEMPIIMAB	350	258684004	3	2022	RH8	<5
Other malignant neoplasms of skin	C44X	3	NULL	Cemiplimab>>	2	CEMPIIMAB	350	258684004	2	2022	RH8	<5
Other malignant neoplasms of skin	C44X	9	NULL	Cemiplimab>>	2	CEMPIIMAB	350	258684004	1	2022	RH8	<5
Other specified types of T/NK-cell lymphoma	C86X	3	1	SMILE>1	2	IFOSFAMIDE	3200	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	NULL	99	Busulfan Oral	2	BUSULFAN	30	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 1 DAY-	2	HYDROXYCARBAMIDE	1000	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	1	NULL	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	12	2021	RH8	<5
Polycythaemia vera	D45X	1	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	1	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	1000	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	3	3	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	500	258684004	10	2021	RH8	6
Polycythaemia vera	D45X	3	5	Busulfan Oral	2	BUSULFAN	2	258684004	3	2022	RH8	<5
Polycythaemia vera	D45X	3	98	Busulfan Oral	2	BUSULFAN	22	258684004	10	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	500	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	2	2022	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 3/4 -	2	HYDROXYCARBAMIDE	1000	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 5/2-	2	HYDROXYCARBAMIDE	500	258684004	11	2021	RH8	<5
Polycythaemia vera	D45X	3	98	HYDROXY 7 DAYS-	2	HYDROXYCARBAMIDE	1500	258684004	1	2022	RH8	<5
Polycythaemia vera	D45X	9	98	RUX COMP PV	2	RUXOLITINIB	15	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	CVP R	2	RITUXIMAB - RIXATHON	600	258684004	2	2022	RH8	<5

Small cell B-cell lymphoma	C830	3	NULL	CVP R	2	VINCRIStINE SULFATE	1	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	CVP R	2	VINCRIStINE SULFATE	2	258684004	2	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	CHLORAMBUCIL	12	258684004	3	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	NULL	R Chlorambucil	2	CHLORAMBUCIL	16	258684004	1	2022	RH8	<5
Small cell B-cell lymphoma	C830	3	98	CVP R	2	VINCRIStINE SULFATE	2	258684004	3	2022	RH8	<5
Waldenström macroglobulinaemia	C880	3	5	Ibrutinib	2	IBRUTINIB	420	258684004	12	2021	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Bendamustine+Rituximab (1st Cc 2		BENDAMUSTINE HYDROCHLORIDE	75	258684004	2	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Bendamustine+Rituximab(Sub Cc 2		BENDAMUSTINE HYDROCHLORIDE	75	258684004	3	2022	RH8	<5
Waldenström macroglobulinaemia	C880	9	98	Ibrutinib	2	IBRUTINIB	420	258684004	12	2021	RH8	<5